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FOREWORD 
 
This dissertation describes the work performed under the supervision of Prof. 
Cláudio M. Gomes, in the Protein Biochemistry Folding and Stability 
Laboratory, Instituto de Tecnologia Química e Biológica from October 2006 
to June 2010.  
The studies here presented aim to contribute to a better understanding of 
human electron transfer flavoprotein (ETF) folding and stability, towards the 
elucidation of the molecular rationale of multiple acyl-CoA dehydrogenase 
deficiency (MADD). First, ETF disease causing missense mutations and the 
impact of three of those mutations on the protein folding and stability is 
overviewed. Subsequently, the role of flavinylation on a mutant variant 
resulting in a mild phenotype was addressed in order to gain a better 
understanding on the molecular rationale for riboflavin supplementation. 
Further, two polymorphic ETF variants were analyzed to explore their effects 
on the protein folding and function and to investigate possible implication in 
MADD.  
This thesis is organised in three parts. The first part is an introduction 
comprising two chapters: the first describing the state of knowledge on the 
protein folding problem and protein homeostasis, and the second presenting 
an overview on mitochondrial fatty acid β-oxidation (FAO) enzymes 
(particularly ETF) and on FAO associated disorders. In addition, a brief 
description on riboflavin as a therapeutic agent is also presented in the second 
chapter. The second part of the thesis is organized in three chapters 
describing the experimental results obtained. The third and last part consists 
of a general discussion integrating the described results. 
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DISSERTATION ABSTRACT 
 
 The work presented in this dissertation concerns the study of the electron 
transfer flavoprotein (ETF), a protein involved in mitochondrial β-oxidation 
whose deficiency is associated to multiple acyl-CoA dehydrogenase deficiency 
(MADD). The thesis will focus on establishing the functional, cellular and 
molecular consequences of the genetic variability in ETF, and in particular it 
aims to clarify the basis for the effect of heat stress on disease progression. 
Moreover, the beneficial effects of vitamin B2 supplementation will be 
addressed.  
 MADD, which is an autosomal recessively inherited disorder of fatty acid, 
amino acid, and choline metabolisms, results from deficiencies in any of the 
following genes: ETFA, ETFB or ETFDH.  ETFA and ETFB genes encode 
for the α and β subunits of ETF, whereas ETFDH encodes for electron 
transfer flavoprotein ubiquinone oxidoreductase (ETF-QO). ETF is a key 
enzyme in a series of mitochondrial metabolic pathways, mediating electron 
transfer from at least 12 dehydrogenases to the membrane-bound ETF-QO, 
thus funneling reducing power to the respiratory chain for subsequent ATP 
production. The clinical features of patients with MADD are heterogeneous 
and fall into 3 classes: a neonatal-onset form with congenital anomalies (type 
I), a neonatal-onset form without congenital anomalies (Type II), and a late-
onset form (Type III). This variety of effects presumably depends on the 
location and nature of the intragenic lesion. Although over 55 distinct 
genotypes have been identified on MADD patients, with approximately one 
third corresponding to missense mutations in ETF, only a limited number of 
genotypes have been characterised. The available data is, in fact, highly 
suggestive of a direct correlation between the genotype and clinical 
 x 
phenotype. Accordingly, while null mutations result in severe phenotypes, 
missense mutations in the above mentioned genes result in proteins with a 
lower enzymatic activity leading to cellular functional deficiency and thus 
milder phenotypes. In these cases, the amino acid alterations are likely to 
cause conformational changes in the expressed gene products which account 
for disease. This effect is mostly evident in late-onset MADD patients, in 
which the disease is often intermittent and only becomes evident during 
periods of illness or catabolic stress. Even so, the molecular genetic basis and 
functional characterisation of MADD genotypes remains elusive, thus a 
detailed in vitro investigation will contribute to a better functional 
understanding of the clinical heterogeneity in MADD.  
 An extensive in silico analysis was carried out on 18 disease associated 
missense mutations found in ETF. The analysis revealed that known 
mutations fall essentially in two groups: 1) mutations affecting protein folding 
and assembly; 2) mutations impairing catalytic activity and interactions with 
partner dehydrogenases. We have focused our studies on three of these 
mutations, ETFβ Cys42Arg, Asp128Asn and Arg191Cys, which typify 
different clinical phenotypes. This part of the investigation involved the study 
of expressed ETF variants, aiming at evaluating the impact of mutagenesis on 
ETF intrinsic conformational stability, enzymatic activity, protein assembly 
and interaction with functionally relevant enzymes.  
 The ETFβ-Cys42Arg mutation, a severe MADD mutation, affects directly 
the AMP binding site and the intersubunit contacts impairing protein folding. 
In vivo assays following the recombinant expression of the protein in an E. coli 
system have shown that the protein is expressed as insoluble aggregates. 
Upon co-expression with GroEL/GroES and dnaK/dnaJ/GrpE an increase 
in soluble protein production was noted, although no enzymatic activity was 
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restored, probably due to a defective insertion of the AMP and FAD 
cofactors.  
 Proteins harboring the other two mutations, ETFβ-Asp128Asn and 
ETFβ-Arg191Cys, which are associated to mild MADD, were purified in the 
soluble form after heterologous expression. We have used a combination of 
biophysical and biochemical methods to address the impact of these last two 
mutations on ETF folding, conformational stability and efficiency in 
mediating electron transfer. The two mutant variants had an overall α/β fold 
topology identical to native ETF, but both have substantially decreased 
enzymatic activity and conformational stability. The ETFβ-Asp128Asn 
mutation has a stronger impact on the protein conformational stability, as this 
mutation is near the dimer interface and the FAD binding site. On the other 
hand, the decreased activity observed for the ETFβ-Arg191Cys variant is 
likely to result from the impairment of interactions with the electron-donor 
dehydrogenases, as the mutated residue is within the predicted interface of 
the complex formation. Thus, combination of in silico analysis of mutations 
with experimental data has allowed to establish structural hotspots within 
ETF fold, which are useful to provide a rationale for the prediction of effects 
of mutations in ETF. 
 Mutations leading to mild clinical phenotypes, such as those selected in 
this study, are frequently associated to poor catalytic activity of the mutant 
variant and deficient FAD insertion. Moreover, the molecular consequences 
of riboflavin supplementation in the functional rescue of defective fatty acid 
β-oxidation flavoenzymes are becoming increasingly clear. This has been 
made possible with the combination of diverse studies made during the last 
decades, ranging from in vitro analysis of purified proteins, to proteomic 
analysis of patients and animal and cellular models. The immediate 
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consequence of riboflavin supplementation is an increase in the cellular 
availability of FAD, which is the key cofactor in many fatty acid β-oxidation 
enzymes. It is becoming clear that apart from being an essential chemical 
component of the active site, FAD may also play a multitude of additional 
roles such as assisting folding.  
 This aspect was investigated in detail using the ETFβ-Asp128Asn variant 
as a model. Clinical data reports that a homozygous patient for this mutation 
developed severe disease symptoms in association with a viral infection and 
fever. In agreement, heat inactivation of this mutant is more significant at 
temperatures above 37°C. We have found that cofactor insertion in vitro 
substantially improves the folding and stability of this ETF variant. Moreover, 
the presence of an excess of flavin in a concentration identical to that 
determined in the mitochondria from muscle of patients that take vitamin B2 
orally, prevented proteolytic digestion by avoiding protein destabilization. To 
mimic a situation of fever in vitro, the flavinylation status was tested at 39°C: 
FAD improves the protein conformation yielding a more stable and active 
enzyme, thus acting as a pharmacological chaperone. 
 The results obtained provide a structural and functional framework for 
the role of vitamin B2 supplementation in the molecular pathogenesis of 
MADD and flavoprotein disorders in general.  
 Apart from disease causing mutations, a number of polymorphic variants 
have been reported in FAO enzymes. In particular, a polymorphic variation in 
the alpha-subunit of ETF, which leads to the incorporation of either a 
threonine or an isoleucine at position 171, has been identified. A previous 
study has indicated that patients suffering from a mild form of very long 
chain acyl-CoA dehydrogenase deficiency (VLCADD) displayed an 
overrepresentation of this ETFα-Thr171 polymorphic variant. This led to the 
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suggestion that this polymorphism could influence disease phenotype, by an 
as yet unknown molecular mechanism. The effect of the variation of the 
ETFα-Thr/Ile171 polymorphism on the ETF folding and dynamics under 
thermal stress was investigated. The results showed that the two variants have 
the identical thermodynamic stabilities (Tm=58°C), although the ETFα-
Thr171 variant has a decreased thermal inactivation midpoint (Tminact=49°C) 
in comparison to that of ETFα-Ile171 (Tminact=58°C). Upon thermal stress, 
the ETFα-Thr171 variant is prone to faster cofactor (FAD) loss and 
conformational destabilization leading to an increase of a heterogeneous 
population of the variant. Also, this variant has higher conformational 
dynamics during thermal stress: upon 2 hours at 39°C, ETFα-Thr171 looses 
half of its activity, whereas ETFα-Ile171 activity remains at ~85%. ETFα-
Thr171 can be rescued by the GroEL chaperonin, which captures and refolds 
the thermally destabilized variant, as observed by the retained enzymatic 
activity. Therefore, this polymorphic position has an impact on protein 
conformation and function under thermal stress. The latter is a common 
metabolic trigger for the manifestation of mitochondrial beta oxidation 
defects. 
 This dissertation has the purpose of contributing towards a molecular and 
functional understanding of MADD. The data gathered in this study were 
correlated to the wealth of data available on the genomics, cell biology and 
clinical presentations in MADD patients and permitted to add some insights 
on the molecular mechanisms underlying this pathology. Eventually, the 
results obtained will contribute for the setup of new therapeutic strategies and 
the improvement of diagnostic methods. The basic knowledge gained in this 
study has also the potential to contribute to a better understanding of many 
other diseases associated to missense gene mutations.  
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RESUMO DA DISSERTAÇÃO 
 
 O trabalho apresentado nesta dissertação centra-se no estudo da 
“flavoproteína de transferência electrónica” (ETF), uma proteína 
mitocondrial envolvida na β-oxidação dos ácidos gordos, cuja deficiência está 
associada à patologia “deficiência múltipla de acil-CoA desidrogenases” 
(MADD). A tese foca-se na avaliação das consequências funcionais, celulares 
e moleculares da variabilidade genética na ETF, e em particular, tem como 
objectivo elucidar a base do efeito de stress térmico na progressão da doença. 
As consequências moleculares do suplemento com vitamina B2 serão também 
abordadas.  
 
 MADD é uma patologia hereditária autossómica recessiva associada ao 
metabolismo mitocondrial dos ácidos gordos, aminoácidos e cholina. A 
patologia resulta de uma deficiência numa das seguintes proteínas: nas 
subunidades alfa (ETFA) ou beta (ETFB) da (ETF), ou na ETF-ubiquinona 
oxidoreductase (ETF-QO). Estas enzimas estão envolvidas no metabolismo 
energético da mitocôndria, actuando concertadamente na matriz mitocondrial 
catalisando a oxidação dos ácidos gordos de modo a obter energia.  
 A base genética e a caracterização funcional das mutações associadas à 
MADD ainda não se encontram bem estabelecidas. A expressão clínica da 
patologia é variável e pode ser agrupada em três classes: uma forma letal em 
recém-nascidos com anomalias congénitas (Tipo I), uma forma letal em 
recém-nascidos sem anomalias congénitas (Tipo II) e várias formas menos 
agressivas com expressão tardia (Tipo III). Esta variabilidade parece depender 
da localização e da natureza da alteração genética, ou seja, da mutação em 
cada caso. Até à data já foram identificados cerca de 55 mutações diferentes 
em doentes com MADD, dos quais cerca de metade correspondem a 
 xvi 
alterações de um único aminoácido na ETF (A/B), mas apenas um número 
limitado de genótipos foi caracterizado. Os dados disponíveis na literatura 
sugerem uma relação directa entre o fenótipo clínico e os níveis de ETF com 
actividade biológica. Claramente, uma mutação nula resulta de um fenótipo 
severo, e uma mutação pontual no gene da ETF resulta numa menor 
actividade enzimática conduzindo a uma deficiência funcional ao nível celular. 
Neste casos, a alteração do aminoácido provavelmente determina alterações 
conformacionais na proteína que está relacionada com a patologia. Este efeito 
é mais proeminente nos pacientes com MADD de expressão tardia, nos quais 
a patologia não é continua, manifestando-se apenas em períodos de doença 
ou stress catabólico. Assim torna-se necessário um estudo para uma melhor 
compreensão da variabilidade da expressão clínica da MADD. 
 
 Uma ampla análise in silico foi realizada em 18 mutações pontuais, 
associadas à MADD, na ETF. A análise revelou que as mutações podem ser 
agrupadas essencialmente em dois grupos: 1) mutações que afectam a 
dobragem proteica e a estabilidade conformacional intrínseca; 2) mutações 
que perturbam actividade enzimática e a interacção com as desidrogenases. 
Três destas mutações, ETFβ Cys42Arg, Asp128Asn e Arg191Cys, que 
tipificam diferentes cenários no que diz respeito ao fenótipo clínico, foram 
alvo de um estudo detalhado. Esta parte do trabalho teve como objectivo 
obter as proteínas variantes da ETF de modo a testar o efeito das mutações 
na estrutura, dobragem, actividade enzimática, e interacção com co-enzimas 
funcionalmente relevantes.  
 A variante ETFα-Cys42Arg, associada a um fenótipo severo da patologia, 
afecta directamente o local de ligação do co-factor AMP, e os contactos entre 
as duas subunidades, logo resulta numa deficiente dobragem proteica. A 
variante foi heterologamente expressa em E. coli observando-se que a proteína 
 xvii 
produzida se encontra na fracção insolúvel, na forma de agregados. 
Recorrendo à co-expressão com chaperões (GroEL/GroES e 
dnaK/dnaJ/GrpE)) foi possível expressar a proteína na fracção solúvel, mas 
não permitiu restaurar a actividade enzimática, provavelmente devido a uma 
inserção deficiente dos co-factores (AMP e FAD). 
 Duas variantes associadas com fenótipos menos severos, ETFβ 
Asp128Asn e ETF-Arg191Cys, foram heterologamente expressas e 
purificadas a partir da fracção solúvel. Usou-se uma combinação de métodos 
bioquímicos e biofísicos de modo a compreender o impacto das mutações na 
dobragem, estabilidade conformacional e na eficiência da transferência 
electrónica. Ambas as variantes dobram com uma estrutura semelhante à da 
proteína selvagem, no entanto, ambas têm a actividade enzimática diminuída 
assim como a estabilidade conformacional. A mutação Asp128Asn tem um 
maior efeito na estabilidade conformacional, uma vez que o resíduo 128 está 
localizado perto da interface do dímero e tem contactos com resíduos que 
pertencem ao local de ligação do FAD. Por outro lado, o decréscimo da 
actividade da variante ETFβ-Arg191Cys parece resultar de ineficiente 
interacção com as desidrogenases, pois a mutação está localizada na interface 
do complexo (ETF-desidrogenase).  
 A combinação da análise in silico das mutações com os resultados 
experimentais permitiu estabelecer “hotspots” estruturais na ETF, que são 
úteis para estabelecer uma correlação entre a variabilidade genética e o 
fenótipo.  
 Mutações que conduzem a fenótipos clínicos menos severos, como as 
seleccionadas neste estudo, são frequentemente associadas a actividade 
enzimática deficiente e reduzida inserção de FAD. O uso de suplementos de 
vitamina B2 no resgate funcional de flavoenzimas da β-oxidação dos ácidos 
gordos tem se tornado cada vez mais recorrente. A elucidação deste processo 
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tem sido possível devido aos diversos estudos realizados durante as últimas 
décadas, que variam desde a análise de proteínas purificadas, análise 
proteómica a células de pacientes e aos modelos animais e celulares. A 
consequência imediata da suplementação com riboflavina é um aumento na 
disponibilidade celular de FAD, que é o co-factor de várias enzimas de β-
oxidação dos ácidos gordos. 
 Este aspecto foi investigado em detalhe usando a variante ETFβ-
Asp128Asn como modelo. Os dados do relatório clínico do paciente 
homozigótico para esta mutação indicam que ele desenvolveu sintomas 
severos da doença, em associação com uma infecção viral e febre. Em 
concordância com os dados clínicos observou-se que a variante é inactivada 
termicamente para temperaturas acima de 37 ° C. Descobriu-se que a inserção 
de FAD in vitro melhora substancialmente a dobragem e estabilidade da 
variante. Além disso, a presença de um excesso de flavina, numa 
concentração idêntica à presente nas mitocôndrias de músculo de pacientes 
que tomam oralmente vitamina B2, impede a digestão proteolítica da variante 
através da estabilização proteica. Para reproduzir uma situação da febre in 
vitro, fez-se o estudo da inserção de flavina a 39 °C. A presença de FAD gera 
uma conformação mais estável e retém a actividade da proteína, actuando 
deste modo como um chaperão farmacológico.  
 Estes resultados fornecem uma ferramenta estrutural e funcional que 
pode ajudar a elucidar a importância do aumento de FAD na célula obtido 
pelo suplemento com vitamina B2. 
 Para além das mutações associadas à patologia, uma série de variantes 
polimórficas foram identificadas nas enzimas da β-oxidação dos ácidos 
gordos. Em particular, foi identificado uma variação polimórfica na 
subunidade alfa da ETF, que leva à incorporação de uma treonina ou uma 
isoleucina na posição 171. Um estudo prévio mostrou que pacientes que 
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sofrem de uma forma ligeira de deficiência da desidrogenase de acil-CoA de 
cadeia longa (VLCADD) apresentam uma sobre-representação do 
polimorfismo ETFα-Thr171, sugerindo que o polimorfismo pode contribuir 
para o fenótipo, através de um mecanismo molecular que ainda não está 
clarificado. Sendo assim, procedemos ao estudo do efeito da variação do 
polimorfismo ETFα-171Thr/Ile na dobragem e na dinâmica da ETF durante 
stress térmico.  
 Os resultados mostraram que as duas variantes têm a mesma estabilidade 
termodinâmica (Tm= 58 °C) embora a ETFα-Thr171 apresente uma menor 
temperatura de inactivação (Tminact= 49 °C) em comparação com a variante 
ETFα-Ile171 (Tminact=58 ° C). Sob stress térmico a variante ETFα-Thr171 é 
mais propensa a rápida dissociação de FAD e desestabilização 
conformacional, levando ao aumento de uma população heterogénea da 
variante. Além disso, a variante ETFα-Thr171 apresenta uma maior dinâmica 
conformacional durante stress térmico e ao fim de 2 horas a 39ºC perde 
metade da sua actividade, enquanto a variante ETFα-Ile171 consegue manter 
a sua actividade por volta dos 85%. O chaperão GroEL consegue reverter 
este efeito na ETFα-Thr171 capturando e re-arranjando 
conformacionalmente a variante termicamente desestabilizada, observado pela 
retenção da actividade enzimática. Deste modo, conclui-se que a posição 
polimorfica tem um impacto na conformação e função proteica durante stress 
térmicos, que é um estimulo metabólico comum para a manifestação destas 
doenças metabólicas.  
 
 A dissertação tem o propósito de contribuir para uma compreensão 
molecular e funcional da MADD. Os dados recolhidos neste estudo foram 
correlacionados com os dados disponíveis sobre a genómica, biologia celular 
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e relatórios clínicos de pacientes com MADD, permitido acrescentar 
conhecimento sobre os efeitos moleculares subjacentes a esta patologia. 
Eventualmente, os resultados obtidos irão contribuir para a aplicação de 
novas estratégias terapêuticas e melhorar os métodos de diagnóstico. O 
conhecimento básico adquirido neste estudo pode também contribuir para 
uma melhor compreensão de outras doenças relacionadas com mutações 
pontuais. 
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ABBREVIATIONS 
 
ACDH Acyl-CoA dehydrogenases 
AMP Adenosine monophosphate 
ATP Adenosine triphosphate nucleotide 
CD Circular dichroism 
Cm Midpoint of chemical denaturation curve 
DLS Dynamic ligth scattering 
ETF Electron transfer flavoprotein 
ETF-QO Electron transfer flavoprotein ubiquinone 
oxidoreductase 
FAD Flavin adenine dinucleotide 
FAO Fatty acid oxidation 
FMN Flavin mononucleotide  
FeS Iron-sulphur 
Hsp Heat shock protein 
KD Dissociation constant 
MCAD Medium-chain acyl-CoA dehydrogenase 
MADD Multiple acyl-CoA dehydrogenase deficiency 
NAD Nicotinamide adenine dinucleotide 
PQC Protein quality control 
SCAD Short-chain acyl-CoA dehydrogenase 
SPR Surface plasmon resonanse 
Tm Midpoint of thermal denaturation curve 
VLCAD Very long-chain acyl-CoA dehydrogenase 
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1.1. The protein folding problem 
 Proteins are the most abundant macromolecules in biology, and are one 
of the key components of the cell, participating virtually in every cellular 
process. These macromolecules are needed in a wide diversity of process such 
as: catalysis, structural and mechanical functions, cell signalling and immune 
response. 
 In cells, proteins are synthesized in ribosomes as linear chains of amino 
acids, from information contained within cellular DNA. Following their 
biosynthesis, and in order to function, they have to acquire a specific three-
dimensional structure; this process is called the protein folding.  
 During the 1960’s, Anfinsen and co-workers, showed that RNase A, a 125 
amino acid long protein, could fold spontaneously in vitro, without the 
involvement of any other cellular component [1]. From this observation it 
was postulated that the information contained in the primary sequence of a 
protein dictates the structure of its native conformation [1-2]. Moreover, 
Anfinsen proposed that the polypeptide chain folds under the driving force of 
a free energy gradient, until the thermodynamically most stable conformation 
is reached [2].  
 Simultaneously, Levinthal focused on the kinetics and dynamics of the 
folding process. He rose the question that if the folding mechanism would be 
a completely random sampling passing all possible conformations, a protein 
with 100 amino acids would take 1029 years to fold. Assuming that sampling 
of a single conformation would be as fast as single molecular vibration(10-13s), 
is clearly that this would be inconsistent with the short time scale 
(milliseconds to seconds) that a protein takes to fold [3]. This is known as the 
Levinthal Paradox, and led the author to suggest that proteins must instead 
fold through specific pathways, during the folding process [4].  
 Over the last 50 years extensive research has been carried out in order to 
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understand the folding mechanism, and several models have been proposed, 
some of which will be briefly addressed here.  
 The classical nucleation model, proposed by Wetlaufer in 1973, suggested 
that at the early stages of the folding process, neighbouring residues would 
form elements of secondary structures that would act as nuclei from which 
the native structure would propagate, in a stepwise manner [5]. Subsequently, 
Karplus and Weaver proposed the diffusion–collision model, in which 
secondary structure elements could form independently of the tertiary 
structure, and would then diffuse until collide and assemble to form tertiary 
contacts (Fig. 1.1) [6]. A variation of the latter is the framework model [7]. 
The hydrophobic collapse model postulated that a protein would rapidly 
collapse around its hydrophobic residues and rearrange starting from that 
restricted conformational space (Fig. 1.1) [8-9]. The framework and the 
hydrophobic collapse models suggested the existence of intermediates, and at 
this point the presence of these species was taken as essential for the folding 
process to occur.  
 
 
 
 
 
 
 
Figure 1.1: Pathways of protein folding. Diffusion-collision model: collision of pre-formed 
elements of secondary structure guides the formation of tertiary structure; hydrophobic 
collapse model: collapse around hydrophobic residues followed by a rearrange to form 
secondary structures; nucleation-condensation model: extended nucleus formation precedes 
secondary structure interactions. From [10]. 
 
 However the finding that small proteins, like the 64-residue long 
chymotrypsin inhibitor 2, fold via a simple two-state kinetic mechanism 
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without formation of any intermediate at equilibrium, lead to the nucleation-
condensation model (Fig. 1.1) [11]. This model combines concepts from the 
framework and the hydrophobic collapse models, suggesting that secondary 
structure is guided by native like tertiary interactions.  
 
1.1.1. Energy landscapes 
 Nowadays, the majority of the authors accept the theoretical formulation 
of energetic funnel to illustrate the mechanism of protein folding (Fig. 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Three 
dimensional representation 
of the folding funnel.  
Adapted from [12]. 
 
 In this view the protein folding process is analysed as a folding funnel, to 
illustrate that the number of possible conformations accessible to a protein 
becomes progressively smaller, as the number of native contacts increases 
[13]. The external border of the energy landscape is populated by the high 
energy denatured states (huge conformational entropy) that can flow through 
the funnel by alternative pathways until they reach, at the bottom, the native 
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conformation, the lowest energy state (Fig. 1.2) [12]. In general native 
contacts between residues are more stable than non-native interactions, so the 
number of possible conformations is reduced, and in principle a protein is 
able to find its lowest energy state [14]. In recent years, reports have described 
that even small proteins go down hill through the folding funnel, through 
structural intermediates due to the roughness of the funnel (Fig 1.2) [15-16]. 
The roughness of the folding funnel, which are local minima, is just a 
consequence of thousands of mutually supportive weak interactions that a 
native protein acquires during folding, that can not be satisfied simultaneously 
[16]. Consequently, the intermediates formed during the process can be 
productive for folding (on-pathway) or kinetic traps that would need major 
reorganization to acquire the native conformation (off- pathway) [17]. 
 In the folding funnel model although the polypeptide chain starts to fold 
from a broad range of conformations at the top of the funnel, it describes the 
folding process for a single chain at an infinite dilution. Therefore, the model 
does not take in to account the complex, highly crowed, molecular 
environment of the cell. Several in vivo studies on newly synthesized 
polypeptides showed that aggregates, such as inclusion body, are typically 
formed from partially folded conformations, rather than from native states or 
fully denatured chains [18-19]. In order to improve the funnel folding 
concept, to depict more accurately protein folding and aggregation 
phenomena in the cell, Clark has performed a new formulation of the energy 
landscape, including additional deep minima (Fig. 1.3) [20]. Partially folded or 
misfolded states, in particular off-pathway intermediates, will have a 
propensity to aggregate, because these forms typically expose hydrophobic 
amino acid and unstructured regions [21]. The intermolecular contacts are 
driven by hydrophobic forces and originate amorphous structures or highly 
ordered fibrillar aggregates, known as amyloid (Fig. 1.3). 
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Figure 1.3: Energy landscape 
scheme of protein folding and 
aggregation. The surface shows 
the huge number of conformations 
“funneling” towards the native state 
via intramolecular contact 
formation (purple area), or toward 
aggregates or amyloid formation via 
intermolecular contacts (pink area). 
The arrow represents the molecular 
chaperone rescue. Adapted from 
[21]. 
 
 
 The new areas depicted in the funnel model take into account, not only 
the off-pathway intermediates, but also illustrate the role of several cellular 
factors such as molecular chaperones and ribosomes that assist the folding 
process (see section 1.3) [20]. In this perspective, molecular chaperones 
would bind to partially folded polypeptide chains in a discrete zone near the 
junction between productive folding and aggregation (represented by the edge 
of the two colours, Fig 1.3) [20]. The interaction with molecular chaperones 
increases the efficiency of the folding reaction, or results in the capture of 
species that could otherwise go downhill into the aggregation pathway.  
 
1.2. The native state and protein stability  
 The native state adopts in solution a unique, highly ordered conformation 
in contrast to the unfolded state that is conformationally heterogeneous and 
usually unstructured. To achieve the native structure a protein must overcome 
the forces that favour the unfolded state, mainly conformational entropy, by 
increasing the number of intramolecular non-covalent interactions [22]. These 
forces, that favour the native state, are a sum of different interaction such as: 
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hydrogen bounds, ion pairs, van der Walls attractions and water-mediated 
hydrophobic interactions (Fig 1.4) [23].  
 
 
 
 
 
 
 
 
Figure 1.4: The various non-
covalent forces that can operate 
in a protein. From [24]. 
 
 In the native state the hydrophobic side chains pack in the interior of the 
protein, and other non-covalent interaction form in order to favour internal 
organization, thus lowering conformational entropy. Of particular interest are 
the hydrogen-bond networks formed by the polypeptide backbone that 
contribute to the formation of secondary structures, such as α-helix and β-
sheets [25]. Covalent and coordinate chemical bounds such as the ones 
formed in disulfide bounds, or prosthetic groups, for example heme and iron 
sulfur centres, also contribute to protein stability.  
 Under physiological conditions the native and unfolded state of a protein 
are in equilibrium (Fig. 1.5), and the free energy change (ΔG) of the reaction 
is usually referred as conformational stability of a protein [26]. The free 
energy change of the equilibrium is described by the following 
thermodynamic equation:  
ΔG = ΔH –TΔS 
where ΔH and ΔS represent the enthalpic and entropic variations, 
~ 3 kcal/mol
2-5 kcal/mol
5 kcal/mol 
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respectively, and T represents the temperature. Therefore, the native structure 
results from a delicate balance between large and opposing forces [22]. The 
folded conformation is favoured by the negative value of enthalpy due to 
internal interaction, and the unfolded state is favoured by a positive value of 
conformational entropy.  
 
 
 
 
 
Figure 1.5: Schematic representation of a folding-unfolding reaction. The reaction 
represents a two-state process without the formation of intermediates. 
 
 Noteworthy,  the native state is known to be only marginally stable and 
the difference in energy between native and unfolded states is only 5-15 
kcal.mol-1[27]. This difference in energy is within the magnitude of only a few 
non-covalent interactions.  
 The determinants of native state stability in aqueous solutions are the 
primary sequence of the protein as well as the variable conditions of pH, 
temperature, and concentrations of salt and ligands [28]. Manipulation of 
environment conditions promoting protein unfolding, such as rise in 
temperature, variation of pH, or addition of a chemical denaturant, will shift 
the equilibrium to the unfolded state. (Fig. 1.5 and 1.6) [25]. The unfolding 
reaction begins with small changes in the folded conformation, such as 
increase in flexibility and localized conformational alterations, to a point 
where massive alterations occur, the transition midpoint (Fig. 1.6). At the 
midpoint of the unfolding curve half of the protein molecules are in the 
unfolded state, and the ΔG is zero [25]. The abruptness of the transition is an 
evidence of the cooperativity of the unfolding reaction. The cooperative 
Unfolded Folded
Unfolding
Folding
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effect results from the fact that although each interaction has a small 
stabilization effect, the disruption influences the surrounding interactions, 
thus lowering the equilibrium constant at each point.  
 
 
 
 
 
 
 
Figure 1.6: Representation of a 
hypothetical denaturation curve. 
The cartoons represent the native 
state (botom) and the unfolded state 
(Top). Tm or Cm represent 
temperature or chemical denaturant 
concentration at the midpoint of the 
unfolding curve. 
 
 The folded and unfolded states have different structural features therefore 
a diversity of biophysical methods are available to monitor the unfolding 
reaction. The experimental techniques, the time scale that can be monitored 
and the information that can be extracted from each technique is summarized 
in table 1.1 [16]. From the experimental data obtained by the different 
techniques it is possible to draw curves similar to the one represented in 
figure 1.6, from which thermodynamic parameters of the reaction can be 
obtained. The midpoint transition determined from the curves, such as 
temperature (Tm) or concentration of chemical denaturant (Cm), is used for 
comparing protein stability.  
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Table 1.1 Experimental techniques that have been applied to the study of 
protein folding [16]. 
Technique Timescale Information content Ref 
Intrinsic tryptophan 
fluorescence > nsª 
Environment of tryptophan 
(through measurement of intensity 
and λmax) 
[29] 
Far UV CD > μsª Secondary-structure content [30] 
Near UV CD > μsª Packing of aromatic residues [30] 
Raman spectroscopy > μsª Solvent accessibility, conformation of aromatic residues [31] 
Infrared 
spectroscopy > nsª Secondary-structure content [32] 
ANS  > μsª Exposure of aromatic surface area [29] 
FRET > psª 
Molecular ruler, dependent on the 
distance between two fluorophores 
(r–6 dependence assuming free 
rotation of the dyes) 
[33] 
FCS > ps Diffusion time (and hence size and shape) [34] 
Anisotropy > μsª 
Correlation time measurements 
provide information about shape 
and size of molecule 
[29] 
Small-angle X-ray 
scattering > μsª Radius of gyration [35] 
Absorbance > nsª Environment of chromophore [36] 
Real-time NMR > min Structural information via chemical shifts and measurement of NOEs [37] 
Native-state 
hydrogen 
exchange 
h Global stability, detection of metastable states [38] 
Pulsed H/D 
exchange by 
NMR 
> ms 
Hydrogen exchange protection of 
folding intermediates on a per-
residue basis 
[38] 
Pulsed H/D 
exchange by 
ESI-MS 
> ms Hydrogen exchange protection of folding populations [39] 
NMR relaxation 
methods ~ ms 
Nonrandom structure in denatured 
states and conformational 
exchange between different species
[37, 
40] 
Protein engineering 
Depends 
on probe 
used 
Role of an individual residue in 
determining the rate of folding and 
stability of a species of interest 
[41] 
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1.3. Protein folding in vivo 
 In vivo the protein folding process can begin when the nascent polypeptide 
is still attached to the ribosome, in a co-translational manner [42]. 
Alternatively,  part of the folding process may take place in the cytosol, and 
many proteins fold in specific compartments, such as the endoplasmic 
reticulum (ER) [43]. Co-translational folding restricts the conformational 
space, so the polypeptide chain will probably start the folding process from a 
more defined trajectory, preventing non-productive pathways [20]. In other 
cases, co-translational folding can have a negative impact, as some proteins 
have extensive contacts between amino acids in the native structure that are 
distant in primary sequence. The translational process is relatively slow (~15-
75 s for a 300-residues protein) potentially leading to the formation of non-
native intramolecular contacts between the N-terminal portion that is being 
elongated, or intermolecular ones with other molecules in the surroundings 
[21]. In this context, high macromolecular concentration inside the cell 
(300/400 mg.ml-1) play an important role in the process [44]. To overcome 
the problem of molecular crowding and increase the efficiency of the folding 
process, nature has developed specific protein machineries - the protein 
quality control system (PQC)- that assists the folding process with no effect 
in the selection of the native structure (Fig. 1.7).  
 
 
Figure 1.7: Schematic function 
of the protein quality control 
system (PQC). Folding 
chaperones promote folding, 
holding chaperones maintain 
solubility, unfolding chaperones 
unfold misfolded proteins or 
disaggregate aggregates and inject 
them into proteolytic chambers. 
From [45]. 
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 The PQC system has the ability to supervise folding, disable aggregation, 
and remove misfolded or damage polypeptide chains before they exert toxic 
effects (Fig. 1.7) [45]. The system is composed by molecular chaperones, 
specialized intracellular proteases and accessory factors that regulate the 
activity of chaperones and proteases or provide communication between the 
various components [45]. Moreover, the PQC system has the ability to 
operate during or after protein synthesis, or upon unfolding to facilitate 
proteins to achieve their correct native structure, or to be degraded. Next, a 
brief description on different components of the PQC will be presented. 
 
1.3.1. Role of molecular chaperones in de novo folding 
 Chaperones that assist de novo protein folding in the cytosol can be divided 
in two classes: chaperones that stabilize nascent polypeptides on ribosomes 
and initiate folding, and chaperones that act downstream in completing the 
folding process [46-47].   
 Included in the first class are chaperones that bind directly to the large 
ribosomal subunit in close proximity to the polypeptide exit site, such as the 
Trigger factor in bacteria, and a specialized Hsp70 system called RAC 
(ribosome associated complex) and NAC (nascent chain associated complex), 
in eukaryotes [48-50] (Fig. 1.8). Trigger factor has an N-terminal domain that 
binds to the ribosome, a domain with prolyl isomerase activity and a C-
terminal chaperone domain. This protein binds not only to the ribosome, but 
also to the nascent chain forming a complex with the elongation chain, which 
dissociates when synthesis is complete [51-52]. In mammals, RAC is a 
heterodimeric complex formed by a J-protein, the Mpp11 that associates with 
the ribosome, and Hsp70L1 [53-54]. NAC is also a heterodimeric protein 
composed of α and β subunits [55]. The β subunit binds to the ribosome and 
both subunits contact with nascent polypeptides [56]. NAC prevents the 
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association of the ribosome with the protein translocation machinery of the 
ER membrane. Therefore, it is believed that it regulates the destiny of the 
newly synthesized polypeptides, whether they are released into cytosol or are 
translocated to the ER [57]. This class of chaperones binds linear chain 
segments enriched in hydrophobic amino acids, and acts by preventing 
premature chain compaction, and by maintaining the elongation of the 
polypeptide in a non-aggregated state until the chain is able to fold correctly 
[21]. 
 
Figure 1.8: Models of molecular chaperones involved in de novo protein folding. a) In 
bacteria the Trigger factor, ribosome bounded, can move with the nascent polypeptide for a 
limited time promoting folding. Some proteins need further assistance by either Hsp70 
chaperone system (dnaK together with its cochaperone dnaJ and the nucleotide exchange 
factor GrpE), or by the Hsp60 (chaperonin GroEL together with is cochaperone GroES). b) 
Eukaryotes have two ribosome bound systems, the NAC and the RAC (Mpp11 and 
Hsp70L1). As in bacteria some proteins will further be assisted by Hsp60 family of 
chaperonins (TriC/CCT) or the Hsp70 system (Hsp70, Hsp40 and NEF). GimC/Prefoldin is 
implicated in the folding of actin and tubulin. Adapted from [48]. 
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 Moreover, Brandt et al have recently provided new insights into the 3D 
organization of the bacterial polysome, demonstrating that its three 
dimensional organization also contributes to prevent interaction of the 
elongated chain with chains from adjacent ribosomes (Fig. 1.9) [58]. The 
pseudo helical arrangement of the polysome places the exit channels of each 
ribosome further apart, thus minimizing unspecific interactions between 
nascent chains.  
 
 
 
 
 
 
 
Figure 1.9: Model of nascent 
chain configurations in a 
representative polysome. From 
[58].  
 
 
 The second class of chaperones, the Hsp70 family (dnaK in bacteria and 
Hsc70 in mammals) acts as a second line of folding assistants (Fig. 1.8). These 
chaperones do not bind to the ribosome, and will interact with longer nascent 
chains during co- or post-translational folding through ATP regulated binding 
cycles. Proteins from this family have an N-terminal ATPase domain and a C-
terminal peptide binding domain with high affinity to hydrophobic structural 
features. The Hsp70 family in general acts in conjunction with Hsp40 
proteins (dnaJ in bacteria) (Fig. 1.8) [59-62]. These molecules function by 
presenting substrates to the chaperone, and at the same time they stimulate its 
ATPase activity, freezing it into an ADP-bound high affinity state. Apart 
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from these cofactors, a nucleotide exchange factor is also involved, Bag-
1/GrpE in mammals and bacteria respectively, to stimulate chaperone activity 
[63-65]. The Hsp70 family is also very important because it organizes the 
chaperone network and distribute subsets of proteins to other downstream 
chaperones, such as Hsp60 (GroEL in bacteria, Hsp60 in mitochondria and 
TriC/CCT in cytosol in eukarya) and Hsp90 families.  
 
1.3.2. Folding, holding and unfolding chaperones  
 The chaperonins, Hsp60 family, assemble into double-ring structures, 
functioning in an ATP dependent way, by enclosing the substrates during the 
folding event, so they are protected from aggregation [47, 66-67] (Fig. 1.8). 
These chaperonins are composed of 14 subunits arranged as two stacked 
rings with a sevenfold rotational symmetry. In general, GroEL and Hsp60 
also need a cofactor, respectively GroES and Hsp10. In eukaryotes, the 
chaperonin interacts directly with Hsp70 and other upstream factors like 
prefoldin, increasing in this way the folding efficiency by directly recruiting 
nascent chains that are unable to fold with the chaperone alone [68-69].  
 Hsp90 acts downstream Hsp70, preventing aggregation of unfolded 
polypeptides [70-71]. These chaperones are proposed to play an important 
role in quality control, assembling into large multichaperone complexes that 
have a broad range of action, including interactions with a wide collection of 
cell-signalling molecules and transcription factors [72-73].  
 In the cytosol, there are also chaperones that lack ATPase activity and 
need to transfer their substrates to folding chaperones to achieve folding [45]. 
These are usually named ‘holding’ chaperones, and include the small heat 
shock proteins (sHsp). These are 12-42kDa proteins that usually form 
oligomers that can range from 9 to 50 subunits, and that under heat-shock 
conditions, bind misfolded proteins [74].  
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 Moreover, the Hsp100/Clp family has an unfolding activity but it can also 
induce structural changes in its substrates, that ultimately change the 
substrate’s biological activity [75]. This family acts on folded and assembled 
complexes and on improperly folded and aggregated proteins [75]. These 
chaperones have the ability to unfold proteins so that they can either be 
folded in their correct form or be otherwise degraded.  
 
1.3.3. The Proteolytic system 
Apart from the molecular chaperones, the PQC also contains the degradation 
machinery constituted by proteases. These proteins are restricted to specific 
locations in the cell, that can only be accessed by polypeptides targeted to 
degradation [45]. The quaternary structure of the different proteases is very 
similar, and resembles a barrel formed by the proteolytic subunits associated 
into oligomeric rings that stack up on each other [76]. The proteolytic sites 
are buried within the central cavity and are only accessible through narrow 
gates, obstructing folded proteins from entering. One of the most studied 
members of this family is the proteasome, a central protease in non-lysosomal 
ubiquitin-dependent protein degradation, which is involved in protein quality 
control, antigen processing, signal transduction, cell cycle control, cell 
differentiation and apoptosis [76].  
 
1.3.4. Endoplasmatic reticulum (ER) chaperones 
 Protein folding in the ER follows analogous chaperone-mediated 
pathways as those described for the cytosol, with the addition that in this 
compartment a complex series of glycosylation and deglycosylation processes 
takes places, which prevent misfolded proteins from being secreted. One of 
the ER chaperones is BiP, a member of the Hsp70 family, that binds 
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transiently to newly synthesized proteins and in a more permanent way to 
misfolded, underglycosylated or unassembled proteins that can not be 
transported from the ER [77]. Other two important ER chaperones, calnexin 
(CNX) and calreticulin (CRT), recognize monoglucosylated glycan chains on 
proteins [78]. CNX is a membrane bound protein, and in addition to its 
chaperone activity, it participates in quality control by delaying the export of 
incompletely assembled proteins from the ER [79].  
 
1.4. Regulation of protein homeostasis 
 To ensure protein homeostasis, the cell contains a set of pathways that 
make up the so called proteostasis network, which regulates protein synthesis, 
folding, trafficking, aggregation, disaggregation and degradation (Fig. 1.10). 
This network has the ability to regulate conformation, concentration, binding 
interactions and location of individual proteins [80]. More than 1000 general 
and specialized chaperones, folding enzymes, degradation and trafficking 
components integrate this network [81]. In normal conditions the proteostasis 
network ensures that each protein reaches its final target in the cell or is 
eliminated in order to prevent cell damage or dysfunction. 
 
 
Figure 1.10: The proteostasis 
network. Illustration of the layers 
of interaction in protein 
homeostasis. First layer is 
constituted by components that 
operate in direct folding and 
pathways that select proteins for 
degradation. Second layer includes 
signalling pathways that influence 
the first layer. Third layer 
comprise factors that affect the 
activity of the two inner layers. 
From reference [81]. 
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 The control of these pathways is accomplished by signalling pathways that 
directly regulate the concentration, distribution and activities of the 
components that make up the proteostasis system. These signalling pathways 
include: the unfolded protein response (UPR), the heat shock response 
(HSR), pathways that regulate the Ca2+ concentration on the ER, 
inflammatory response and histone deacetylase (Fig. 1.10).   
 Several components of the first layer were object of discussion in the 
section above; here a brief overview on the signalling pathways will be given.  
 Prolonged exposure to stress can cause proteins to unfold, misfold or 
aggregate leading to an inefficient function of the cell, demanding an 
increased synthesis of the proteins from the quality control system. The heat 
shock response (HSR) controls the proteostasis reaction to these changes at 
the cytoplasmic level [80]. This signalling pathway is regulated at the 
transcriptional level by the activity of a family of heat shock transcription 
factors (HSF) [82]. Transcription of heat shock genes is activated by various 
acute and chronic conditions such as elevated temperatures, heavy metals, 
small molecules, infection, and oxidative stress [83]. Several disease states like 
inflammation, ischemia, tissue wounding and repair, cancer, protein 
mutations and neurodegenerative diseases are also associated with increase 
expression of proteins from the heat shock response [83]. Upon activation, an 
instant induction of genes encoding molecular chaperones, proteases, and 
other proteins associated with protection and recovery from cellular damage 
associated to misfolded proteins result in a rapid increase of the cellular levels 
of these proteins. The heat shock gene superfamily includes Hsp100/Clp, 
Hsp90, Hsp70, Hsp60, Hsp40, and small heat shock protein (sHsp) families, 
as referred above. 
 The HSR has been implicated in many neurodegenerative diseases 
because the association of theses chaperones with intracellular aggregates 
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formed in these types of disorders was identified. It was observed that for 
example the protein huntingtin aggregates transiently in association with 
Hsp70, and that the association/dissociation properties identified for these 
complexes are similar to chaperone interactions with unfolded polypeptides 
[84]. Also, it is important to mention that neurodegenerative disorders often 
occur later in life, when the heat shock genes seem to be poorly induced [85-
86]. Cancer is another type of disorder where the HSR as been implicated. 
Tumor cells typically express higher levels of heat shock proteins compared 
with non-transformed cells, suggesting that the abnormal expression of 
chaperones is associated with the tumorigenic state [87]. 
 The ER is extremely important to cell regulation as all proteins that enter 
the secretory pathway first enter in the ER, where they fold and assemble 
[88]. The “unfolded protein response” (UPR), is the ‘supervising’ pathway for 
the quality of the folded proteins in this organelle. Unfolded or misfolded 
proteins identified by the UPR are retained within the ER lumen in complex 
with chaperones, or are targeted for degradation through the ubiquitin-
proteasome, the ER-associated degradation (ERAD) [89].  
Cystic fibrosis is related to the UPR response, this is a loss-of-function 
disease associated to mutations on the cystic fibrosis transmembrane 
conductance regulator (CFTR), a transmenbranar protein that function as a 
cAMP-stimulated chloride channel [90] This is the most fatal genetic disease 
in Caucasians and is caused by mutations on CFTR,  a deletion of the 
phenylalanine in position 508 (Δ508) is the most prevalent one [91]. This 
mutation causes a defect in protein maturation and on its transit to the plasma 
membrane, due to a change in the protein folding pathway [92]. Due to the 
UPR actions in the ER misfolded proteins are recognize, retained in ER and 
rapidly degraded by the ubiquitin-dependent proteasomal system, thus Δ508 
is rapidly degraded [93].  
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1.5. Emerging strategies in proteostasis regulation 
 A decreased ability of the proteostasis network to control the diverse 
pathways will jeopardize the cell, and can potentially affect in a progressive 
way, cell, tissue, organ or the organism function. Different factors can 
compromise protein homeostasis such as genetic and epigenetic pathways, 
physiological stressors, and metabolites that affect activity of the proteostasis 
network components (Fig. 1.10). When the cell is no longer able to restore 
proteostasis, the so call loss- or gain- of function effects emerge. A loss of 
function disorder is characterized by misfolded proteins that have decreased 
function and/or are degraded rapidly resulting in a decreased steady-state 
amount of protein. This type of disorders comprises several inherited 
autosomal recessive disorders, such as cystic fibrosis, phenylketonuria, fatty 
acid oxidation defects, and Gaucher’s disease. On the other hand, gain of-
toxic function diseases are associated with intra- or extra-cellular 
accumulation of protein aggregates, like in amyotrophic lateral sclerosis, 
Alzheimer’s, Parkinson’s and Huntington’s disease. The pathology occurs 
because the cell is unable to degrade misfolded proteins, leading to the 
formation of toxic species, in the form of oligomers, aggregates and/or 
amyloid fibres. 
 A novel approach to treat protein functional disorders is to regulate at 
different level the proteostasis network by manipulating the innate biology of 
the cell with protein replacement, protein stabilization or adaptation of 
proteostasis network using proteostasis regulators (Fig. 1.11).  
 Protein replacement is currently used for treatment in loss-of-function 
diseases; therapy is process injecting patients with a recombinant form of the 
wild type variant of the deficient protein [94-96]. The major limitations of this 
therapy is the fact that the injected proteins have to cross several barriers to 
get to the target site, and in most cases only a lower amount of the 
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recombinant protein reach it destination. The case of lysosomal disorders is 
one of these examples in which only 5 % of the protein injected enter the 
lysosome [97]. However, in neuropathic forms of these diseases this therapy 
is completely useless because recombinant proteins can not cross the blood-
brain barrier [98].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Proteostasis Regulation. Schematic representation of the different control 
points of protein homeostasis: red arrows represent the proteostasis pathways, magenta 
circles represent proteostasis regulators and green squares represent pharmacological 
chaperones. From [80]. 
 
 Modulation of the proteostasis network by direct protein stabilization can 
be achieved using low molecular weight compounds that chemically-mediate 
protein stabilization or refolding. These compounds are called chemical 
chaperones, or for a more restricted group that interact with a specific protein 
some authors denominate them as pharmacological chaperones (Fig. 1.11) 
[93, 99-100]. This restricted class comprises protein cofactors, including metal 
ions, ligands, competitive inhibitors, and agonist/antagonist. The binding of a 
cofactor, by covalent or non-covalent interaction, contribute to the net of 
stabilizer interaction within the tertiary structure of a protein, so establish this 
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interaction will prevent an increase in the intrinsic breathing of the protein 
that could lead to protein misfolding [101]. This is the case of P-glyco-
protein, an energy dependent transporter, for which as been shown that 
several mutants in the presence of substrates (vinblastine and capsaicin) and 
inhibitors (cyclosporine and verapamil) increase the presence of functional 
protein in cell surface, probably due to a stabilization of a folding 
intermediate near native conformation [102-103]. Studies on MNK a copper 
transporting p-type ATPase showed that the presence of copper can increase 
stability of the protein [104]. 
 Moreover, cells had already developed their own chemical chaperones to 
deal with environmental stress; these compounds are the cellular osmolytes 
and comprise carbohydrates, free amino acids and methylamines. The first 
two groups include glycerol, sorbitol, arabitol, trehalose, glycine, alanine, 
proline, taurine that can accumulate to higher concentrations in the cell 
without affecting it normal function [101]. The methylamines such as betaine, 
trimethylamine N-oxide (TMAO) and glycero-phosphorycholine are 
produced to offset the protein denaturing effects of urea. Beside these 
chemical chaperones other hydrophobic compound can bound to proteins 
and stabilize their structure in a native like conformation. This is the case of 
sodium 4-phenylbutyrate (PBA), an orally bioavailable short-chain fatty acid, 
that can be used as an ammonia-scavenging agent in urea metabolism 
disorders and it also has beneficial effects in stabilizing CFTR and alpha-1 
antitrypsin (AAT) [105-106].  
 A broader strategy consists in the use of proteostasis regulators, molecules 
that rather regulate the concentration, conformation and/or location of a 
specific protein (or family of proteins), by manipulating one or more 
signalling pathways in order to rebalance the whole network (Fig. 1.11). These 
proteostasis regulators can be small compounds or biological molecules like 
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small interfering RNA (siRNA), cDNA, or proteins. It is described in 
literature that proteostasis regulators can modulate synthesis, folding, 
trafficking, disaggregation, and aggregation pathways [50, 107-117]. In fact, 
RNA interference studies have been use with success in cellular models of 
gain-of function disorders, like Alzheimer and Huntington’s disease. Also, 
small molecules like diltiazem and verapamil have been used to restore 
protein homeostasis in lysosomal storage disorders [98]. These two L-type 
voltage gate calcium channel blockers restore mutant lysosome enzyme 
function by modulating protein folding in the ER. Unlike the pharmacological 
chaperones that directly bind to the protein stabilizing the native form for 
trafficking to the Golgi and to lysosome, the proteostasis regulators diminish 
the Ca2+ content in the cytoplasm resulting in the increase of transcription 
and translation of several cytoplasmatic and ER chaperones, like BiP and 
Hsp40 that interact with lysosomal enzymes. One important aspect is the fact 
that diltiazem can cross the blood-brain barrier, in contrast to the protein 
replacement therapy [98]. Celastrol, a natural product derived from the 
Celastraceae family of plants, induced HSF1 protein expression leading to up-
regulation of cytoplasmatic chaperone network [117].  Some of the molecules 
know to act as chemical chaperones as already mentioned can also be called 
proteostasis regulators once they also can regulate folding and trafficking 
machinery, one exemple is the use of 4-PBA and taurine-conjugated 
ursodeoxycholic acid to alleviated ER-stress in cells and whole animals [118].  
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 Mitochondria are essential cell organelles whose one of the principal 
functions is to produce energy through the oxidation of carbohydrates, amino 
acids and fatty acids. Oxidation of sugar and fatty acids yields two-carbon 
fragments in the form of acetyl group of acetyl-coenzyme A (acetyl-CoA), 
which will enter the citric acid cycle to further oxidation to CO2. In the case 
of amino acids after losing the amino group, the α-keto acids will go through 
oxidation or, form three- and four-carbon units that will be converted to 
glucose. The energy produced during these oxidation cycles will be used to 
reduce electron carriers, like nicotinamide adenine dinucleotide (NAD) and 
flavin adenine dinucleotide (FAD). These carriers are re-oxidized in the 
respiratory chain in a series of reactions that are coupled with the synthesis of 
adenosine triphosphate (ATP). 
 Electron transfer flavoprotein (ETF) and electron transfer flavoprotein 
ubiquinone oxidoreductase (ETF-QO) are two extremely important 
mitochondrial proteins as they are the entry point of reducing power to the 
respiratory chain from fatty acid β-oxidation, as well as choline and amino 
acid catabolism.  
 A brief overview of the mitochondrial fatty acid β-oxidation will be given 
in the first section of the chapter, since ETF is at a key point of this pathway, 
acting as a hub. Following the general presentation of the pathway, special 
attention will be given to ETF and ETF-QO. On the third section of the 
chapter, fatty acid oxidation (FAO) disorders will be discussed, in order to 
frame the reader with these diseases, in which multiple acyl-CoA 
dehydrogenase deficiency (MADD) is included. The last section is dedicated 
to riboflavin (vitamin B2), as it is widely used in the treatment of several FAO 
disorders.   
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2.1. Mitochondrial fatty acid β-oxidation enzymes 
 Fatty acids are carboxylic acids with long straight or branched 
hydrocarbon chains, and they are very important in cells as they are needed 
for enzymes, hormones, cell membrane and as a source of energy. In 
mammals fatty acid oxidation provides a major source of ATP for the heart 
and the skeletal muscle [1-3]. In the liver, kidney, small intestine and also 
white adipose tissue, β-oxidation provides the formation of ketone bodies 
which are used as energy source on other tissues [4]. Fatty acid oxidation is 
particularly important during fasting, sustained exercise, stress, and during 
neonatal-suckling period, when glucose supplies become limited [5].  
 The cell can metabolize fatty acids by three different pathways that take 
place in the mitochondria or in the peroxisomes. The best characterized 
pathway is the mitochondrial fatty acid β−oxidation (Fig. 2.1). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic representation of the mitochondrial fatty acid β-oxidation 
pathway. Please see details in text.  
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 Fatty acids are activated in the cytosol in an ATP-dependent acylation 
forming acyl-CoAs. The very-long-chain and long-chain fatty acids cross the 
inner mitochondrial membrane as carnitine-derivatives mediated by three 
proteins, carnitine palmitoyl transferase I (CPT I), acyl-carnitine translocase 
(CAT) and carnitine palmitoyl transferase II (CPT II) (Fig. 2.1). Once in the 
mitochondrial matrix, the acyl-CoA fatty acids undergo dehydrogenation by 
acyl-CoA dehydrogenases with different chain-length specificities. These 
enzymes are located in the matrix, with the exception of very-long chain acyl-
CoA dehydrogenase that is associated with the inner membrane, and has high 
specificity for C12-C24 acyl-CoA fatty acids (Fig. 2.1). The subsequent steps 
are catalyzed by enoyl-CoA hydratase, 3-L-hydroxyacyl-CoA dehydrogenase 
and β-ketoacyl-CoA thiolase and lead to the formation of acetyl-CoA and 
fatty acyl-CoA two carbon shorter [4] (Fig. 2.1). Unsaturated fatty acids 
undergo the same reaction until the cis-configuration double-bound prevents 
the formation of a substrate for the acyl-CoA dehydrogenase and enoyl-CoA 
hydratase. At this point additional enzymes are required, like the 3,2 trans-
enoyl-CoA isomerase and 2,4-dienoyl CoA reductase 1. Fatty acids with an 
odd number of carbons are degraded in the same way, but the final product 
has three carbons, propionyl-CoA, which is converted to succinyl-CoA to 
enter the citric acid cycle.   
 Some enzymes of the first step of the fatty acid β-oxidation will be briefly 
described since these enzymes are ETF substrates (Table 2.1). The acyl-CoA 
dehydrogenases are homo-dimers (the membrane-associated very-long-chain 
acyl-CoA dehydrogenase (VLCAD) and acyl-CoA dehydrogenase no 9 
(ACAD-9)) or homo-tetramers (the soluble matrix enzymes short-chain acyl-
CoA dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase 
(MCAD) and long-chain acyl-CoA dehydrogenase (LCAD)). All these 
ACDHs carry one non-covalently bound FAD molecule per subunit and the 
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binding sites reside within each monomer, i.e., FAD interacts only one 
subunit at a time. 
 The ACDHs involved in fatty acid β-oxidation form a gene family with 
four additional acyl-CoA dehydrogenases involved in amino acid metabolism: 
glutaryl-CoA dehydrogenase (GCD) [6], isovaleryl-CoA dehydrogenase (IVD) 
[7], short-branched chain acyl-CoA dehydrogenase (SBCAD) [8] and 
isobutyryl-CoA dehydrogenase (IBD) [9]. These dehydrogenases also belong 
to the group of ETF substrates (Table 2.1).  
 
2.1.1. Medium-chain acyl-CoA dehydrogenase 
 MCAD is the most studied enzyme of the β-oxidation, and is responsible 
for the oxidation of fatty acids with a chain length between 6 to 10 carbons 
Table 2.1: Mitochondrial flavoenzymes properties. The proteins described in the table 
participate in electron transfer reactions with ETF.   
Protein Structure
Preferred 
Substrate(s) 
MIM 
Gene 
symbol 
Mutationa Ref 
VLCAD 3B96 C16 609575 ACADVL 65 [10]
LCAD n.a. C14 609576 ACADL  [11]
MCAD 1EGE C8 607008 ACADM 51 [12-13]
SCAD 2VIG C4 606885 ACADS 14 [14]
ACAD-9 n.a. C16:1 611103 ACAD9  [15]
GCD 1SIQ glutaryl-CoA 608801 GCDH 95 [16-17]
IVD 1IVH 3-methylbutyryl-CoA 607036 IVD 22 [18]
SBCAD 2JIF 
(s)-2-
methylbutyryl-
CoA 
600301 ACADSB 7 [19]
IBD 1RX0 isobutyryl-CoA 604773 ACAD8 18 [9]
608053 ETFA 13 
ETF 1EFV 
reduced  
acyl-CoA 
dehydrogenases 130410 ETFB 5 
[20-21]
ETF-QO 2GMJ ETF 231675 ETFDH 21 [22-23]
Accession numbers: Protein Data Bank  
a Number of missense mutation, data extracted from The Human Gene Mutation 
Database http://www.hgmd.cf.ac.uk/ac/index.php (accessed 30.08.10).  
n.a. not available 
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[24]. In 1986 Matsubara and colleagues allocate the ACADM gene to 
chromosome 1p31 [25]. As most of the mitochondrial proteins MCAD is 
nuclear encoded and synthesized in the cytosol as a precursor protein of 47 
kDa, the N-terminal leader peptide is cleaved after the import into 
mitochondria producing a mature protein of 44 kDa [26-28].  
 Native MCAD is formed by the assembly of 4 monomers, and each 
monomer is folded into three domains [29]. The N- and C-terminal domains 
are mainly α-helices packed together and the middle domain is formed by 
two β-sheets (Fig. 2.2). The flavin cofactor is positioned in the cleft between 
the β-domain and the C-terminal domain of one subunit and the C-terminal 
domain of the neighboring subunit. The soluble flavoprotein has a glutamic 
acid in position 376 as a catalytic residue, which is responsible for the α-
proton abstraction of the fatty acid [12].  
 
 
 
Figure 2.2: Representation of the 
structure of human MCAD. Protein 
structure is represented as cartoon with 
helices represented as cylinders and beta-
strands as arrows, cofactors are 
represented as orange sticks, and each 
subunit is represented by a different color. 
The structure was obtained from the 
Protein Data Bank (PDB: 1ege). 
 
 
 
 
 
2.1.2. Short-chain acyl-CoA dehydrogenase 
 The SCAD gene, located on chromosome 12q22, encodes a cytosolic 
precursor SCAD that is transported to mitochondria where the N-terminal 
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mitochondrial targeting peptide is proteolytically cleaved [30-32]. In vitro 
studies have shown that SCAD has two preferred substrates, hexanoyl- and 
butyryl-CoA. However, it is generally assumed that its physiological role is 
specific to butyryl-CoA, as in vivo none of the other ACDHs are active with 
this substrate [33].  
 The crystal structure of SCAD from rat was determined, and reveals an 
overall fold very similar with the other ACDHs [14]. A special feature of this 
acyl-CoA dehydrogenase is the presence of a glutamine in position 254 and 
threonine in position 364 that seem to shorten the substrate binding pocket, 
contributing to its substrate specificity [34].  
 
2.1.3. Very long-chain acyl-CoA dehydrogenase 
 In the 1990’s a enzyme specific for the oxidation of long-chain fatty acids 
was identified in rat liver [35], and one year later human VLCAD deficiency 
(VLCADD) (MIM 201475) was reported [36-38]. This enzyme catalyzes the 
first step of the β-oxidation of long-chain fatty acids with a chain length of 14 
to 18 carbons [39]. ACADVL gene was mapped to chromosome 17p11.2-
11.13 [40-41].  
 The crystal structure of this enzyme in complex with C14-CoA showed 
that the N-terminal domain has a fold similar to soluble ACDHS, and that the 
substrate binding pocket extends for an additional 12 Å in relation to the 
MCAD pocket, allowing it to bind to long chain substrates [10]. The authors 
also proposed that the disordered region in the crystal structure, from 
residues 441 to 476, is optimally positioned in the novel C-terminal domain 
for membrane interaction (Fig 2.3) [10]. 
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Figure 2.3: Representation 
of the structure of human 
VLCAD. Protein structure 
is represented as cartoon 
with helices represented as 
cylinders and beta-strands as 
arrows, cofactors are 
represented as orange sticks. 
The structure was obtained 
from the Protein Data Bank 
(PDB: 3b96). 
 
 
 
2.2. The ETF and ETF-QO hub 
2.2.1. Electron transfer flavoprotein (ETF) 
 In 1956, Crane and Beinert described a flavoprotein that was essential for 
oxidation of another flavoenzyme that oxidized fatty acyl derivatives of CoA 
[42]. At that time the authors decided to name that “new” protein electron 
transferring flavoprotein since it serves to transfer the electrons gained by the 
dehydrogenase to a conventional electron acceptor like indophenol, 
ferricyanide or oxygen.  
 In 1975 Hall and Kamin reported the purification, biochemical and 
spectroscopic properties of ETF and several dehydrogenases from pig liver 
mitochondria [43]. ETF was described as containing two subunits and two 
FAD mol per mol and a global molecular weight of 58 kDa [43]. Seven years 
later Thorpe et al purified ETF from pig kidney and reported for the first time 
that ETF binds only one FAD per dimer [44]. A subsequent report on the 
purification of pig liver ETF corroborated this finding establishing that in fact 
mammalian ETF has only one FAD per dimer [45]. Only in 1993 it was 
Men      membrane
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uncovered that ETF has an additional AMP-binding site, and that this 
cofactor has no influence in the activity of the protein [46]. Moreover, it 
seems that the AMP cofactor is important for the assembly of the holo 
structure [47].  
 In parallel to this structural and biochemical characterization, it was found 
that both ETF subunits are nuclear encoded, the α-subunit is synthesized as a 
precursor protein of 35 kDa, while the β-subunit is synthesized in cytosol in a 
form that is indistinguishable from the mitochondrial form [48]. The α-
subunit precursor sequence is cleaved after import into the mitochondria 
yielding a mature form with 32kDa [48]. In this work, abnormal α-ETF 
synthesis was for the first time described as the primary lesion causing 
MADD (see below). The cDNA encoding the α and β human ETF was 
subsequently cloned, and the genes mapped to chromosomes 15q23-q25 and 
19q13.3, respectively [49-50]. 
 The crystal structure of human ETF was solved to 2.1 Å resolution, 
reveling that ETF consists of three distinct domains: domain I is composed 
of the N-terminal portion of α-subunit; domain II, consists of C-terminal 
portion of α-subunit and a small C-terminal portion of the β-subunit, and; 
domain III is made up from the majority of the β-subunit (Fig. 2.4) [20]. The 
flavin cofactor is in the cleft between the two subunits, mainly interacting 
with the C-terminal portion of the α-subunit (Fig. 2.4). Moreover, the C7 and 
C8 of the methyl groups in the dimethylbenzene ring make van der Waals 
contact with Tyr16 and Phe41 from the β-subunit. The AMP cofactor is 
buried deeply within domain III, making mostly backbone interaction (Fig. 
2.4). The phosphate moiety of the cofactor forms hydrogen bounds with 
residues Ala126, Asp29, Asn32, Gln33 and Thr34 from the β subunit. 
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Figure 2.4: Ribbon representation of the structure of human ETF. FAD (orange) binds 
in a cleft formed by the α (grey) and β (green) subunits. The AMP (yellow) is located entirely 
within the β subunit. The structure was obtained from Protein Data Bank (PDB: 1efv).   
 
 ETF function is described in several reports has an electron acceptor for 
several dehydrogenases of fatty acid β-oxidation and for amino acid and 
choline catabolism [51]. Reduction of ETF by dehydrogenases results in the 
rapid formation of an anionic semiquinone, but its further reduction is slower 
[52-54]. The reoxidation of ETF is catalyzed by the membrane-bound iron-
sulfur flavoprotein ETF-QO [55] (see below). The redox potential for human 
ETF are 37mV and 25mV for the oxidized/semiquinone and 
semiquinone/hydroquinone couple, respectively [21].  
 The crystal structure of ETF:MCAD complex was resolved and revealed a 
dual mode of protein-protein interaction, showing both specificity and 
promiscuity in the interaction with the different dehydrogenases [56]. The 
authors identified an anchor region, the “recognition loop”, which is centered 
on the conserved residue Leu195 and docked to a hydrophobic patch on the 
I
II
ETFα
III ETFβ
AMP
FAD
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dehydrogenase, and a highly dynamic region on the ETF FAD domain, 
allowing fast interprotein electron transfer (Fig. 2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Structure of MCAD:ETFβ-Glu165Ala complex. Protein are represented by 
ribbon cartoon, ETF shown as green (α and β subunits shown as light and dark green, 
respectively), and MCAD shown as grey. Only a dimmer of MCAD and one ETF molecule 
were presented for clarity. The recognition loop of ETF is highlighted as red. FAD and AMP 
are shown as orange and yellow sticks, respectively. The structure was obtained from Protein 
Data Bank (PDB: 2A1T).   
 
 ETFs homologous are found in all kingdoms of life, and participate on 
electron transfer reactions in a variety of metabolic pathways. ETFs belong to 
the family of α/β-heterodimeric FAD-contaning proteins [57-59]. Based on 
sequence homology and functional types the members of this family can be 
clustered in different groups. Group I comprises mammalian and also a few 
bacterial ETFs, while group II contains proteins from nitrogen-fixing and 
diazotrophic bacteria [60]. Group I ETFs are usually physiologically electron 
acceptors of several dehydrogenases, and electrons flow to a membrane-
bound ETF ubiquinone oxidoreductase. A well studied homologue of 
mammalian ETF is the ETF from the bacterium Paracoccus denitrificans [61-63]. 
MCAD
ETF
FAD
Recognition loop
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In group II the α-ETF and β-ETF are homologous of FixB and FixA 
proteins, respectively [64]. Moreover, they receive electrons from the usual 
dehydrogenases, and also from ferredoxin and NADH [65]. It is postulated 
that the electron pathway to dinitrogen is via  ETF:ferredoxin oxidoreductase, 
ferredoxin, nitrogenase reductase and nitrogenase [64]. The best studied ETF 
of this group is from the bacterium Methylophilus methylotrophus strain W3A1. 
Another well study ETF is the one from the anaerobe Megasphaera elsdenii, 
which is atypical, as it contains two FAD-binding sites and no AMP cofactor 
[58, 66]. 
 
2.2.2. Electron transfer flavoprotein ubiquinone oxidoreductase 
(ETF-QO) 
 ETF-QO is the link between several mitochondrial oxidative processes 
and the respiratory chain. Briefly, ETF-QO was first purified by Ruzicka and 
colleagues, who characterized it as a monomeric protein containing a [4Fe-4S] 
cluster and a FAD cofactor [67]. The ETF-QO gene has been mapped to 
chromosome 4q32-q35 [68], and its cDNA cloned and characterized [69].  
 The 66 kDa protein can be fully reduced by chemical reductants, such as 
dithionite, but its two electron reduction is only achieved in the presence of 
catalytic amounts of ETF [55]. The reduction potential of ETF-QO from pig 
liver mitochondria was determined using an EPR-spectroelectrochemical cell 
and dithionite as a reductant [23]. The reduction potential values were 28 mV, 
-6 mV and 47 mV, for first and second electron transfer to FAD and for the 
iron-sulfur cluster, respectively [23].  
 The crystal structure has revealed that the iron-sulfur cluster is closer to 
the protein surface while FAD molecule is closer to the ubiquinone, therefore 
it was postulated that the redox cluster is responsible for accepting electrons 
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from ETF and the flavin cofactor for reducing ubiquinone (Fig. 2.6) [22]. 
This proposed mechanism is supported by the recent work of Swanson on 
the determination of redox potential of Rhodobacter sphaeroides ETF-QO 
mutants [70]. The mutations had no impact on the reduction potential for the 
iron-sulfur cluster, but significantly decreased the first reduction potential of 
FAD. Lowering the midpoint potentials resulted in a decrease in the quinone 
reductase activity and negligible impact on disproportionation of ETF-
semiquinone catalyzed by ETF-QO. 
 
 
 
 
 
 
 
 
Figure 2.6: Representation of the 
structure of pig ETF-QO. Protein 
structure is represented as cartoon 
with helices represented as cylinders 
and beta-strands as arrows, 
cofactors are represented as sticks. 
The structure was obtained from 
the Protein Data Bank (PDB: 
2gmj). 
 
 
2.3. Fatty acid oxidation disorders 
 The disorders associated with the enzymes and transport proteins of the 
pathway described in the sections above are commonly denominated by fatty 
acid oxidation (FAO) disorders. The first report on these disorders dates to 
1973, DiMauro and DiMauro, described CPT II deficiency [71]. Two years 
later, Karpati et al. described CAT deficiency [72], and in 1976 Gregersen et al 
reported MCAD deficiency [73] and Przyrembel et al reported multiple acyl-
CoA dehydrogenase deficiency (MADD) [74]. Up until now defects in 18 
enzymes of the pathway have been identified [4]. FAO disorders are inherited 
Men      membrane
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autosomal recessive disorders with a wide spectrum of symptoms. In the 
beginning diagnosis was based only on metabolite profiles and no direct 
enzymatic studies or genetic analysis could confirm the exact enzyme 
alteration. More recently fatty acid oxidation defects are diagnosed via clinical, 
biochemical, pathological studies and mutational analysis of the genes 
encoding the suspected enzyme deficiencies [75].  
 Symptoms, which in some cases only manifest during episodes of 
metabolic crisis, are associated with energetic deficiency in tissues that depend 
on fatty acid oxidation. Other problems arise from the accumulation of 
intermediates of the pathway as these species may have toxic properties. In 
mild cases, disease symptoms can be triggered by prolonged fasting, exercise, 
infection, exposure to cold, or a fat-rich diet [4, 76].  
 Since the mid 1990s FAO disorders are part of the newborn screening 
programs in many countries, allowing an early diagnosis and treatment, 
decreasing morbidity and mortality. The newborn screening uses tandem 
mass spectrometry (MS/MS) to determine acylcarnitine profiles in blood 
spots allowing the identification of enzyme-specific anomalies in fatty acid 
oxidation [24]. 
 In the following subsection a brief description of a selection of FAO 
disorders will be presented, namely MADD, MCADD, VLCADD and 
SCADD.  
 
2.3.1. Multiple acyl-CoA dehydrogenase deficiency 
 Glutaric aciduria type 2 (GA2) (MIM 231680) was first described in 1976, 
and at that time the name was given because glutarate was described as the 
major urinary metabolite, in comparison to glutaric aciduria type 1 in which 
glutarate and its metabolites accumulate [74]. In 1980, Goodman and 
colleagues reported a new case where the amino and organic acids 
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abnormities were consistent with a defect in the flavoproteins which transfer 
electrons from the dehydrogenases to the respiratory chain, so the disorder 
should be renamed as “multiple acyl-CoA dehydrogenase deficiency” 
(MADD) [77]. Four years later a report suggested that the cause of MADD 
would be a defect in either ETF or ETF-QO [78], and this was confirmed by 
Frerman and Goodman through the immunological analysis of fibroblasts 
from five patients [79].   
 MADD is an autosomal recessively inherited disorder, and patients are 
affected in at least 12 mitochondrial flavoenzyme dehydrogenase activities, 
since their common flavin-dependent electron pathway to ubiquinone in the 
electron transport chain is partially or fully blocked. Over fifty-disease causing 
mutations are reported: 21 mutations on ETFA, 8 mutations on ETFB and 
35 mutations on ETFDH genes, most of which are missense mutations (data 
extracted from The Human Gene Mutation Database accessed 30.08.2010) 
[80].  
 MADD clinical picture is rather heterogeneous, ranging from neonatal 
lethal forms (severe MADD or S:MADD) to later-onset forms with a milder 
clinical course and symptoms that may be ameliorated by high doses of 
riboflavin (mild MADD or M:MADD) [81-82]. Patients with the severe form 
can either present or not congenital anomalies. In the first case infants are 
often premature, and during the first 24-48 hrs of life present hypotonia, 
hepatomegaly, hypoglycemia, metabolic acidosis and sweaty feet odor. Usually 
kidneys are often palpably enlarged and cystic, and the patient can present 
facial dysmorphisms and rocker-bottom feet [83]. In the case of neonatal 
onset without congenital anomalies infants develop problems within the first 
few days of life, and the few patients who survive the first week die within a 
few months usually with severe cardiomyopathy. In the case of mild MADD 
the symptoms are extremely variable and characterized by recurrent episodes 
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of lethargy, vomiting, hypoglycemia, metabolic acidosis, and hepatomegaly 
often preceded by metabolic stress [83]. In some cases muscle involvement in 
the form of pain, weakness, and lipid storage myopathies has been reported.  
 The diagnosis of MADD is established by plasma acylcarnitines and urine 
organic acid and acylglycine profiles, but solely based on these data, the 
severity of the phenotype can not be established (Table 2.2). The diagnosis 
must be subsequently confirmed by enzymatic assays in fibroblasts cultures, 
and in some countries by molecular genetic analyses. A correlation between 
clinical phenotypes and both enzymatic defects and molecular genotypes as 
been suggested [83-84].  
 
Table 2.2: Acylcarnitines that occur at elevated levels in 
MADD 
 Acylcarnitine MADD 
Group I – almost always elevated levels in all MADD 
patients 
C8:0 octanoyl Up 
C10:0 decanoyl Up 
C12:0 dodecanoyl Up 
Group II – may have elevated levels (in severe 
forms/metabolic decompensation) 
C4 Butyryl Up 
C5 Isovaleryl Up 
C5-DC Glutaryl Up 
C6:0 hexanoyl Up 
Group III – very rarely elevated levels (only in very 
severe forms/metabolic decompensation) 
C12:1 Dodecenoyl Up 
C14:0 tetradecanoyl Up 
C14:1 Tetradecenoyl Up 
C14:2 Tetradecadienoyl Up 
C16:0 Palmitoyl Up 
C18:0 Octadecanoyl Up 
C18:1 Linoleoyl Up 
C16:1 hexadecenoyl Up 
 
 Treatment of MADD include avoidance of fasting, a diet low in fat and 
proteins and high in carbohydrates. In some cases additional supplements of 
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riboflavin and L-carnitine can be given. These treatments have been more 
successful when applied to patients with milder forms of the disease [85]. 
 
2.3.2. Medium-chain acyl-CoA deficiency  
 MCAD deficiency (MCADD) (MIM 201450) is in general associated to 
missense mutations on ACADM gene that compromise protein folding 
affecting the native conformation but not the thermal stability of the tetramer 
[86]. It is the most common defect of β-oxidation in humans, with a 
frequency in the population estimated at 1/15,000 [87]. The most prevalent 
mutation is a change of a lysine in position 304 for a glutamic acid 
(Lys304Glu), resulting in protein misfolding and aggregation [88-89].  
 The enzymatic deficiency results in a decreased ketone production and in 
an increase in medium chain fatty acids. Episodes of fasting or fever, 
commonly result in low appetite, hypoglycaemia and energy deficiency 
develop due to the rapid exhaustion of glycogen reserves. Usually patients are 
considered normal at birth, then around 3-24 months of age, acute 
decompensation may occur in response to prolonged or intercurrent fasting 
and common infections [24]. The disorder is characterized by a broad 
spectrum of symptoms that can range from hypoglycaemia to seizure, coma 
and sudden death.  
 Although, unexpected death during the first metabolic decompensation is 
common, the prognosis is excellent once the diagnosis is established, 
especially if detected by newborn screening before onset of symptoms [90-
91]. 
 
2.3.3. Very-long chain acyl-CoA deficiency  
 VLCADD is considered as one of the most common β-oxidation 
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disorders, it results from mutations in the ACADVL gene and therefore 
patients have accumulation of C14 to C18 acylcarnitines. Patient with 
VLCADD can have a rather wide range of symptoms, so according to the 
phenotype the disorder can be classified in three different categories: a 
neonatal form, with cardiomyopathy, liver disease and myopathy; a childhood 
onset form, characterized by hypoketotic hypoglycemia; and a late-onset form 
with recurrent rhabdomyolysis and myoglobinuria [92].  
 Early diagnosis is highly important since the disease can be rapidly fatal 
due to cardiac or hepatic involvement. Clinical treatment include low-fat diet 
supplemented with medium-chain triglycerides and fasting precautions [93]. 
Until now around one hundred mutations have been described in the 
literature, and although a general correlation between genotype-phenotype 
has been reported [92], the molecular basis of VLCADD is very complex and 
genotypic analysis alone remains limited to the prediction of fatal cases [94-
95].  
 
2.3.4. Short–chain acyl-CoA deficiency 
 SCAD deficiency (SCADD) (MIM 201470) is less frequent, and results 
from multiple mutations or two common coding polymorphisms, which 
diminish or completely abolish SCAD enzymatic activity [96]. Impaired 
butyryl-CoA oxidation results in accumulation of butyrylcarnitine, 
butyrylglycine, ethylmalonic (EMA) acid, and methylsuccinic acid in blood, 
urine and cells [97]. The first case associated with SCAD was reported in 1984 
by Turnbull and co-workers [98], but only in 1987 Amendt et al described a 
SCADD patient case, confirmed by enzymatic assays in skin fibroblasts [99]. 
The main features of the disorder are neuromuscular symptoms such as 
developmental delay, hypotonia, and seizures [86, 100].  
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 More than one hundred patients have been reported, and although in the 
past the phenotypes were relatively severe now most patient are diagnosed 
through newborn screening and remain asymptomatic [33]. Moreover, the 
SCAD p.Gly209Ser variant, which has a mild effect on protein 
folding/stability [101], is found in the general population with a homozygous 
frequency of 7% but is over-represented in patients with ethylmalonic 
aciduria, a marker for SCAD deficiency (60%), indicating that other 
environmental and genetic factors contribute to disease development [94, 97, 
102]. Therefore, there is still on going debate on whether the genetic variation 
accounts for the disorder or whether it is a simple result of polymorphic 
variation [94].   
 
2.4. Riboflavin, a pharmacological chaperone 
2.4.1. Riboflavin metabolism and deficiency 
 Riboflavin is widely used as therapy in different FAO disorders, therefore 
a brief description of its metabolism and of the known therapeutic effects will 
be presented. Riboflavin, or vitamin B2, was first described in the late 19th 
century by A. Wynter Blyth in a paper for the Transactions of the Chemical Society, 
where it was called ‘lacto-chrome’. Approximately fifty years later, due to the 
need to clarify the nomenclature, the compound was renamed riboflavin. This 
designation derives from its ribityl side chain and yellow color (Fig. 2.7) [103]. 
Vitamin B2 is the precursor of flavin mononucleotide (FMN) and flavin 
adenine dinucleotide (FAD) (Fig. 2.7), two very important protein cofactors 
present in a broad range of flavoenzymes, including oxidases, reductases and 
dehydrogenases [104]. 
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Figure 2.7: Chemical structures of riboflavin and its derivates FMN and FAD. 
 
 Vitamin B2 intake is made through regular diet, it is ingested in a protein 
bound form, or already as FAD and FMN in flavoproteins. The major 
sources of vitamin B2 are eggs, milk, some meat products, yeast and 
vegetables [105]. The normal intake for an adult is 1.6-2.6 mg/day, and 
deficiency symptoms are rarely observed with a normal diet [105]. The 
vitamin or its derivatives are released by stomach acid and via the action of 
gastric/intestinal proteases. FMN and FAD are sequentially hydrolysed to 
riboflavin by alkaline phosphatases and FMN/FAD pyrophosphatase [106]. 
The free riboflavin is transported into the enterocyte by an energy-dependent 
and sodium independent riboflavin carrier, probably the recently identified 
riboflavin transporter 2 (RFT2) [107]. After release to the hepatic portal vein, 
riboflavin is taken up by the hepatocyte riboflavin transporter which is 
regulated by intracellular Ca2+/calmodulin [106]. Inside the cell, riboflavin is 
then phosphorylated by ATP and flavokinase to FMN, which is converted to 
FAD by FAD synthetase also in the presence of ATP (Fig. 2.8). The 
conversion of FMN and FAD can also occur inside the mitochondria, as this 
organelle also contains riboflavin kinase and FAD synthetase enzymes [106]. 
Free FAD can be incorporated in mitochondrial apoflavoproteins or, it can 
be carried by the Flx1p FAD carrier to the cytosol (Fig. 2.8) [108-109].  
R
Riboflavin R =    – H
FMN R =    – PO32‐
FAD R =
Ribityl
chain
Isoalloxazine ring
adenineribose
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Figure 2.8: Riboflavin cellular 
processing pathways. Riboflavin is 
imported into the cell and later into the 
mitochondria via specific transporters 
(white circles in membranes). In the 
cytoplasm, Flavin kinase (FK) and FAD 
synthetase (FADS) consecutively convert 
riboflavin into FMN and FAD, at the 
expense of ATP. An identical mechanism 
is also thought to be present inside the 
mitochondria, although a mitochondrial 
FK remains to be identified. FAD can 
also be imported into the mitochondria, or diffuse passively when the riboflavin 
concentration is high.  
 
 
 
 Riboflavin is present, at least in small amounts, in all animal tissues. In 
humans the main storage site for riboflavin, mostly in the form of FAD, is 
the liver; it is also stored in spleen, kidney and cardiac muscle, so these organs 
and tissues are naturally protected against riboflavin deficiency. In the 
circulating plasma there is an equilibrium between the three species: riboflavin 
(50%), FAD (40%) and FMN (10%), where the total flavin concentration is 
30 nM [106]. 
 A diet low in riboflavin or an error in its metabolic pathway would result 
in low FAD and FMN contents in the cell, reducing the activity of a series of 
enzymes [110-113]. Different cellular systems can be affected directly or 
indirectly by lower amounts of riboflavin and several studies report the 
cellular consequences of reduced levels of riboflavin. In fact, the acyl-CoA 
dehydrogenases involved in the first dehydrogenation step of fatty acid 
oxidation (FAO) are among the first flavoenzymes to be affected during 
moderate riboflavin deficiency [114-117]. Reports using rodent models have 
shown that the major impact of moderate riboflavin deficiency is at the level 
of mitochondrial β-oxidation, due to the impairment of enzymatic activity of 
Riboflavin FMN
FAD
ATP ADP
ATP
ADP
FK
FADS
FAD
↑ riboflavin
Riboflavin
Riboflavin
FMN
FAD
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the acyl-CoA dehydrogenases [114, 116]. Certain ACDHs have been shown 
to be specifically sensitive – namely short chain acyl-CoA dehydrogenase 
(SCAD) and isovaleryl-CoA dehydrogenase (IVD) [118-119].  Research work 
by the Tanaka laboratory in the 1990s has suggested that FAD regulates the 
ACDHs at different stages: fatty acid oxidation enzymes are regulated at the 
level of gene expression, and all ACDHs have an improvement of the 
ACDHs m-RNA translation, and an increase in stability of the mature protein 
[120].  
 Another type of mitochondrial disorders that seem to benefit from 
riboflavin supplementation are deficiencies involving enzymes from the 
respiratory chain, namely complex I (NADH:quinone oxidoreductase) and 
complex II (Succinate:quinone oxidoreductase). Bernsen and colleagues 
reported for the first time an improvement of enzymatic activity of complex I 
after riboflavin supplementation on a 6 year old boy with myopathy and pure 
motor neuropathy [121]. Later, additional cases were described and riboflavin 
supplementation was shown to improve the clinical condition of patients with 
myopathy and encephalomyopathy [122]. Riboflavin treatment also restored 
cognitive and motor development in a girl with mitochondrial myopathy 
associated with impaired NADH-dehydrogenase activity [123]. One report 
describes three patients which were treated with riboflavin for 4 to 6 years 
and whose clinical features did not improve, although disease progression was 
halted. In these cases, the activity of complex II increased 2-fold in fibroblast 
culture supplemented with 0.2 mg.ml-1 riboflavin [124]. Another case of 
complex II deficiency, a 10 month old boy with severe neurological features 
showed improvements after riboflavin intake and by the age of 5 only a 
moderate psychomotor delay was observed [125]. Thus, riboflavin 
supplementation in mitochondrial disorders associated with complex II 
deficiencies thus appears to at least reduce disease progression. 
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 Tests in HepG2 liver cells have revealed that a deficient riboflavin 
medium causes oxidative stress and cell damage, as decreased glutathione 
reductase activity, increased protein carbonylation (a process associated with 
oxidative damage), and increased DNA strand breaks are detected [126]. In 
addition, riboflavin deficiency impairs oxidative folding: in yeast it is known 
that Ero1, a protein involved in the control of disulfide formation during 
oxidative folding in the ER, is FAD dependent [127]; in human lymphoid 
cells cultured under flavin-deficient conditions, interleukin-2 accumulates 
intracellularly, probably due to an impairment of the human homologue of 
Ero1 [128]; and in flavin deficient human liver cells, it causes ER stress, 
activation of the unfolded protein response and decreased secretion of apoB 
which may interfere with lipid homeostasis in vivo [129]. Riboflavin deficiency 
can also affect heme biosynthesis via protoporphyrinogen oxidase, a FAD 
dependent enzyme of the pathway [106, 130]. It may also be involved, in 
some cases of anaemia [131] and other biological processes as reviewed in 
[132]. 
 
2.4.2. FAO disorders responsive to riboflavin  
 For most FAO disorders vitamin B2 supplementation is not suggested as 
first treatment approach, however some clinical reports have shown the 
beneficial effects of this vitamin. Duran and co-workers measured MCAD 
activities in lymphocytes of five MCAD deficient patients before and after a 
three weeks treatment with riboflavin (50-150 mg/day). All five MCAD 
deficient patients have at least double their MCAD activity. The smallest 
improvement registered was from 5 to 12% of control mean after treatment, 
however one of the patients had his MCAD activity increased to heterozygote 
levels. The clinical response and primary gene defects were not reported 
[133]. In another study involving eight patients with MCAD deficiency, no 
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effect on fibroblast MCAD enzyme activity was detected upon 
supplementation with 20 µM FAD [134]. Amendt and co-workers measured 
in vitro FAD response in fibroblasts from three patients with defects of long-
chain fatty acid acyl-CoA dehydrogenation. Long-chain dehydrogenation 
activities in mitochondrial extracts were increased from 17-21% of controls to 
27-36% of controls upon addition of 20µM FAD and the authors suggested 
merit of therapeutic riboflavin trials in patients [135].  
 Three papers have reported riboflavin responsiveness in patients with 
short-chain acyl-CoA dehydrogenase (SCAD) deficiency. In one paper the 
genetic defects were not addressed [136], but on the other two papers 
riboflavin responsiveness was associated to the p.Gly209Ser / c.625G>A 
SCAD variant [137-138]. Subclinical or biochemical riboflavin deficiency is 
quite common in the general population [139] and moderate riboflavin 
deficiency is known to selectively impair mitochondrial fatty acid oxidation by 
decreasing the activities of the flavin-dependant acyl-CoA dehydrogenases, in 
particular short-chain acyl-CoA dehydrogenase [115, 117]. Thus, 
mitochondrial flavin content and consequently riboflavin status could be a 
contributing factor to the development of SCAD deficiency. Recently van 
Maldegem and co-workers assessed the FAD status and evaluated the effect 
of riboflavin treatment in 16 patients with SCAD deficiency [138]. Blood 
FAD levels were normal in all patients before riboflavin supplementation 
therapy, but significantly lower in homozygous or heterozygous patients 
harboring the c.625G>A variation, as compared to heterozygous patients 
harboring two rare SCAD mutations. The common c.625G>A variation may 
be an example of a diet-gene interaction where a sizeable percentage of the 
population (7%) has a higher riboflavin requirement because of a 
polymorphic flavoenzyme as suggested by Ames et al [140]. However, even 
though van Meldegem and co-workers found the c.625G>A variant to be 
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associated with low FAD status, only a subgroup of patients (4/13) actually 
responded biochemically and clinically to the treatment with riboflavin. So the 
authors did not recommend riboflavin as a general treatment in SCAD 
deficiency [138].  
 In contrast to disorders of single fatty acid oxidation flavoenzymes like 
SCAD, MCAD and VLCAD, where riboflavin treatment has been tried only 
in single cases with appropriate deficiency states, riboflavin therapy is used as 
a general treatment in patients with multiple acyl-CoA dehydrogenase 
deficiency [141].  
 A certain group of MADD patients – the so-called riboflavin-responsive 
multiple acyl-CoA dehydrogenase deficiency (RR-MADD) patients – is 
spectacularly responsive to riboflavin supplementation with clinical and 
biochemical abnormalities being normalized or near normalized after 
treatment. 
 The first patient, described in 1982 by Gregersen et al., was a boy with 
episodic vomiting, lethargy and hypoglycemia during early childhood. He was 
diagnosed at 3 years of age during a Reye’s syndrome-like crisis with 
metabolic acidosis, hepatomegaly and muscle hypotonia [142]. Since then, 
several further cases have been reported with heterogeneous clinical 
symptoms; mainly with encephalopathy or muscle weakness or a combination 
of these and often preceded by cyclical vomiting. In the late teenage years or 
adulthood these patients may develop a severe progressive proximal muscle 
weakness with lipid storage and secondary carnitine deficiency. In its most 
severe forms RR-MADD patients may end up being bound to the bed or a 
wheelchair and the acute metabolic crisis can be lethal [51, 143-144]. Since 
high levels of riboflavin can cure these symptoms and prevent lethal attacks, 
correct and timely diagnosis is important.  
 RR-MADD patients have metabolic profiles compatible with classical 
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MADD or ethylmalonic-adipic aciduria caused by genetic defects of ETF or 
ETF-QO, and also, in many cases, have decreased activities of single 
flavoenzymes, including acyl-CoA dehydrogenases and components of the 
respiratory chain, and decreased mitochondrial flavin content; all of which 
can be improved or corrected by high doses of riboflavin [51, 143-148]. These 
abnormalities resemble those found in rats fed with a riboflavin-deficient diet 
[117], and because they are not easily explained by ETF/ETF-QO mutations, 
it was for many years thought that RR-MADD patients had genetic defects of 
mitochondrial flavin metabolism or transport rather than defects of the 
ETFA, ETFB and ETFDH genes.   
 Today we know that mutations of ETF-QO are the most common cause 
of RR-MADD. This was established in 2007 when ETF-QO mutations were 
identified in all RR-MADD patients from 11 pedigrees [51]. At the same time 
Gempel et al reported ETF-QO mutations in a group of patients with the 
myopathic form of coenzyme Q10 deficiency, who had biochemical profiles 
consistent with RR-MADD [149]. Since then the molecular defect in RR-
MADD has been confined to the ETFDH gene in a number of cases [144, 
150-154] and to the ETFA gene in a single case [154] suggesting that RR-
MADD may be caused by mutations in any of the three genes forming this 
flavin-dependent electron transfer pathway. At least one of two mutations, in 
all of these RR-MADD patients, are of the missense type and none of the 40 
different missense mutations have been reported in classical MADD patients 
indicating that they are unique to RR-MADD.  
 Although RR-MADD in a large fraction of patients is clearly associated 
with ETF-QO mutations, the role of these mutant proteins on secondary  
mitochondrial dysfunction - with impaired function of multiple acyl-CoA 
dehydrogenases, respiratory chain complexes and coenzyme Q10 - remains 
controversial [94]. As low mitochondrial concentrations of flavins have been 
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observed in some patients with RR-MADD [145-147] it has been argued that 
the global changes of mitochondrial proteins could be due to genetic or 
environment related disturbances of flavin homeostasis. It could also be 
argued that the mitochondrial dysfunction is secondary to the ETF-QO 
mutations themselves.  
 New data show that MADD cells with null mutations of ETF/ETF-QO 
reduce oxidative phosphorylation and increase aerobic glycolysis, the 
consequences of which is a proliferative, apoptosis resistant phenotype, 
controlled by cell proliferative signaling pathways like the PPARG-ERK 
pathway [155]. Obviously, one could suggest that a similar metabolic switch 
accounts for the mitochondrial protein changes observed in pre-treated 
muscle samples from RR-MADD patients.   
 Although it might seem that MADD and RR-MADD share a similar 
metabolic adaptation to the genetic deficiencies of ETF/ETF-QO there are 
differences: the nonketotic hypoglycemic phenotype of classical MADD 
reflects the metabolic switch to glycolysis accompanied by decreased 
gluconeogenesis and decreased acetyl-CoA production as a consequence of 
genetic blockage of fatty acid oxidation and perhaps redirection of the 
pyruvate generated in glycolysis away from acetyl-CoA production and to 
lactate production. However, RR-MADD patients often show normal glucose 
levels and ketosis [51] reflecting that the acetyl-CoAs that are produced 
during β-oxidation of fatty acids are mostly used for ketone bodies. 
Moreover, dysfunction of respiratory chain components, including coenzyme 
Q10, seems to be variably deficient in different RR-MADD patients [146, 
149-150]. Moreover the specific activities of FAO acyl-CoA dehydrogenases 
appear normal in MADD fibroblasts whereas they are decreased in muscle 
samples from RR-MADD patients, with SCAD and MCAD activities being 
more impaired than VLCAD activity, in most cases [156-158]. It remains to 
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be clarified if these observed differences are due to differences in the 
technical set-ups or whether they truly reflect different cell pathological 
responses to ETF-QO mutations. Oxidative stress and/or toxic metabolites 
have been suggested to be the link between ETF-QO mutations and general 
mitochondrial dysregulation [51, 94]. However, the exact trigger(s) of the 
metabolic switch and the implicated molecular pathways and mechanisms 
remain elusive. 
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3.1. Summary 
 We have carried out an extensive in silico analysis on 18 disease associated 
missense mutations found in electron transfer flavoprotein (ETF), and found 
that mutations fall essentially in two groups, one in which mutations affect 
protein folding and assembly, and another one in which mutations impair 
catalytic activity and disrupt interactions with partner dehydrogenases. We 
have further experimentally analyzed three of these mutations, ETFβ-
p.Cys42Arg, ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys, which have been 
found in homozygous form in patients and which typify different scenarios in 
respect to the clinical phenotypes.  
 The ETFβ-p.Cys42Arg mutation, related to a severe form of multiple 
acyl-CoA dehydrogenase deficiency (MADD), affects directly the AMP 
binding site and intersubunit contacts and impairs correct protein folding. 
The two other variations, ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys, are 
both associated with mild MADD, but have a different impact on ETF. 
Although none affects the overall α/β fold topology as shown by far-UV CD, 
analysis of the purified proteins shows that both have substantially decreased 
enzymatic activity and conformational stability.  
 Altogether, this study combines in silico analysis of mutations with 
experimental data and has allowed establishing structural hotspots within the 
ETF fold that are useful to provide a rationale for the prediction of effects of 
mutations in ETF. 
 
3.2. Introduction 
 Mutations in the ETFA, ETFB or ETFDH genes, which encode the two 
subunits of Electron Transfer Flavoprotein (ETF) and ETF-ubiquinone 
oxidoreductase (ETF-QO), respectively, cause multiple acyl-CoA 
dehydrogenase deficiency (MADD), a congenital metabolic disease with a 
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broad clinical expression [1]. The systematic application of newborn screening 
programs has allowed for a wider coverage of MADD genotypes that range 
from missense or nonsense mutations to frameshifts.  
 One of the proteins affected in this disorder is ETF, a key enzyme in the 
mitochondrial fatty acid β-oxidation and amino acid degradation pathways, 
which transfers electrons from at least 12 dehydrogenases via ETF-QO to the 
respiratory chain. As in many other metabolic disorders, clear genotype-
phenotype relationships remain elusive in MADD: in particular for milder 
disease forms, it is expected that the mutant proteins are partially functional 
and that cellular and environmental factors such as temperature and cofactors 
can modulate disease expression [2]. Progress in this issue has however also 
been constrained by the fact that only a very limited number of mutations has 
been characterized upon recombinant expression of the variant proteins. 
However, substantial steps forward can be achieved if the available data on 
clinical mutations are merged with a structural and functional analysis of the 
affected protein.  
 In this paper we have investigated for mutational hotspots on the ETF 
structure by analysing the protein for particularly susceptible regions in which 
MADD-related ETF variations detected in patients map. Complementary 
experimental validation for the putative mutational hotspots identified was 
subsequently obtained by carrying out a biochemical and biophysical analysis 
of purified ETF variants with representative disease-causing mutations. The 
data gathered by this strategy contribute to a better understanding of the 
molecular factors underlying functional deficiency and may, in the long term, 
provide a framework for the design of novel therapies. 
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3.3. Material and methods 
 Chemicals  
 All reagents were of the highest purity grade commercially available. 
Octanoyl-CoA, FAD, AMP and urea were purchased from Sigma. Isopropyl-
β-D-thiogalactopyranoside (IPTG) was purchased from VWR International. 
 
 Structural Analysis 
 The crystallographic structures of human ETF (PDB code: 1efv, [3]) and 
ETF:MCAD complex (PDB code: 1T9G, [4]) were inspected using PyMOL 
(DeLano Scientific). Analysis of the molecular interactions, cofactor contacts, 
topological features and generation of models for the variants was carried out 
using the WhatIF web server [5] and the PDBsum database [6]. The PolyPhen 
(Polymorphism Phenotyping) web server was used to predict the effect of 
amino acid variations on protein structure and function [7]. The input for this 
server was the UniProt accession number (ETFα: P13804 and 
ETFβ:P38117), sequence position and the two amino acid variants 
characterizing the desired mutation.   
 
 ETF expression in E. coli JM109 cells 
 The pK-lac-ETF-αβ3(C/T) plasmid encoding both ETF subunits (here 
named pWt), described previously [8], was used as DNA template in the 
production of the two novel mutants, the ETFβ−p.Cys42Arg and 
ETFβ−p.Arg191Cys. The mutants were generated using the Quick change 
mutagenesis kit (Stratagene) as recommended by the manufacturer. Mutagenic 
primers were 5’-CCATGAACCCCTTCCGTGAGATCGCGGTGG-3’ for 
the ETFβ−p.Cys42Arg variant, and 5’-
GAGGCTCAACGAGCCCTGCTACGCCACGCTG-3’ for the 
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ETFβ−p.Arg191Cys mutant (altered bases are underlined and in bold type). 
The second mutagenic primers required were the reverse complements of 
those shown. After PCR screening the sections containing the mutation were 
sequenced to exclude PCR errors and subcloned back into the original 
plasmid. The ETFβ−D128N mutant, also used in these studies, was already 
available [9]. 
 E. coli JM109 cells transformed with the respective plasmid, pWt, pC42R, 
pD128N, pR191C, were grown in LB (Luria–Bertani) supplemented with 10 
μg.ml-1 kanamycin at 30ºC or 37ºC in a shaking incubator until OD532 of 0.5-
0.8 was reached. The cells were than induced with 1 mM IPTG for 4 hours. 
Cells were harvested by centrifugation, re-suspended in 10 mM Hepes, 10% 
ethylene glycol and 0.5 mM phenylmethylsulphonylfluoride (Roth) in 
presence of DNase (Applichem) and disrupted in a French press. The soluble 
extract was obtained by centrifugation at 12,000 g for 30 minutes and used 
for the ETF activity assays [10] and for SDS-PAGE followed by western 
blotting analyses according to [11]. An ETF polyclonal antibody raised in 
rabbits against purified recombinant wild type ETF protein was used to 
identify ETF proteins and visualized with peroxidase conjugated secondary 
antibody reaction with 1-step TMB-Blotting (Pierce). 
 
 Co-expression of molecular chaperones with ETFβ−p.Cys42Arg 
 Different conditions were used to improve ETFβ−p.Cys42Arg mutant 
expression, always using LB as growth medium. First, E. coli cells transformed 
with pC42R plasmid were expressed at 30ºC and 18ºC. Induction was made 
with 1 mM IPTG.  
 Further, JM109 E. coli cells were co-transformed with the pC42R plasmid 
and a molecular chaperone plasmid, pOFX-BADSL2 and pOFX-BADKJE2, 
respectively for the expression of GroES/EL complex and dnaK, dnaJ and 
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GrpE [12]. Cells transformed with the ETFβ−p.Cys42Arg and with pOFX-
BAD2 empty plasmid, control vector, or with the plasmid encoding the 
respective molecular chaperone system, were grown in LB supplemented with 
10 μg.ml-1 kanamycin and 10 μg.ml-1 tetracycline at 30ºC and 18ºC until 
OD532 of 0.5-0.8 was reached. Cells were then induced with 0.2% arabinose 
and 30 minutes later with 1mM IPTG. Samples were withdrawn at 1, 3, 6 and 
20 hours after the induction with IPTG. Cells were harvested by 
centrifugation and treated with Bug Buster solution (Novagen), soluble and 
insoluble fractions were analysed by SDS-PAGE and western blot analysis. 
Soluble fractions were also used for ETF activity assays [10].  
 
 Protein purification and biochemical assays 
 Soluble extract from 3L culture growth of wild type, ETFβ-p.Asp128Asn 
and ETFβ-p.Arg191Cys mutants, was applied on a Q-Sepharose fast flow 
column (GE Healthcare, 20 ml) previously equilibrated in 10 mM Hepes, 
10% ethylene glycol and 0.5 mM phenylmethylsulphonylfluoride (buffer A). 
The column was washed with 5 volumes buffer A, and bound proteins were 
eluted by a linear gradient of 0 - 1M NaCl in buffer A. Pure ETF was eluted 
at a salt concentration around 250 mM, and purity was confirmed by 
SDS/PAGE. Protein concentration was determined using the Bradford assay. 
Flavin content was determined using the molar extinction coefficient 
ε436nm=13400 M-1.cm-1 reported for FAD bound to ETF [13]. ETF enzyme 
activity was measured following 2,6-dichlorophenolindophenol (DCPIP) 
reduction at 600 nm in a coupled assay in which recombinant human MCAD 
and octanoyl-CoA were employed, as described in [10]. The unit of activity 
measurements is defined as nmol of DCPIP reduced per minute, in the 
conditions used in the assay. All specific activities reported are based on total 
flavin content. Pure ETF fractions with a 2.5 fold molar excess FAD were 
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fast-frozen using liquid nitrogen and stored at -80ºC. 
 
 Spectroscopic methods 
 Before each experiment FAD excess added to buffers as a preservative 
was removed by extensive washing using ultra filtration/dilution, and all 
experiments were performed with pure proteins containing full occupancy of 
FAD site.  
 UV/visible spectra were recorded at room temperature in a Shimadzu 
UVPC-1601 spectrometer with cell stirring. Fluorescence spectroscopy was 
performed using a Cary Eclipse instrument. For tryptophan emission 
excitation wavelength was set at 280 nm, and FAD emission was followed 
setting excitation wavelength at 436 nm; slits were 5 and 10 nm for excitation 
and emission, respectively. Typically protein concentration was 1 μM. CD 
spectra were recorded on a Jasco J-815 spectropolarimeter with a cell holder 
thermostatically controlled with a Peltier. A quartz polarized 1 mm path 
length quartz cuvette (Hellma) was used, and protein concentrations were 
typically 0.1 mg.ml-1. 
 
 Surface plasmon resonance 
 Surface plasmon resonance (SPR) experiments were performed on a 
BIAcore™ 2000 Instrument using NTA sensor chip (BIAcore, Inc.). The 
NTA sensor chip is designed to bind histidine tagged molecules after nickel 
activation of the surface. The surface was prepared as recommended by the 
manufacturer. The running buffer consisted of 10 mM Hepes, pH 7.4, 10% 
ethylene glycol, 50 mM NaCl, 0.005% Tween 20. Recombinant human 
MCAD with a histidine tag was immobilized in flow cell 2. The 
dehydrogenase was captured by manually injecting 25μl of a 200 nM solution 
at a flow rate of 5 μl.min-1. Flow cell 1 was used to correct for refractive index 
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changes and nonspecific binding. ETF (ETF-WT, ETFβ−p.Asp128Asn or 
ETFβ−p.Arg191Cys) in 50 nM solutions was injected over flow cells 1 and 2 
at a flow rate of 40 μl.min-1, during 90 seconds. All SPR experiments were 
done at 25ºC. 
 
 Thermal stability 
 Thermal unfolding with a linear temperature increase was followed using 
circular dichroism (ellipticity variation at 222 nm) and fluorescence 
spectroscopy, tryptophan emission (λex =280 nm; λem =340 nm), FAD 
emission (λex =436nm; λem =530 nm) and FRET from tryptophan emission to 
FAD cofactor (λex =280 nm; λem =530 nm). In all experiments, a heating rate 
of 1ºC.min-1 was used, and temperature was increased from 30 to 90ºC. Data 
were analysed according to a two-state model, and fits to the transition curves 
were made using OriginPro8.  
  
 Chemical stability  
 The denaturation curves were measured diluting ETF (ETF-WT, 
ETFβ−p.Asp128Asn or ETFβ−p.Arg191Cys) in different urea concentrations 
and the tryptophan emission spectrum was recorded after 15 minutes of 
incubation at 25°C. Transition curves were determined plotting the average 
emission wavelength against urea concentrations. Data were analysed 
according to a two-state model, and fits to the transition curves were made 
using OriginPro8.  
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3.4. Results and Discussion  
 Mutational hotspots in the ETF structure 
  A number of genetic defects in the ETFA/ETFB gene account for 
MADD. Most of the variations detected in patients are of the missense type, 
although frameshift and nonsense mutations are also described [14]. As the 
effect of modifying a single amino acid in ETF can be rather broad with 
respect to clinical expression, the possibility to predict whether a point 
mutation in a particular region of the protein would affect the folding, 
stability or activity, would be a potentially very useful parameter to establish 
genotype-phenotype relationships. In order to fill this gap we have set to 
define a structural mapping of mutations in ETF. For this purpose our 
strategy was twofold.  
 First, we have compiled a list of known disease-associated missense 
mutations described for human ETF, whose predicted effects were analysed 
using a combination of in silico tools for mutagenesis predictions and 
structural analysis (Table 3.1).  
 Secondly, we have analysed the ETF crystal structure (Fig. 3.1) in respect 
to specific structural factors that, if affected by mutations, are expected to 
perturb the structural integrity or the biological activity of the protein [3-4]. In 
this respect, we have analysed: i. positions that correspond to AMP-protein 
interactions; ii. residues that are involved in H-bond connections at the 
ETFα/ETFβ contact surface; iii. highly conserved segments throughout ETF 
ortologues; iv. amino acids involved in FAD binding or in the stabilization of 
the FAD moiety, and; v. positions involved in interactions with medium-
chain acyl-CoA dehydrogenase (MCAD), both the anchor loop and the FAD 
domain. At this stage positions involved in the interaction with ETF-QO 
were not possible to analyze since there is no structural information available 
on the ETF:ETF-QO complex.  
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Table 3.1 : Mutations in ETF related to MADD.  
The PSIC score is the position-specific independent count parameter computed by 
PolyPhen.  
 
PSIC 
score 
Structural rationale Ref 
ETF α    
p.Leu95Val 0.085 Near inter subunit H-bonded region. [15] 
p.Gly116Arg 2.667 Changes at buried site: hydrophobicity, overpacking and charge.  
[16-
17] 
p.Arg122Lys 1.507 
Change at buried site hydrophobicity. Closest 
contact is ETFβ-Gln146. Affects subunits 
interface. 
[18] 
p.Phe144Ser 1.781 Changes at buried site: hydrophobicity and cavity creation. [18] 
p.Val157Gly 2.346 Closest contact is ETFβ-Ser223. Cavity creation. Increase in flexibility. Affects subunits interface. [19] 
p.Val165Ala 1.373 Near inter subunit H-bonded region. [18] 
p.Leu212Pro 2.798 Change at buried site hydrophobicity. [18] 
p.Arg249Cys 3.472 Disruption of FAD binding site. Stabilizes FAD semiquinone. Contacts with MCAD. [18] 
p.Gly255Val 2.988 Maps at FAD interacting region. [20] 
p.Thr266Met 2.834 Disruption of FAD binding site. Hydrophobicity change at buried site. Contacts with MCAD. 
[9, 
16-
17] 
p.Gly267Arg 2.982 Maps at FAD interacting region. Charged residue inserted in turn. Contacts with MCAD. [20] 
ETF β    
p.Ala17Pro 1.612 Maps at FAD and AMP interacting regions. Maps nearby ETFα-Ile284. [21] 
p.Cys42Arg 3.343 
Disruption of AMP binding site. Changes at 
buried site: overpacking, hydrophobicity and 
charge. 
[18, 
22] 
p.Asp128Asn 2.438 Charge change at buried site. Maps at AMP interacting regions. Maps nearby ETFα-Tyr149.  
[9, 
23] 
p.Arg164Gln 2.492 Charge change at buried site. Near inter subunit H-bonded region. Maps nearby ETFα-Asn118.   [24] 
p.Arg191Cys 3.515 Removal of charged residue. Contacts with MCAD. [18] 
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Figure 3.1 – Cartoon of human ETF structure (PDB: 1efv) highlighting the analysed 
mutations. Details on mutations are listed in Table 3.1, the two figures have been rotated 
180° in respect to each other along the y-axis. Figure prepared using Pymol.  
 
 Merging the data obtained by these two complementary approaches 
shows that particular regions of the ETF structure are more susceptible to 
deleterious modifications than others and the clustering of the known 
mutations in those structure segments is rather suggestive of structural 
hotspots for MADD mutations (Fig 3.1 and 3.2).  
This is clearly noted on ETFα, in which mutations map essentially in two 
regions: one corresponding to the region involved essentially in interactions 
with the ETFβ subunit (Glu91-Val165), and the other a conserved region rich 
in FAD and MCAD interacting residues and inter-subunit interactions 
(Ala244-Thr295).  
 Clearly mutations in the first region may result in folding defects due to 
poor dimer assembly or protein destabilisation, as changes in these positions 
modify the chemistry of buried sites and may result in cavity creation. The 
latter may arise if an amino acid with a bulkier side chain is replaced by 
another with a smaller volume (e.g. ETFα-p.Val157Gly) or if a charged 
residue replaces a hydrophobic one (e.g. ETFα-p.Gly116Arg) (Table 3.1). 
 On the other hand, mutations in the second region have an impact on 
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catalysis. This occurs either by disturbing directly the FAD protein 
interactions or the second coordination sphere ligands, which are important 
modulators of the redox properties of the cofactor. In fact, the chemical and 
catalytic properties of the flavin are tightly controlled by the polypeptide, not 
only at the level of the residues involved in direct close-range interactions (i.e. 
within the first coordination sphere), but also by those which are further away 
from the organic cofactor but that are nevertheless connected to it through 
hydrogen-bond networks or other weak interactions (i.e. second coordination 
sphere). Also, this segment comprises positions of the FAD domain that are 
known to be involved in complex formation with MCAD [25]. Therefore, 
mutations in this region are expected to affect mostly the biological activity of 
the protein, although concurrent destabilization may also occur.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Structural features mapped on ETF sequence. Analysis of the ETF 
structure (PDB: 1efv) allowed the identification of the regions involved in FAD and AMP 
binding, MCAD interactions, and H-bonding between the ETFα and ETFβ subunits, which 
are represented as boxed segments in respect to the primary sequence positions. Stars denote 
MADD mutations [14] and are filled according to the clinical phenotype: severe forms (filled 
stars) and mild (open stars). 
 
 In respect to the ETFβ subunit, the scenario is not so clear as a result of 
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the fact that only 5 missense mutations are known in this subunit. 
Nevertheless, some highly susceptible regions can be defined: those involving 
two N-terminal segments of ETFβ which harbour simultaneously FAD and 
AMP binding residues (ETFβ Arg5-Ile20 and ETFβ Val34-Ala45), a region 
rich in AMP-protein interactions (ETFβ Gly123-Thr134), and segments 
involved in interactions with partner proteins, namely the recognition peptide 
within the anchor domain that constitutes the primary interaction site of 
partner proteins with ETF (ETFβ Asp184-Lys200) [4], and also a short 
segment centred around ETFβ−Glu165, an essential residue that destabilises 
positions compatible with fast inter-protein electron transfer, thus ensuring 
high complex dissociation rates [25], a strict requirement for subsequent 
interaction of reduced ETF with ETF-QO (Fig. 3.1 and 3.2).  
 
 Analysis of prototypic mutations 
 In order to provide complementary experimental validation of the 
putative mutational hotspots identified in ETF, three mutations in 
ETFβ were selected for subsequent analysis: ETFβ−p.Cys42Arg, 
ETFβ−p.Asp128Asn and ETFβ−p.Arg191Cys. With the exception of 
ETFβ−p.Asp128Asn [9, 23], none of these mutations had been previously 
expressed and purified for a thorough in vitro functional and structural 
characterization. All three mutations were detected in patients homozygous 
for the respective mutations allowing to relate the results to the phenotypes. 
Also, this selection fills a gap in respect to the characterisation of mutations in 
the ETFβ subunit, in which a lower number of MADD related mutations 
have been described compared to ETFα.  
 Although an all-embracing division cannot be established, these mutations 
typify different functional and folding effects. To better predict the structural 
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effect of these individual mutations we have built molecular models of these 
variants by homology modelling with respect to the wild type protein (Fig. 
3.3).  
 The ETFβ−p.Cys42Arg mutation, associated to a severe clinical 
expression, is expected to severely affect the interaction with the AMP 
cofactor, which plays a key role in the assembly of the ETF dimer [26-27]. 
 The ETFβ−p.Asp128Asn modification, which occurs at an outer layer of 
the FAD interacting moieties, has been shown to affect the plasticity of the 
tertiary structure and decrease directly the specific activity [23], and its 
mutation likely affects a stabilizing H-bond to ETFβ−Lys11 (Fig. 3.3).  
 Finally, the ETFβ−p.Arg191Cys mutation is hypothesised to affect 
catalysis by impairing interaction with the partner dehydrogenase, as this 
residue is localized in the anchor domain. Also, analysis of the model of the 
mutant variation shows that removal of ETFβ−Arg191 may destabilize the 
fold by disrupting electrostatic interactions with the nearby ETFβ−Glu47, 
ETFβ−Arg51 and ETFβ−Glu54 (Fig. 3.3).  
 The patients with the latter two mutations display mild forms of the 
disease, indicating that the modified conformation is nevertheless able to fold 
and assemble as a dimer, retaining some catalytic proficiency.  
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Figure 3.3– Structural details around the mutated positions The cartoons represent 
magnifications of the ETF structural regions in which the MADD variations are identified, 
overlaying the mutated and the original residues, as well nearby important. Straight dotted 
lines represent hydrogen bonds. Structures prepared using PyMOL. 
 
 Mutations affect folding efficiency 
 The effect of each mutation on the efficiency of protein folding was 
investigated by heterologous expression of the different variants and 
differential analysis of the soluble versus insoluble protein produced, in 
respect to that of wild type ETF and comparing cell cultures with 
standardized induction protocols displaying superimposable cell growth 
characteristics. Therefore, any difference strictly results from distinct 
expression levels of the heterologously expressed protein. Since it has been 
previously demonstrated that expression of ETFβ-p.Asp128Asn was 
improved upon cell growth at 30ºC [9], over expression of all the analysed 
ETF variants was carried out both at 30 and 37°C (Fig. 3.4). The results 
obtained show that while wild type ETF and the mild mutant variants 
(ETFβ−p.Asp128Asn and ETFβ−p.Arg191Cys) were well expressed as 
soluble proteins, the severe phenotype mutation (ETFβ−p.Cys42Arg) was not 
(Fig. 3.4).  
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Figure 3.4 – Expression levels of ETF variants at 30 and 37°C. Expression of ETF 
variants at 30 and 37°C was quantified from Western Blot analysis (left) and expressed in a 
bar graph (right) in respect to that of the wild type protein. See text and materials and 
methods for details. 
  
 The expression level of ETFβ−p.Arg191Cys was 87% of that of the 
soluble protein detected in the wild type whereas that of ETFβ−p.Asp128Asn 
was decreased to 48%. This suggests that while the expression of the variant 
ETFβ−p.Arg191Cys is almost unaffected, the ETFβ−p.Asp128Asn 
modification has a destabilizing effect on the folding process, making it rather 
susceptible to misfold and aggregate, or be degraded. This observation during 
cell expression agrees with the data obtained in vitro using purified 
ETFβ−p.Asp128Asn for which a higher proteolytic susceptibility was 
determined [23].  
 On the other hand, expression of the ETFβ−p.Cys42Arg variant yielded 
only 10% of ETF protein in the soluble fraction, indicating that this mutation 
affecting the AMP binding severely impairs ETF folding and assembly. 
Further expression assays lowering the E. coli growth temperature to 18ºC in 
an attempt to further improve conditions for in cell folding did not change the 
scenario, and even at this low temperature almost all the ETFβ−p.Cys42Arg 
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protein expressed went to the insoluble fraction. This result agrees with 
western blot analysis of skin fibroblasts from a patient carrying this mutation 
that showed no detectable ETF protein [18, 22]. 
 
 Molecular chaperones partly rescue ETFβ−p.Cys42Arg folding 
 An approach for the rescue of folding defects resulting from disease-
causing mutations is that of stimulating the so called proteostasis network 
[28]. This involves recruiting the protein quality control machinery and/or the 
action of small molecule substrates and cofactors as effectors of the folding 
process. In order to investigate if molecular chaperones could rescue the 
defective folding resulting from the ETFβ−p.Cys42Arg mutation, we have 
carried out co-expression experiments with the chaperonins GroEL and 
GroES (homologs of the human mitochondrial Hsp60 and Hsp10 chaperone 
system), and the chaperone dnaK (homolog of mammalian Hsp70s) and its 
cofactors dnaJ and GrpE. This strategy has been shown to result in the 
effective rescue of proteins with folding defects in other cases [17, 29-31]. 
 The results obtained show that the molecular chaperones could in fact 
partially rescue the protein to the soluble fraction (Fig. 3.5). However, 
enzymatic activity assays on the soluble fractions showed no detectable ETF 
activity, indicating that although molecular chaperones successfully rescue 
some soluble conformations these are still be incorrectly folded and/or with 
defective cofactor insertion: presumably these soluble forms are still 
substantially destabilised and poor incorporation of FAD and/or deficient 
interaction with the partner dehydrogenases impair activity.  
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Figure 3.5 – Effect of molecular chaperones on the expression of soluble ETFβ-
p.Cys42Arg. The amount of the ETFβ-p.Cys42Arg variant expressed in the soluble (s) and 
insoluble (i) form was quantified from western blots of cell extracts after inducing for 1 and 
6h the co-expression of the molecular chaperones GroEL/ES (left) or DnaK/J/GrpE 
(right). The bar graph shows the relative fraction of soluble (light grey) and insoluble (dark 
grey) protein. See text and materials and methods for details. 
 
 Structural and conformational properties of the ETFβ−p.Asp128Asn 
and ETFβ−p.Arg191Cys variant proteins 
 The ETFβ−p.Arg191Cys variant was purified to homogeneity and 
spectroscopically characterised. The ETFβ−p.Asp128Asn was also purified 
and characterized as described in [23] and the spectroscopic data from this 
variant were redrawn from published data [23] in order to allow a direct 
comparison with the new variant described. The protein fold and secondary 
structure were analysed using far-UV circular dichroism (Fig. 3.6). The spectra 
obtained are typical of folded proteins with a α/β fold, and with the clear α-
helix fingerprint with minima at 208 and 222nm.  
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Figure 3.6 - Spectroscopic analysis (A) far-UV CD (B) Visible absorption. The different 
variants were analysed in respect to their far-UV CD (A) and visible absorption (B) spectra 
(the legend is common for both panels): a. ETFβ-p.Asp128Asn, b. ETFβ–WT, c. ETFβ–
p.Arg191Cys. Spectra were slightly offset for clarity of comparison.  
 
 
 The mutant variants have superimposable spectra with respect to that of 
wild type ETF, indicating that the mutations do not disrupt the protein fold 
nor the secondary structure. Tryptophan emission spectra, which are 
indicative of tertiary structure interactions, were also recorded. ETF contains 
two tryptophan residues, and the fluorescence emission properties of this 
amino acid ranges typically from 315 to 350 nm and are related to solvent 
accessibility: a more solvent exposed tryptophan will emit at higher 
wavelengths. The results obtained show that both mutants have 10 nm red-
shifted maxima of the emitting band, with maximum emission at 330 nm 
versus 320 nm of the wild type ETF. This suggests that the structure of the 
mutant variants is not as constrained as that of the wild type ETF and that 
they displays a more dynamic tertiary structure. The spectroscopic fingerprint 
of the catalytic FAD cofactor was also analysed using visible absorption 
spectroscopy, which is very sensitive to changes in the H-bound interaction 
A
200 220 240 260
‐3
‐2
‐1
0
1
Δε
m
rw
(M
‐1
.c
m
‐1
)
Wavelength (nm)
a 
b 
c 
B
300 350 400 450 500
0.0
0.1
0.2
0.3
A
bs
or
ba
nc
e 
(a
.u
.)
Wavelength (nm)
600550
a 
b 
c 
b. ETF‐WT
a. ETFβ‐p.Asp128Asn
c. ETFβ‐p.Arg191Cys
Δε
m
rw
(M
‐1
.c
m
‐1
)
Δε
m
rw
(M
‐1
.c
m
‐1
)
A
bs
or
ba
nc
e 
(a
.u
.)
A
bs
or
ba
nc
e 
(a
.u
.)
Mutational hotspots in ETF  
 
 87 
C
h
ap
te
r 
3 
network around the cofactor. From the results obtained we could conclude 
that the environment of the functional cofactor does not change significantly 
in any of the mutants, as the two characteristic absorption bands with typical 
emission maxima at around 376 nm and 436 nm, are retained.  
 Overall, these results indicate that the ETFβ−p.Asp128Asn and 
ETFβ−p.Arg191Cys variants retain the fold and FAD interactions identical to 
those of the wild type protein but the differences in tryptophan fluorescence 
properties suggest decreased compactness and structural constraints in 
comparison to the wild type [23]. The latter aspect may have an impact on the 
enzymatic activity of the mutants as it likely contributes to a less efficient 
interaction with the partner acyl-CoA dehydrogenases and to increased 
protein instability. 
  
Protein instability and MCAD interactions underpin functional 
deficiency 
 The specific activity of the ETFβ−p.Asp128Asn and ETFβ−p.Arg191Cys 
variants was only 30% of that of the wild type protein (400 U/mg vs. 1300 
U/mg), which shows that, in addition to the lower folding efficiency, these 
mutant variants also display a decreased specific activity [23]. Since the 
mutant proteins retain structural features identical to those of the wild type 
protein under physiological conditions, we have investigated if differences in 
stability and interaction with the partner dehydrogenases could play a role. 
The interaction between the ETF variants and the medium chain acyl-CoA 
dehydrogenase (MCAD) was investigated in preliminary experiments by 
surface plasmon resonance, using MCAD immobilized in a NTA-sensor chip.  
 
 
 
 
Chapter 3 
 88 
 
 
 
 
 
 
Figure 3.7 – Sensograms showing 
interaction of wild type ETF (—), 
ETFβ-Asp128Asn (– – –) and ETFβ-
Arg191Cys (····) to MCAD. ETF variants 
in 50 nM solutions were injected over flow 
cells 1 and 2 at a flow rate of 40 μl.min-1. 
The sensograms represented are the result 
of RFU intensity in flow cell 2 minus RFU 
intensity of flow cell 1.  
 
 
 The results obtained showed that the ETFβ−p.Asp128Asn and 
ETFβ−p.Arg191Cys variants interact with MCAD, as an increase in the 
resonance signal is observed; however, the magnitude of the interaction at 
equilibrium was only 20-30% of that observed for wild type ETF, which is 
suggestive of a weaker interaction (Fig. 3.7).  
 The effect of the β−p.Asp128Asn and ETFβ−p.Arg191Cys mutations on 
the conformational stability was also investigated spectroscopically using far-
UV CD and fluorescence. Thermal denaturation of the proteins was 
monitored by following secondary and tertiary structure from far-UV CD and 
tryptophan and FAD fluorescence emissions (Fig. 3.8A). All the techniques 
used yielded similar transition curves for each of the proteins analysed, 
showing that all methods are monitoring the same unfolding event with no 
noticeable intermediates formed. The analysis showed the same order of 
relative stabilities of the proteins involved: ETF-WT > ETFβ−p.Arg191Cys 
> ETFβ−p.Asp128Asn. The thermal stability studies showed that wild type 
ETF unfolds at an apparent midpoint unfolding temperature (Tm) of 60 ºC, 
and that ETFβ−p.Arg191Cys is just slightly destabilised (ΔTm=-3°C, Tm = 57 
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°C), whereas ETFβ−p.Asp128Asn exhibits a more significant destabilization 
(ΔTm =-8°C, Tm = 52 °C) (Fig. 3.8A).  
Figure 3.8 – Stability profiles of ETFβ-p.Asp128Asn and ETFβ–p.Arg191Cys variants 
The thermal (A) and chemical (B) denaturation profiles of the ETFβ-p.Asp128Asn (inverted 
triangles) and ETFβ–p.Arg191Cys (open circles) were compared in respect to that of wild 
type ETF (closed squares). The solid curves represent two-state sigmoid curves from which 
the apparent midpoint denaturations were determined: melting temperatures (Tm) of 52, 57 
and 60 °C and midpoint denaturant concentrations (Cm) of 2.2, 2.9 and 3.9 M urea for 
ETFβ−p.Asp128Asn, ETFβ−p.Arg191Cys, and ETF-WT, respectively. See text and materials 
and methods for details. 
 
 Chemical denaturation was followed using tryptophan emission, and the 
curves allowed the determination of apparent midpoint urea concentrations 
(Cm). The obtained values were 2.2, 2.9 and 3.9 M for ETFβ−p.Asp128Asn, 
ETFβ−p.Arg191Cys, and ETF-WT, respectively (Fig. 3.8B). Again, the order 
of stabilities was the same as in thermal denaturations indicating that the 
ETFβ−p.Asp128Asn variation has a stronger destabilizing effect than 
ETFβ−p.Arg191Cys. In fact it was already described that 
ETFβ−p.Asp128Asn exhibits some plasticity in tertiary structure and 
decreased specific activity as a function of time during incubation at 39°C, in 
an in vitro mimic of a fever episode (see next chapter) [23].  
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 These differences among the studied variants can be rationalised from the 
molecular models made for the ETFβ−p.Asp128Asn and 
ETFβ−p.Arg191Cys variants (Fig. 3.3). The replacement of ETFβ−Asp128 
propagates to the AMP coordination sphere by affecting an hydrogen bond 
between Asp128 and Lys11, therefore substantially destabilising the protein 
fold, as shown by thermal and chemical unfolding studies (Fig. 3.8). Likewise, 
the ETFβ−p.Arg191Cys variation also impacts on the conformational stability 
of the fold as removal of ETFβ−Arg191 disrupts salt bridges with Glu47 and 
Glu57 at the nearby α1 helix. This case illustrates how a mutation in a 
functional region can also have an impact on overall protein stability. 
 
3.5. Conclusion  
 In this work we have analysed the effects of missense mutations in ETF 
which correspond to different clinical presentations in MADD patients, 
combining in silico studies with experimental biophysical and biochemical data. 
Overall, this study showed that ETF mutations map to structural hotspots 
with respect to subunit interaction, cofactor binding and interaction with 
partner proteins, and this provides a framework that allows to predict more 
accurately the probability for a given mutation to affect protein function. 
Variations leading to severe phenotypes do not map to a particular structural 
region and a direct correlation with the clinical display can not be generalised, 
a general problem that has hampered the prediction of mutation effects for 
many disease-relevant proteins. However, it appears that amino acid changes 
that lead to drastic alterations of the chemical properties of residues involved 
in catalytic regions and subunit interactions have a higher probability to result 
in severe effects. Among these is ETFβ-p.Cys42Arg which results in a protein 
that is unable to fold: such mutations will be clearly associated with severe 
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clinical phenotypes. Other mutations will affect folding, cofactor binding, and 
assembly to different degrees, and most of them will be associated with mild 
phenotypes. The degree of impairment in respect to the clinical display is 
rather difficult to predict, as different effects can be observed: cofactor 
binding, interaction with partner proteins and conformational stability. A key 
aspect arising from our study is the fact that conformational instability of 
dynamic substructures may be transferred to other parts of the protein, 
affecting the protein as a whole [32-34]. That is for example the case of 
ETFβ-p.Asp128Asn variant, in which the modification of a residue which has 
long range interactions with the cofactor, increases cofactor lability, decreases 
protein stability and interaction with the partner dehydrogenase. Likewise, the 
ETFβ–p.Arg191Cys variation directly affecting the recognition loop also 
decreases protein stability, as removal of the positively charged arginine will 
disrupt electrostatic interactions with the acidic residues within helix α1 (Fig. 
3.3). This effect then propagates to the whole structure, affecting its 
conformational stability. The observations made for ETF represent a 
scenario, which is also relevant for many other proteins, as it underpins the 
necessity to perform and carefully evaluate experimental expression of clinical 
protein variants in order to collect more data that will contribute to establish 
general principles that can be used to more accurately predict the functional 
outcome of genomic variations in metabolic disease.  
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4.1. Summary 
Mutations in the genes encoding the α-subunit and β-subunit of the 
mitochondrial electron transfer flavoprotein (ETF) and the electron transfer 
flavoprotein:ubiquinone oxidoreductase (ETF-QO) cause multiple acyl-CoA 
dehydrogenase deficiency (MADD), a disorder of fatty acid and amino acid 
metabolism. Point mutations in ETF, which may compromise folding, and/or 
activity, are associated with both mild and severe forms of MADD.  
Here we report the investigation on the conformational and stability 
properties of the disease-causing variant ETFβ-Asp128Asn, and our findings 
on the effect of flavinylation in modulating protein conformational stability 
and activity. A combination of biochemical and biophysical methods 
including circular dichroism, visible absorption, flavin, and tryptophan 
fluorescence emission allowed the analysis of structural changes and of the 
FAD moiety. The ETFβ-Asp128Asn variant retains the overall fold of the 
wild type, but under stress conditions its flavin becomes less tightly bound. 
Flavinylation is shown to improve the conformational stability and biological 
activity of the destabilized variant protein. Moreover, the presence of flavin 
prevented proteolytic digestion by avoiding protein destabilization. A patient 
homozygous for the ETFβ-Asp128Asn mutation developed severe disease 
symptoms in association with a viral infection and fever. In agreement, our 
results suggest that heat inactivation of the mutant may be more relevant at 
temperatures above 37 °C. To mimic a situation of fever in vitro, the 
flavinylation status was tested at 39 °C. FAD exerts the effect of a 
pharmacological chaperone, improving ETF conformation, and yielding a 
more stable and active enzyme. Our results provide a structural and 
functional framework that could help to elucidate the role that an increased 
cellular FAD content obtained from riboflavin supplementation may play in 
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the molecular pathogenesis of not only MADD, but genetic disorders of 
flavoproteins in general. 
 
4.2. Introduction 
 Multiple acyl-CoA dehydrogenase deficiency (MADD, MIM 231680; also 
designated glutaric acidemia type II (GAII)) is caused by mutations in either 
of the genes encoding the two subunits of electron transfer flavoprotein 
(ETF) or the monomeric enzyme ETF:ubiquinone oxidoreductase (ETF-QO) 
[1-2]. The clinical features of patients suffering from MADD are rather 
heterogeneous. It ranges from lethal cases with neonatal anomalies to mildly 
affected individuals, presenting in childhood or adulthood with hypoglycemic, 
encephalopathy and/or myopathy [1, 3].  
 There is evidence that the severity of the clinical phenotype, to some 
extent, depends on the location and nature of mutations in the genes 
encoding ETF or ETF-QO, with null mutations severely affecting mRNA 
expression, processing and/or stability being associated with lethal disease 
and missense mutations leaving some residual ETF/ETF-QO enzyme activity 
being associated with milder clinical forms [3-6]. In patients with milder 
disease variants, symptoms are often intermittent and only become evident 
during periods of illness and catabolic stress, indicating that in this group of 
patients - in whom residual ETF/ETF-QO enzyme activity allows 
modulation of the enzymatic phenotype – the disease severity does not 
depend only on the nature of the gene defect but also on cellular factors that 
may modulate the enzymatic phenotype [3]. This potential for in vitro 
modulation of the enzymatic phenotype has been established for a large 
number of disease-causing mutations affecting flavin-containing 
mitochondrial acyl-CoA dehydrogenases [7]. In these cases, missense 
mutations have been shown to impair folding to the native structure and/or 
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destabilize the native folded structure, resulting in decreased enzyme levels, 
which are subject to modification by environmental conditions like 
temperature and availability of quality control chaperones and proteases [8-
10].  
 The cofactor FAD is another cellular factor that may modulate the 
enzymatic phenotype of disease-causing mutations in mitochondrial 
flavoproteins. It has been observed for acyl-CoA dehydrogenases and for 
ETF that levels of available FAD have a strong impact on folding and 
maintenance of the native structure [11-14]. Moreover, supplementation of 
certain MADD patients [15-20], and some patients with isolated deficiencies 
of acyl-CoA dehydrogenases [21-23], with FAD or its precursor riboflavin 
results in an increase of the enzymatic activities and improvement of clinical 
symptoms (as reviewed in [24]), indicating that the enzymatic phenotype can 
be amenable to modulation by FAD in vivo also. Decreased dietary intake of 
riboflavin, and also certain physiological conditions like pregnancy (reviewed 
in [25]), fasting [26], exercise (reviewed in [27]), and infections (reviewed in 
[28]) may induce a depletion in FAD content, which will pose high demands 
on flavoproteins and perhaps especially on those with folding defects. This 
raises the interesting hypothesis that availability of FAD may be a 
predisposing factor in the cellular pathogenesis of genetic disorders of acyl-
CoA dehydrogenations. However, the additional possibility of a ligand-
induced folding effect exerted upon FAD binding to a mutant protein, which 
becomes destabilized upon an adverse physiological condition, has not yet 
been explored.  
 Here we address this hypothesis by studying in vitro the effect of 
flavinylation on the folding, conformational quality and proteolytic 
susceptibility of a mild variant of human ETF (ETFβ-Asp128Asn). Studies 
were also performed under physiological heat stress conditions, to mimic the 
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adverse physiological factors of a fever event.   
 
4.3. Material and methods 
 Chemicals  
 All reagents were of the highest purity grade commercially available. 
Octanoyl-CoA, FAD, AMP and urea were purchased from Sigma. 
Isopropyl−β−D-thiogalactopyranoside (IPTG) was purchased from VWR 
International. 
 
 Gene expression and protein purification  
 Escherichia coli JM109 cells from Promega transformed with ETF plasmids 
for the wild type (WT) and ETFβ-Asp128Asn variants were grown as 
described previously [3]. Briefly, cells were grown in dYT medium (16 g Bacto 
Tryptone, 10 g Bacto Yeast extract and 5 g NaCl) supplemented with 10 
μg.ml-1 kanamycin at 37ºC or 30ºC, up to a O.D. at 532 nm between 0.5-0.8, 
and then induced with 0.1 mM IPTG, for 4h. Cells were harvested by 
centrifugation, re-suspended in 10 mM Hepes, 10% ethylene glycol and 0.5 
mM phenylmethylsulphonylfluoride (Roth) (Buffer A) in presence of 0.1 
mg.ml-1 FAD, DNase (PVL) and disrupted in a French press. The soluble 
extract was applied to a 20 ml Q-Sepharose fast flow (Amersham Biosciences) 
equilibrated in buffer A. The column was washed with 5 column volumes  of 
buffer A, and bound proteins were eluted by a linear gradient ranging from 0-
1 M NaCl, in buffer A. ETF eluted as a pure protein at ~ 250 mM salt, as 
shown by SDS/PAGE. The proteins were fast-frozen using liquid nitrogen 
and stored at -80ºC. To ensure full occupancy of FAD sites, the protein was 
incubated with 2.5 fold molar excess FAD at 4 ºC overnight, and the free 
cofactor was removed with extensive washings by ultra filtration/dilution. 
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This procedure yielded FAD-to-protein ratios higher than 0.95 both for WT 
and ETFβ−Asp128Asn. Unless otherwise mentioned, all experiments were 
performed with the proteins containing full occupancy of FAD sites. 
 
 Structural analysis 
 The crystallographic structure of human ETF (PDB code: 1efv) was 
visualized using PyMOL (DeLano Scientific, USA). Analysis of the molecular 
interactions, cofactor contacts, topological features and generation of the 
model of the ETFβ-Asp128Asn was carried out using the WhatIF web server 
and the PDBsum database [29]. 
 
 Biochemical methods and activity assays 
 Protein concentration was determined using the Bradford assay. Flavin 
content was determined using the molar extinction coefficient ε436nm=13400 
M-1.cm-1 reported for FAD bound to ETF [30]. The enzymatic activity of the 
purified proteins was measured monitoring DCPIP reduction, in a coupled 
assay in which recombinant human MCAD (0.13 μM) and octanoyl-CoA (13 
μM), were employed, as described in [17]. The unit of activity measurements 
is defined as nmol of DCPIP reduced per minute, in the conditions used in 
the assay. All specific activities reported are based on total flavin content.  
 
 Spectroscopic techniques 
 UV/visible spectra were recorded at room temperature in a Shimadzu 
UVPC-1601 spectrometer. Far-UV CD spectra were recorded on a Jasco J-
715 spectropolarimeter with Peltier temperature control. A quartz polarized 1 
mm path length quartz cuvette (Hellma) was used, and protein concentrations 
ranged from 0.1-0.2 mg.ml-1. Fluorescence spectroscopy was performed using 
a Cary Eclipse instrument. For tryptophan emission studies, excitation was set 
Chapter 4 
 102 
at 280 nm, whereas for FAD emission, excitation was carried out at 436 nm. 
Unless otherwise noted, the slits for excitation and emission were set to 5 and 
10 nm, respectively. Typically, ETF protein concentration in fluorescence 
studies was 1 μM. 
  
 Flavin depleted ETF  
 Apo ETF was prepared using KBr solutions as in [31]. Briefly,  proteins 
were incubated in 3 M KBr, 10 mM Hepes pH 7.0 and 20% ethylene glycol 
solution for 1 hour. Released FAD was washed by repeated 
ultrafiltrations/dilutions in the presence of 1 mM dithiothreitol (DTT) and a 
10 fold molar excess AMP. In the case of the Asp128Asn variant, we also 
used a milder procedure taking advantage of the spontaneous process of 
flavin release, which had already been described for ETF [32], to produce a 
FAD-depleted fraction: when the protein is stored at -20ºC during 60 days, a 
decrease in FAD content and in the specific activity was observed, without a 
significant alteration of the protein folding, as determined by far-UV CD. 
Unbound FAD was removed by repeated ultrafiltrations/dilutions, yielding a 
sample with FAD content as low as 10%.  
 
 Dissociation constant for FAD binding 
 Apo ETF (1 – 4 μM) in the presence of 1 mM dithiothreitol, 10 fold 
molar excess of AMP, 10 mM Hepes pH 7.0 and 20% ethylene glycol was 
placed in a quartz cuvette at 15 ºC. After each addition of known amounts of 
FAD the mixture was allowed to equilibrate for 2 minutes and the visible 
spectrum was measured. The spectra of free and bound FAD are clearly 
distinct, making possible to quantify the concentration of each species at a 
given point. The fraction of bound FAD (fbound) was calculated using the 
proportionality fbound ∝ A1 – (ε1/ε2)×A2, where Ai is absorbance at the 
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wavelength i, and εi is extinction coefficient of free FAD at the wavelength. In 
this case, the wavelengths 465 nm (ε1= 10190 M-1cm-1) and 435 nm 
(ε2=10150 M-1 cm-1) were used to distinguish between bound and free FAD, 
respectively. The concentration of free FAD in the equilibrium was measured 
by the equation [FAD]free = [FAD]total – [ETF]total×fbound. The dissociation 
constant (KD) was obtained by fitting the data of two independent 
experiments, using the equation, fbound = [FAD]free/(KD + [FAD]free). 
 
 Kinetics of flavin release  
 Wild type ETF and the ETFβ−Asp128Asn (1 μM), both with full 
occupancy of FAD sites, were incubated at 39ºC for up to 60 minutes in 10 
mM Hepes, 20% ethylene glycol, pH 7.0. The kinetics of flavin release were 
monitored from the increase of the 530 nm emission peak arising from free 
FAD upon excitation at 436 nm. After 1 hour of incubation the samples were 
boiled for 5 minutes, to release the remaining FAD and a spectrum was 
collected at 39ºC. The fraction of bound FAD was determined at each point 
in respect to the point of 100% release of FAD. 
 
 Chemical stability studies 
 ETFβ-Asp128Asn (16 μM) depleted of flavin by milder procedure (see 
above), was incubated overnight with 10 mM Hepes, 10% ethylene glycol pH 
7.8 at 4ºC, in the absence and in the presence of a 2.5 –fold excess of FAD 
(40 μM). Samples were diluted in different urea solutions, in 2 mM Hepes pH 
7.8, equilibrated at room temperature for 15 minutes, after which the Trp 
emission spectra were recorded. Accurate concentration of the urea stock 
solutions was confirmed by refractive index measurements [33], and the pH 
was verified before the experiment. Fluorescence emission data in the 300-
400 nm interval was analyzed determining the average emission wavelength 
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(AEW), which takes into account both  variations in the emission intensity 
and position [34]. The denaturation curves were determined plotting the 
AEW as a function of urea concentration. Data were fitted to a sigmoid curve 
allowing the determination of an apparent Cm (denaturant concentration at 
the curve midpoint). The biological activity of the samples incubated 
overnight was also determined using the assay described above [17]. 
 
 Limited proteolysis with trypsin 
 Wild type and ETFβ-Asp128Asn with full occupancy of FAD sites were 
incubated overnight in 10 mM Hepes, 10% ethylene glycol pH 7.8 at 4ºC, in 
the presence of a 2.5–fold molar excess of FAD. Control samples without 
added FAD were also prepared. These fractions were used to test the 
susceptibility towards trypsin digestion. Samples were incubated with trypsin 
(bovine pancreas trypsin; PVL) at 35ºC in 0.1 M Tris/HCl pH 8.5, at a 10-
fold excess over the protease. As a control, identical samples  without trypsin 
were submitted to the same procedure. Aliquots with 0.05 nmol of protein 
were sampled at different time points up to 2 hours, and the reaction was 
stopped by adding SDS-PAGE loading buffer (2 % SDS and 5 % β-
mercaptoethanol). As an internal standard for the quantity of loaded protein 
in the gel, bovine serum albumin (BSA) 5 μM final concentration was also 
added to loading buffer solution. The products of the proteolysis reaction 
were analyzed by 12% SDS/PAGE, which were stained with Coomassie. 
Protein was quantified densitometrically (Biorad Chemidoc XRS) and the 
percentage of undigested protein was calculated in respect to the total amount 
of protein at time zero. Reported values refer to the sum of intensities of α 
and β bands. 
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 Thermal stress studies 
 ETFβ-Asp128Asn and wild type ETF (12 μM), in 10 mM Hepes, 20% 
ethylene glycol pH 7.0, were incubated (100 µL) different temperatures (33 - 
44ºC) for one hour, and the residual activity was determined in relation to 
the activity at time zero (duplicate measurements were preformed for each 
temperature, and two independent protein batches were assayed). To study 
the effect of FAD on the loss of activity, ETFβ-Asp128Asn (16 μM) was 
incubated at 39ºC up to 90 minutes, in the presence of a 2.5 -fold excess of 
FAD (40 μM). Control samples without added FAD were also prepared and 
treated in the same conditions. At ~ 10 min intervals, 3.5 µL of the samples 
were collected to determine the residual activity as indicated above. For the 
measurements using fluorescence spectroscopy, spectra were collected at 2 
minutes intervals, up to 1 hour. Tryptophan emission was recorded from 
300-400 nm with excitation at 280 nm. Unless otherwise noted, ETF 
concentration used was 1 μM. 
 
4.4. Results 
 Impact of the ETFβ-Asp128Asn mutation  
 ETF is a heterodimer composed of 30 kDa (ETFα) and 28 kDa (ETFβ) 
subunits, containing one structural AMP, and one catalytic FAD group [2]. 
The MADD ETFβ-Asp128Asn mutation [3, 35] which is here investigated 
occurs in a β-turn within a very conserved region of the β−subunit, that 
comprises the segment 126-AIDDD-130. These residues have contacts with 
the AMP and are involved in inter-subunit interactions with residues from 
the α−subunit, via hydrogen bonds and non-bonded contacts. In particular, 
Asp 128 is directly involved in a network of interactions: it is salt bridged to 
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the nearby Lys 11 (2.96 Å) from the β−subunit N-terminus; and it contacts 
with several residues from the α−subunit (Ile148, Tyr149, Asn152). Also, 
ETFβ−Asp130 is hydrogen bonded to ETFα−Gln265, a residue that contacts 
with the FAD ring. Therefore, although Asp128 is not directly involved in an 
interaction with the flavin, it is located in a relatively sensitive region of the 
protein, in respect to dimer contacts and flavin binding. Indeed, this is noted 
by the decreased catalytic activity of purified ETFβ-Asp128Asn variant (400 
units.mg-1), which is only ~30 % of that of the wild type protein. Also, the 
temperature deactivation profile of the ETFβ-Asp128Asn variant is much 
more pronounced than that of the wild type protein (Fig. 4.1). For the ETFβ-
Asp128Asn variant, a rapid drop of the activity is observed if the protein is 
incubated for 60 min at temperatures above 37 ºC, whereas at 37 ºC and 
below, more than 85 % of the initial activity is retained.  
 
 
 
 
 
Figure 4.1: Thermal inactivation profile 
of ETFβ-Asp128Asn (—) and wild-type 
ETF (---). For each protein, independent 
samples were incubated for 60 min at 
different temperatures, and the remaining 
catalytic activity was determined (see 
“Experimental Procedures”). Two 
independent replicates were assayed, and 
each point represents the average of two 
experiments obtained with different protein 
batches (standard errors are plotted). 
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 Folding and conformation of ETFβ-Asp128Asn 
 In order to define the structural characteristics of the ETFβ-Asp128Asn 
variant protein, we have investigated the folding and conformational 
properties of the purified protein. Circular dichroism (CD) analysis on the 
far-UV region showed that the spectrum of the mutant protein, is dominated 
by minima at 222 and 209 nm, which are typical of a well folded α/β protein 
(see Fig. 3.6). In fact, the two ETF subunits, although they share very little 
sequence identity, have the same structural topology, consisting of a three-
layered αβα sandwich Rossman fold architecture. A comparison between the 
far-UV CD spectra of the mutant and wild type ETF shows that the mutation 
has no impact on the overall fold of the protein.  
 More subtle effects on the tertiary structure were monitored using 
fluorescence spectroscopy. The protein contains two tryptophan residues, 
one in each subunit (ETFα-Trp199 and ETFβ-Trp144), which are relatively 
accessible to the solvent, making them particularly sensitive conformational 
probes. The tryptophan emission maximum of ETFβ-Asp128Asn is 10 nm 
red-shifted in respect to that of wild type protein (Fig. 4.2). As a lower 
emission maximum denotes a more solvent-shielded tryptophan, this shift in 
the emission from ~320 to ~330 nm indicates that the aromatic moieties in 
ETFβ-Asp128Asn are more easily accessible to water molecules. This result 
suggests looser tertiary contacts in ETFβ-Asp128Asn, in comparison to wild 
type ETF.  
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Figure 4.2: Fluorescence emission 
spectra of ETFβ- Asp128Asn (—) and 
wild type ETF (·····) and denatured 
ETFβ– Asp128Asn (– – –). Emission 
spectra were determined using λex = 280 
nm in 10 mM Hepes, pH 7.0, containing 
20% ethylene glycol, at 39ºC; the 
concentration of proteins was 1 μM. The 
spectrum of denatured ETFβ– Asp128Asn 
was measured after boiling the protein for 
5 min. 
 
 The FAD moiety in ETFβ-Asp128Asn was analyzed by visible absorption 
spectroscopy. The two bands typical of flavin, with maxima at 436 and 373 
nm, were observed (see Fig. 3.6). The latter, is ~3 nm blue shifted in respect 
to the band observed in wild type ETF, which has a maximum at 376 nm. 
Additionally, the intensity of the FAD fluorescence is a reporter of the status 
of the flavin moiety, as the FAD emission is quenched when it is bound to 
the protein [36]. The FAD, which is in an extended conformation according 
to the crystal structure, has a similar emission spectrum in both proteins, 
denoting a characteristic weak band centered at ~500 nm.  
 
 Cofactor dissociation in ETF 
 To verify if the β-Asp128Asn mutation induces a perturbation of the 
flavin binding site, the dissociation constants for FAD binding to wild type 
ETF and ETFβ-Asp128Asn mutant were measured. When sub-
stoichiometric quantities of FAD were added to wild type ETF apoprotein, 
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the characteristic ETF visible spectrum became immediately evident (Fig. 
4.3A). In the case of ETFβ-Asp128Asn, an increased aggregation of the 
apoprotein was noted during the experiment, as evidenced from the increase 
of absorbance at lower wavelengths due to scattering (Fig. 4.3B). 
Nevertheless, the absorption spectrum characteristic of ETF was still 
observed. 
 
Figure 4.3: Binding of FAD to apoprotein wild-type ETF (A) and apoprotein ETFβ-
Asp128Asn (B). Known amounts of FAD were added successively to the solution 
containing 4 μM apoprotein wild-type ETF or 1.4 μM apoprotein ETFβ-Asp128Asn in the 
presence of 10 mM Hepes, 20% pH 7.0, 20% ethylene glycol, containing 1 mM dithiothreitol 
and 10-fold molar excess AMP, at 15 °C. Spectra were measured after each addition of FAD, 
and the difference in respect to the apoprotein is shown (arrows point the spectral variation 
upon increasing concentrations of FAD). The binding curves (inset) were obtained by 
computing the fraction of bound FAD (see “Experimental Procedures”), and are the sum of 
two independent experiments. The solid lines in the inset correspond to a fit with a 
KD= (0.04±0.01) μM for the wild-type ETF and KD= (0.04±0.02) μM for ETFβ-Asp128Asn. 
 
 Since the spectra of free and bound FAD are distinct, it is possible to 
quantify the concentration of each species at a given point (as described in 
Experimental Procedures). By fitting the data with a one-site binding equation 
(Figure 4.3, A and B, inset) the dissociation constant of KD = 0.04 ±0.01 µM 
and KD = 0.04 ±0.02 µM was obtained for the wild type protein and ETFβ-
Asp128Asn, respectively. These low values are close to the detection limit 
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that can be measured in these conditions, and should correspond to an upper 
limit.  
 Considering that the effect of the mutation on the specific activity is more 
pronounced above 37 °C (Fig. 4.1), the kinetics of flavin dissociation at 39°C 
was investigated for the ETFβ−Asp128Asn in comparison to wild type ETF 
(Fig. 4.4). Given that the intensity of the emission spectrum of free FAD is 
higher than that of bound FAD, the release of flavin was determined 
monitoring the increase in flavin fluorescence emission, similarly to a 
previously described methodology [31]. The point of 100% flavin release was 
measured after boiling the protein for 5 min. To rule out that the increase in 
intensity was due to conversion of FAD into FMN (10 fold more 
fluorescent), commercial FAD was treated in the same conditions, and no 
significant change in intensity was observed. Replicate assays were made, 
allowing to determine an apparent koff of 0.38±0.06 h-1 for ETFβ-Asp128Asn 
and 0.13±0.02 h-1 for WT (n = 3). The value obtained for the wild type ETF 
is in excellent agreement with the reported value in the value in literature 
(0.12 h-1 [31]).  
 
 
 
 
Figure 4.4: Kinetics of flavin release. 
ETFβ-Asp128Asn (—) and wild-type ETF (-
--) were incubated in 10 mM Hepes, 20% 
ethylene glycol pH 7 at 39 °C. The release of 
flavin was monitored as a function of time, 
following the emission of released FAD 
upon excitation at 436 nm. 
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 After incubation at 39ºC, the original fluorescence spectrum could not be 
reverted by incubation at 4ºC for 24H. Moreover, the release of flavin 
correlates with a decrease in specific activity, which could not be rescued by 
incubation with excess FAD. The results showed that under these conditions, 
the ETFβ-Asp128Asn variant releases FAD irreversibly at a 3 fold higher rate 
than wild type ETF, denoting a weaker interaction of the cofactor with the 
protein at 39 °C or a less stable apoprotein.  
 
 Flavinylation improves the conformational stability of apo 
Asp128Asn variant 
 In order to test if flavin insertion or its absence has an effect on the 
conformational stability and overall folding of the protein, we analyzed the 
effect of flavinylation on the ETFβ-Asp128Asn variant. For this purpose, we 
determined urea denaturation curves, monitoring tertiary structure and 
packing changes in the protein from tryptophan-fluorescence emission. The 
effect of FAD was tested using as a starting point a fraction of apo ETFβ-
Asp128Asn, which was depleted in flavin (<0.1 mol FAD/ mol protein) but 
that nevertheless retained, at least partially, the secondary structure and 
overall folding, as inferred from far-UV CD (see experimental procedures). In 
agreement with the lack of FAD, the enzymatic activity of this fraction was 
residual. The urea denaturation profile of this fraction yielded a cooperative 
transition, with an apparent midpoint denaturant transition (Cm) of 1.4 M 
(Fig. 4.5 A). However, incubation with FAD resulted in a dramatic increase of 
the Cm up to 2.3 M, and improved the cooperativity of the transition as 
reflected by the steeper slope (Fig. 4.5 A). These effects, which are indicative 
of a substantial increase in the conformational stability of ETF, correlate with 
an insertion of FAD in the protein, as denoted from the 14-fold increase in 
Chapter 4 
 112 
the enzymatic activity upon incubation (from 12 to 166 units.mg-1). 
Nevertheless this increase was less than the initial activity, when a ratio of 
0.95 FAD:Protein was obtained, meaning that apoprotein could not be totally 
rescued. This suggests that a heterogeneous solution of apoprotein was 
obtained, in agreement with some degree of irreversible aggregation seen 
before for the apoprotein of ETFβ-Asp128Asn mutant in the reconstitution 
experiments. Inspection of the tryptophan emission spectrum at the different 
conditions, allowed us to evaluate the changes in the protein packing and 
tertiary contacts, as a result of FAD binding. The presence of flavin induced a 
more compact conformation as seen by the tryptophan emission shift from 
337 nm in apoprotein to 333 nm in the reconstituted form, which denotes a 
more solvent-shielded Trp moiety [37] (Fig. 4.5 B).  
 
Figure 4.5: Urea-unfolding curves (A) and Trp fluorescence emission spectra (B) for 
ETFβ-Asp128Asn, in the presence (?) and in the absence (?) of FAD. Independent 
samples were incubated, with and without FAD, at different urea concentrations and the 
conformational changes were followed monitoring the average emission wavelength (AEW) 
in the 300–400 nm interval (see “Experimental Procedures”). The protein concentration used 
was 1 μM, and in the cases in which FAD was present, a 2.5-fold excess of cofactor over 
protein was added. The buffer used was 2 mM Hepes, pH 7.8, and the measurements were 
carried out at 25 °C. The curves correspond to a sigmoid fit to the experimental data. 
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Overall, ETF deflavinylation, which results in a structure with poorer tertiary 
interactions and decreased biological activity, in spite of the maintenance of 
an α/β fold, can be rescued to some extent by reincorporation of FAD in the 
protein. 
 
 Flavinylation modulates the proteolytic susceptibility of ETFβ-
Asp128Asn 
  In order to test if the conformational stabilization afforded by 
flavinylation could contribute to minimize the propensity of the mutant 
ETFβ-Asp128Asn to be degraded, the resistance towards proteolysis was 
investigated. The assay used consisted of monitoring the extent of limited 
proteolysis by trypsin in the presence of FAD, and in its absence. The 
rationale for this approach is that a destabilized conformation will have a 
higher number of cleavage sites accessible to digestion, as a result of a higher 
flexibility of the polypeptide chain [38]. Therefore, this approach allows us to 
evaluate the propensity for in vivo degradation. Trypsin digestion was carried 
out at 35°C for up to 2 hours. Samples drawn every 30 minutes were analyzed 
by SDS-PAGE (Fig. 4.6). The protein samples without trypsin were heated 
for 2 hours. In the absence of FAD, the two subunits start to be substantially 
degraded after 60 minutes of incubation with trypsin (Fig. 4.6). After 120 
minutes the protein amount decreases to 70% (Fig. 4.6). Interestingly, the 
presence of FAD could preserve the native conformation at 85% (Fig. 4.6). 
Control experiments in the absence of trypsin and on wild type ETF were 
also carried out (Fig. 4.6). 
 
 
 
 
Chapter 4 
 114 
 
Figure 4.6: Effect of flavinylation on ETFβ-Asp128Asn - limited proteolysis. Proteolytic 
digestion during 2 h at 35°C was analyzed by SDS-PAGE. Protein was previously incubated 
overnight at 4 °C in 10 mM Hepes, 10% ethylene glycol in the absence and presence of 2.5 
fold excess of FAD. The control represents protein treated in the same conditions and heated 
for 2 h in absence of trypsin. Bovine serum albumin was added to loading buffer as an 
internal standard and to correct for variations in the amount of loaded protein. The graph 
corresponds to the densiometric quantification of undigested protein. The sum of α and β 
band intensities are plotted as a percentage of undigested protein in respect to the total 
amount of protein at time zero.  
 
 These results suggest that flavinylation, and the presence of FAD, induce 
a protease-resistant conformation in ETF. Moreover, the presence of FAD 
induce changes in the conformation of the ETFβ-Asp128Asn variant, which 
restore its proteolytic resistance to levels of the wild type protein (Fig. 4.6).  
 
 External FAD preserves folding and enzymatic activity during 
thermal stress  
 We have designed an in vitro experiment aimed at testing a possible effect 
of dietary riboflavin supplementation for a mild mutation like 
ETFβ−Asp128Asn during thermal stress. To analyze the relevance of an 
increased FAD level during a fever episode, the effect of incubating 
ETFβ−Asp128Asn during 60 minutes at 39°C, in the absence and in the 
presence of a 2.5 fold excess of FAD, was investigated (Fig. 4.7). Activity 
measurements during the thermal perturbation showed that the presence of 
FAD prevents loss of activity that goes down to 50% of the initial value (225 
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units.mg-1), in comparison to control samples (Fig. 4.7A). In contrast, in the 
control samples in the absence of FAD, the increased Trp emission is 
indicative of poorer and less compact tertiary structure (Fig. 4.7B). In 
conclusion, the presence of FAD during thermal stress of ETFβ−Asp128Asn 
prevents the loss of tertiary structure and protein compactness, as well as the 
loss of enzymatic activity. 
Figure 4.7: Effect of FAD during a thermal stress. Independent samples were incubated 
in 10mM Hepes, 20% ethylene glycol in absence (?,---) and presence of 2.5-fold excess of 
FAD (?,—) at 39 °C. Panel A represents loss of biological activity in relation to the initial 
value. Panel B shows decrease in tertiary contacts determined from the variation of the 
maximum wavelength on the tryptophan region (300–400 nm). 
 
4.5. Discussion 
 In numerous diseases involving missense mutations in mitochondrial 
flavoproteins, symptoms are in some cases improved by dietary riboflavin 
supplementation [18-21, 24]. Perhaps because of the many reports on 
successful treatment of a variant group of MADD patients, the “riboflavin-
responsive MADD patients” [18-20, 39-42], milder forms of MADD in 
general are treated with riboflavin, but without knowing the molecular 
mechanism of this treatment. MADD is therefore a good candidate to study 
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FAD sensitive conformational instability of flavoproteins due to disease-
causing missense mutations. We chose the ETFβ-Asp128Asn protein for the 
following reasons: it was identified in homozygous form in a patient with 
MADD, who had no obvious symptoms until the age of two years when 
disease symptoms were precipitated in connection with virus infection and 
fever. The patient died after 2 days. A sibling from whom no genetic material 
was available, had died suddenly and unexpectedly at the age of 6 months 
[35]. Subsequent analysis in cultured fibroblasts from the patient showed 
residual activity and presence of reduced levels of both ETF subunits [3]. 
Upon expression of the mutant protein in an E. coli system, decreased levels 
of the mutant protein compared to wild type were observed. This could be 
partially rescued by growing the bacterial cells at lower temperature, but not 
by chaperone co-overexpression. Furthermore, the ETFβ-Asp128Asn mutant 
protein displayed reduced thermal stability [3]. Based on these observations, it 
was hypothesized that the mutant protein displays decreased conformational 
stability, which is sensitive to environmental conditions like temperature, and 
likely to the availability of FAD cofactor.  
 With our detailed analysis we have here shown that the ETFβ-Asp128Asn 
mutation decreases significantly the specific activity and introduces some 
plasticity on the tertiary structure, but does not negatively impact the overall 
protein fold. In agreement, the level and activity of this protein during 
heterologous expression was found to be improved when the cells were 
grown at low temperature [3], an indication that the mutation had a 
destabilizing effect on the protein. In more detail, the temperature 
inactivation profile of ETFβ-Asp128Asn demonstrates that the activity of the 
protein remains mainly unaltered by incubation at low temperatures, but starts 
to become more unstable at temperatures above 37 ºC. In agreement with 
this observation, we found that FAD binds very tightly in both ETFβ-
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Asp128Asn and wild type protein at 15 ºC, but during heat stress (39 ºC) the 
flavin is irreversibly released three fold faster in the mutant, resulting in a 
concomitant loss in the specific activity. This in vitro result is in line with the in 
vivo situation where the symptoms emerged associated to an episode of stress. 
We then moved to analyze if flavinylation would have an effect on ETF 
stability, and found that apart from the expected increase in the enzymatic 
activity, saturation of the FAD binding site significantly improved the stability 
and conformation of the apoprotein, and rescued destabilized forms, as 
inferred from urea unfolding studies. The marked decrease in stability of the 
apoprotein and the fact that the irreversible deactivation at 39ºC is 
accompanied by flavin release suggest that if the cell is challenged with a 
stress condition or a decreased level of FAD, then the protein could become 
deflavinylated and as a consequence more destabilized. In addition, the 
presence of external FAD in the medium also increased the proteolytic 
stability of the protein, a finding which may be important as it again suggests 
that an excess of FAD in the patient cell may increase the lifetime and 
availability of an active form of the protein. Analysis of this effect in the 
context of a physiological heat stress condition, which mimicked a fever 
episode (incubation at 39°C for one hour), clearly showed that exogenous 
FAD prevented conformational destabilization and activity loss. Studies of 
tissue samples  or cultured fibroblasts from patients with MADD have shown 
an activity increase upon supplementation  with riboflavin or FAD [24]. This 
increase in activity may result from a direct saturation of the active site, or 
from an improvement of the in vivo maturation and assembly of the protein 
involved. It has been shown that FAD plays an important role during in vitro 
folding of mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD), 
nucleating the formation of a competent oligomeric conformation during 
hsp60 assisted folding [12]. Here we postulate another possibility, which may 
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occur concomitantly to the previous one. The hypothesis is based on the fact 
that externally added riboflavin leads to an increase in the FAD content, as 
shown in yeast mitochondria [43] and human mitochondria [41-42]. In this 
scenario, increased availability of the FAD ligand would promote its binding, 
which induces conformational changes which propagate to the overall 
structure. This may occur by a structure nucleation effect, by which certain 
motions in the molecule are restrained, leading to a decreased ‘breathing’ of 
the protein structure. This results in a better packed conformation, with 
improved local interactions, yielding a protein with a higher conformational 
stability. More importantly, in the context of the cell, this effect also leads to a 
reduction of the sites, which are available to proteolytic degradation by 
cellular proteases. A protein with decreased conformational packing and 
stability is a better substrate for the protein degradation machinery, as in this 
case, the structural destabilization makes digestion sites accessible which 
would be otherwise unavailable.  
 As the ETFβ-Asp128Asn mutation is not located in the FAD binding 
domain, our observations provide a structural and molecular rationale to 
understand the basis of one of the many possible effects of riboflavin 
supplementation in patients with milder forms of genetic deficiencies of acyl-
CoA dehydrogenation, where the mutation sites are distributed all over the 
structure, suggesting that destabilization of local interaction may lead to long-
distance conformational changes that may affect FAD binding. In these 
patients with mutations that do not totally impair protein folding, but result in 
a less stable or inactive conformation, the increase in FAD concentration 
resulting from riboflavin supplementation may enhance the conformational 
quality of the affected protein, increasing the cellular availability and life time 
of a biologically active molecule, by a mechanism identical to the one we 
report in this work. This effect could be particularly relevant under certain 
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pathophysiological conditions like fever but also fasting, infections, pregnancy 
and low dietary intake of riboflavin that may cause low cellular FAD content 
and thereby poses high demands on folding defective flavoproteins that are 
up-regulated under less favorable folding conditions. We have experimentally 
shown that flavinylation recovered the properties of the ETF mutant variant 
after a heat stress condition, which simulated a fever event, a condition which 
is known to aggravate the symptoms of patients suffering from mild fatty acid 
β-oxidation disorders [3]. These observations establish a proof of principle, 
which can be generalized and tested in many other genetic defects in 
mitochondrial flavoproteins. 
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5.1.  Summary 
 The electron transfer flavoprotein (ETF) is a dimeric flavoenzyme 
involved in mitochondrial beta-oxidation. Genetic defects in this pathway 
result in disease as a result of impaired folding and catalysis. ETF harbors a 
polymorphic variation at position 171 in its alpha-subunit, resulting in either a 
threonine (ETFα-Thr171) or an isoleucine (ETFα-Ile171). Interestingly, the 
ETFα-Thr171 variant is overrepresented in patients suffering from a mild 
form of very long chain acyl-CoA dehydrogenase deficiency, suggesting that 
this polymorphism may contribute to the phenotype, by an as yet unknown 
molecular mechanism.  
 Here we report an investigation on the effect of the variation of the 
ETFα-Thr/Ile171 polymorphism on the ETF folding, stability and dynamics 
under thermal stress. Our results show that the two variants have the same 
thermodynamic stability (Tm=58°C), although the ETFα-Thr171 variant has a 
decreased thermal inactivation midpoint (Tminact=49°C) in comparison to that 
of ETFα-Ile171 (Tminact =58°C). We found that upon thermal stress, the 
ETFα-Thr171 variant is prone to faster cofactor (FAD) loss and 
conformational destabilization. This variant also exhibits an increased 
conformational dynamics during thermal stress mimicking a fever episode in 
vitro: upon 2 hours at 39°C, ETFα-Thr171 looses half of its activity, whereas 
that of ETFα-Ile171 remains at ~85%. The GroEL chaperonin can rescue 
this effect, as it captures and refolds the dynamic populations of thermally 
destabilized ETFα-Thr171.  
 This polymorphic position thus affects the conformational landscape and 
protein function under thermal stress, a common metabolic trigger for the 
manifestation of the phenotype in mitochondrial beta oxidation defects. 
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5.2. Introduction 
 The mitochondrial oxidation of fatty acids and amino acid and choline 
catabolic reactions constitute important pathways through which energy is 
produced. Among others, it involves a series of acyl-CoA dehydrogenases 
(ACDHs) that selectively oxidize acyl-chains of different lengths, transferring 
this reducing power to the respiratory chain via electron transfer flavoprotein 
(ETF) and its partner ETF:ubiquinone oxidoreductase (ETF-QO), the 
terminal membrane-bound enzyme of this pathway [1-2]. Mutations in either 
ETF or ETF-QO account for a disease called multiple acyl-CoA 
dehydrogenase deficiency (MAAD) [3].  
 Besides rare disease-associated mutations, a few single nucleotide 
polymorphisms (SNPs) have also been reported. In particular, two 
polymorphisms have been described for human ETF, one in codon 171 of 
ETFα, and the other in codon 154 of ETFβ [4-5]. The polymorphism in 
ETFα replaces a threonine for an isoleucine, whereas at ETFβ a methionine 
is replaced by a threonine. The four possible combinations have been studied 
in vitro by heterologous prokaryotic expression [6]. It has been shown that the 
ETFα-Thr171 variant had a decreased enzymatic stability. The authors also 
assessed the frequency of the polymorphisms in a control group and patient 
groups associated with fatty acid oxidation disorders. Patients with the mild 
form of VLCAD deficiency [7] were found to have a significant 
overrepresentation of the α-Thr171 variant [6]. Although only a small 
number of patients was analysed, this suggested that the ETFα-Thr171 might 
modulate the phenotype by an as yet unknown mechanism [6]. 
 Polymorphisms are nucleotide sequence variations occurring at a 
frequency greater than 1% within the general population. As suggested above 
these genetic variations may play a role as modulators of disease, especially in 
combination with other metabolic stressors such as increased body 
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temperature (fever), which has been documented to trigger and exacerbate 
the phenotype in patients with beta oxidation defects [8]. However, little is 
known about the molecular mechanisms through which this effect is exerted.  
 In this study we show that the polymorphic position ETFα-171 plays a 
role in modulating the conformational dynamics and biological activity under 
thermal stress conditions.  
 
5.3. Materials and Methods 
 Chemicals 
 All reagents were of the highest purity grade commercially available. 
Octanoyl-CoA, and FAD were purchased from Sigma. Isopropyl-β-D-
thiogalactopyranoside (IPTG) was purchased from VWR International. 
 
 Gene expression and protein purification 
 E. coli JM109 cells transformed with the ETF plasmids, ETFα-171Ile and 
ETFα-171Thr respectively [6], were grown in LB (Luria–Bertani) 
supplemented with 10 μg.ml-1 kanamycin at 37ºC in a shaking incubator until 
OD532 of 0.5-0.8 was reached. The cells were then induced with 1 mM IPTG 
for 4 hours. Cells were harvested by centrifugation, re-suspended in 10 mM 
Hepes, 10% ethylene glycol and 0.5 mM phenylmethylsulphonylfluoride 
(Roth) (Buffer A) in presence of DNase (PVL) and disrupted in a French 
press. The soluble extract was applied to a Q-Sepharose fast flow (GE 
Healthcare, 20 ml) equilibrated in buffer A. The column was washed with 5 
volumes of buffer A, and bound proteins were eluted by a linear gradient 
from 0-1 M NaCl, in buffer A. Pure ETF eluted at salt concentration around 
250 mM salt, and purity was confirmed by SDS/PAGE. Protein 
concentration was determined using the Bradford assay. Flavin content was 
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determined using the molar extinction coefficient ε436nm=13400 M-1.cm-1 
reported for FAD bound to ETF [9]. Pure ETF fractions with a 2.5 fold 
molar excess FAD were fast-frozen using liquid nitrogen and stored at -80ºC. 
 
 GroEL expression and purification 
 The E. coli chaperonin, GroEL was isolated and purified as described 
earlier [10]. Briefly, the GroEL was purified using an Affi-Gel Blue treatment, 
after which the samples were precipitated in 45% (V/V) acetone at room 
temperature for 5 min. The precipitate was centrifuged at 10,000 g for 30 min 
and, after the removal of acetone, re-suspended in buffer. Residual protein 
aggregates and acetone were removed by a brief centrifugation followed by an 
extensive dialysis. Protein purity was confirmed by SDS-PAGE and by the 
second derivative analysis of the absorbance spectra.  
  
 Activity assays 
 ETF enzyme activity was measured following 2,6-dichlorophenol 
indophenol (DCPIP) reduction at 600 nm in a coupled assay in which 
recombinant human MCAD and octanoyl-CoA were employed, as described 
in [11]. The unit of activity measurements is defined as nmol of DCPIP 
reduced per minute, in the conditions used in the assay. All specific activities 
reported are based on total flavin content. 
 
 Spectroscopic methods 
 Before each experiment FAD excess added to buffers as a preservative 
was removed by extensive washing using ultra filtration/dilution, and all 
experiments were performed with pure proteins containing full occupancy of 
FAD site. UV/visible spectra were recorded at room temperature in a 
Shimadzu UVPC-1601 spectrometer with cell stirring. Fluorescence 
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spectroscopy was performed using a Cary Eclipse instrument. For aromatic 
emission excitation wavelength was set at 280 nm, and FAD emission was 
followed setting excitation wavelength at 436 nm; slits were 5 and 10 nm for 
excitation and emission, respectively. Typically protein concentration was 1 
μM. CD spectra were recorded on a Jasco J-815 spectropolarimeter with a cell 
holder thermostatically controlled with a Peltier. A quartz polarized 1 mm or 
10 mm path length quartz cuvettes (Hellma) was used, and protein 
concentrations were typically 0.1 or 1.0 mg.ml-1, for far-UV and near-UV 
measurements, respectively. 
 
 Thermal stability  
 Thermal unfolding with a linear temperature increase was followed using 
circular dichroism (ellipticity variation at 222 nm and 288 nm) and 
fluorescence spectroscopy, tryptophan emission (λex =280 nm; λem =340 nm), 
FAD emission (λex =436nm; λem =530 nm) and FRET from tryptophan 
emission to FAD cofactor (λex =280 nm; λem=530 nm). In all experiments, a 
heating rate of 1ºC.min-1 was used, and temperature was increased from 30 to 
90ºC. For the thermal stability stepwise following activity, samples incubate 
for 10 minutes at different temperatures, from 30 to 75 ºC, and activity was 
measure for each time point. Data were analysed according to a two-state 
model, and fits to the transition curves were made using OriginPro8. 
  
 Kinetics of flavin release 
 ETF variants 1 μM were incubated at different temperatures (39, 45, 50 
and 55 ºC) for up to 60 minutes in 10 mM Hepes, pH 7.8. The kinetics of 
flavin release were monitored from the increase of the 530 nm emission peak 
arising from free FAD upon excitation at 436 nm. After 1 hour of incubation 
the samples were boiled for 5 minutes, to release the remaining FAD and a 
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spectrum was collected at 25 ºC. The fraction of bound FAD was determined 
at each point in respect to the point of 100% release of FAD. 
 
 Aggregation  
 DLS measurements were performed at 90ºC scattering angle on a Malvern 
Instrument Zetasizer Nano-ZS. Measurements were carried out at 50ºC using 
a built-in temperature controller, and protein concentration of 1μM at pH 
7.8. Protein samples were passed through a 0.22 μm filter before each 
experiment.   
 
 Thermal stress studies 
 ETF (8 μM) in 10 mM Hepes pH 7.8, was incubated at 39ºC up to 120 
minutes and the residual activity was determined in relation to the activity at 
time zero (duplicate measurements were performed for each time point). The 
experiment was repeated in presence of 1.7 μM GroEL oligomer (10 mM 
Hepes, 1 mM ATP, 15 mM KCl, 5 mM MgCl2, pH 7.8). A control with BSA 
instead of GroEL was made in order to distinguish unspecific effects.   
 
5.4. Results 
 Effect of the ETFα-Thr/Ile171 variation on the conformational 
stability 
ETF is composed of three structural domains: domain I and II are formed 
by the N- and C-terminal portions of the α subunit, respectively, while 
domain III is formed by the β subunit [12]. The polymorphic position 
ETFα−171 is located in domain I at the interface with domain II (Fig. 5.1). 
The Ile or Thr at this position have thus contacts with a set of side chains 
from the three nearby hydrophobic residues: Ile 269, Val 270 and Ala 271.  
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Figure 5.1: Structural model of human Electron Transfer Flavoprotein. This cartoon 
highlights the ETFα-171 position (shown by sticks).The three domains are represent in light 
gray (domain I), grey (domain II), and dark grey (domain III),  the interactions of position 
171 with the surrounding residues are highlighted. The cartoon was made using PyMOL, on 
the basis of PDB coordinates: 1efv.  
 
 The effect of the polymorphic variation at this interfacial position on 
protein stability was investigated from thermal melting experiments. Protein 
unfolding was monitored as a function of temperature using a combination of 
biophysical methods: far-UV CD for monitoring secondary structure changes, 
near-UV CD and aromatic fluorescence to monitor tertiary interactions and 
FAD fluorescence to report on cofactor contacts.  
 The data obtained showed that all these probes reported the same 
midpoint of thermal denaturation (Tm = 58°C) for the two variants (Fig. 
5.2A). Also, there were no differences between the spectra of native 
preparations of the variants, in any of the spectroscopies used. This indicates 
that the alternation between an isoleucine and a threonine at the ETFα-171 
position does not affect the fold nor the thermal stability of ETF. 
 
Domain I
Domain II
T/I171
Ile269
Val 270
Ala271
FAD
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Figure 5.2: Thermal stability (A) and thermal inactivation (B) of ETF variants. A: The 
thermal unfolding curves for ETFα-Ile171 (?) and ETFα-Thr171 (?) were determined 
monitoring ETF unfolding using far-UV CD and aromatic fluorescence emission. Both 
techniques yielded the same results but for clarity purposes only the normalized variation of 
the CD signal at 222 nm is shown. Although ETF is a dimeric protein, its thermal unfolding 
can be described by a two-state process, as shown by the solid sigmoid curve (see materials 
and methods for details). The protein concentration used was 1.7 μM, in 2 mM Hepes, pH 
7.8. B: The thermal inactivation of the ETF activity was monitored for the ETFα-Ile171 (?) 
and ETFα-Thr171 (?) variants up to 75 ºC. The plot represents the residual activity upon 10 
minute incubation at the different temperatures tested (see materials and methods), each 
point represents the average of two experiments obtained with different protein batches 
(standard errors less than 0.05). 
 
 Thermal inactivation profiles  
 A previous study had shown that ETFα-Thr171 is more susceptible to 
thermal inactivation than the ETFα-Ile171 variant [6]. This variant was found 
to be overrepresented among patients suffering from deficiency in the very 
long chain acyl-CoA dehydrogenase (VLCADD) and it was suggested to have 
a negative modulating effect in this disease [6]. However, the molecular 
origins of this different behaviour were not further addressed. Our data 
corroborate this difference between the two variants (Fig. 5.2B): upon 
incubation at different temperatures for 10 minutes, the ETFα-Thr171 
activity decays at lower temperatures than that of ETFα-Ile171. This indicates 
that this difference is not preparation dependent. ETF is a protein known to 
undergo extensive conformational sampling during catalysis, some of which 
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are compatible with fast electron transfer [13-15]. Therefore, the observed 
discrepancy between the thermal denaturation and activity profile suggests 
that the ETFα-Ile/Thr171 polymorphism may influence the structural and 
most likely dynamic properties of the protein upon thermal perturbation, as 
suggested for other enzymes [16]. 
  
 ETFα-Thr171 has a decreased kinetic stability upon thermal 
perturbation 
 In order to gain further insight into the structural changes occurring 
during thermal perturbation of the two ETF variants, the kinetics of thermal 
perturbation were determined under different conditions of thermal stress. 
Changes in protein folding were evaluated using fluorescence spectroscopy 
and FAD as a probe for structural changes. The dissociation rate of the 
cofactor was monitored at conditions of increasing thermal stress: 39, 45, 50 
and 55°C. The results obtained showed that the two variants differ in kinetic 
stability, as the rates of FAD release during thermal perturbation by ETFα-
Thr171 were always higher that those observed for ETFα-Ile171 and the 
difference between the variants increases with temperature (Fig. 5.3). Thus, 
the ETFα-Thr171 variant is more prone to undergo thermally driven 
conformational transitions that result in FAD release.  
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Figure 5.3: Kinetics of flavin release. A: ETFα-Ile171 (?) and ETFα-Thr171 (?) were 
incubated in 10 mM Hepes, pH 7.8 at 55 ºC and flavin release was followed monitoring 
increase in fluorescence emission at 530 nm upon excitation at 436 nm. B: Plot of the 
observed kinetic rates for flavin release at 39ºC, 45ºC, 50ºC and 55 ºC, according to a first 
order process (ETFα-Ile171 dark grey bars and ETFα-Thr171 light grey bars). 
 
 ETFα-Thr171 exhibits decreased conformational stability upon 
thermal stress  
 Thermal stress unmasked kinetic differences between the two 
polymorphic variants, which likely underlie distinct dynamic properties. We 
have further investigated this aspect by comparing the dynamic behavior of 
the two variants upon thermal stress at 50°C, a temperature below the 
midpoint of the thermal transition (Tm = 58°C). Incubation during 10 min 
under these conditions has a distinctly stronger effect on the enzymatic 
activity of the ETFα-Thr171 in respect to that observed for ETFα-Ile171 as 
it results in a residual activity of 38% versus 79%, respectively. However, this 
difference does not result from a macroscopic effect on the structural 
parameters, as both variants are equally affected in their secondary structure 
and FAD release. This suggests that a more dynamic behavior of the ETFα-
Thr171 variant may allow a broader sampling of the conformational space 
thus resulting in subpopulations of inactive ETF. This possibility was 
investigated using dynamic light scattering (DLS) to monitor fluctuations in 
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the hydrodynamic radius of the two polymorphic variants, upon thermal 
stress in the conditions above. This experiment shows that at a very early 
stage (< 20 min) a substantial variation of particle size is observed exclusively 
on the ETFα-Thr171 variant (from ~3.2 to 34 nm). This suggests that a 
heterogeneous population is formed upon thermal stress. 
 
 Activity decay under physiological thermal stress 
 Fatty acid oxidation defect phenotypes are known to be triggered or 
exacerbated by stress factors such as fever. Following the finding that the 
polymorphic variation at ETFα-171 modulates the conformational dynamics 
under thermal stress, we have investigated if this effect would be notorious 
under conditions mimicking a fever episode. For this purpose, we have 
incubated the two variants at 39°C for up to 120 minutes, sampling 
periodically for activity measurements. In agreement with the previous results 
we have observed that the ETFα-Thr171 has an increased susceptibility 
towards thermal inactivation, in comparison to ETFα-Ile171 (Fig. 5.4).  
 
 
 
 
 
Figure 5.4: Thermal inactivation 
profile of ETFα-Ile171 (?) and 
ETFα-Thr171 (?). Each protein 
sample was incubated for 120 min at 
39ºC, samples were taken at different 
time point and the remaining catalytic 
activity was determined (see 
Experimental Procedures). Two 
independent replicates were assayed, and 
each point represents the average of two 
experiments obtained with different 
protein batches (standard errors less than 
5%). 
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 Throughout the thermal perturbation assay, the activity of the ETFα-
Ile171 variant was always higher, and the relative decrease in activity was of 
only 15%, whereas 50% of the ETFα-Thr171 was lost during this 
physiological thermal stress. This result suggests that the presence of the 
ETFα-Thr171 variant may decrease β-oxidation flux during fever episodes.  
 
 GroEL rescues the activity of ETFα-Thr171 during a fever-like 
thermal stress  
 As already stated above heat stress results in a deterioration of 
mitochondrial β-oxidation in cultured fibroblasts obtained from patients with 
fatty acid oxidation disorders [8]. Our findings on the decreased 
conformational stability of ETFα-Thr171 upon thermal stress contribute to a 
molecular understanding of this process at the protein level. Altogether these 
findings suggest that the homeostasis of proteins involved in this pathway is 
susceptible to thermal stress and we have investigated if the GroEL 
chaperonin could rescue destabilized conformations of ETF. GroEL binds to 
partially folded proteins in solution and then uses the energy of ATP 
hydrolysis to drive the protein to a folding-competent state.  
 In this experiment we have measured the residual activity of ETFα-
Thr171 during incubation at 39°C, in the presence and in the absence of 
GroEL and excess ATP (Fig. 5.5). The results obtained showed that GroEL 
is rather efficient in rescuing the conformational destabilisation during 
thermal stress: after 120 min of incubation at 39°C the protein has still ~95% 
of its original activity when GroEL is present, whereas in its absence the 
activity has decayed to 50% (Fig. 5.5). A control experiment for unspecific 
interactions was carried out, in which BSA was added to the assay resulting in 
a decay comparable with the one observed in absence of GroEL, thus 
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showing the specificity of the effect.  
 
Figure 5.5: GroEL conformational 
rescue for ETFα-Thr171. Thermal 
inactivation profile of ETFα-Thr171 in 
presence (?) and absence (?) of 
GroEL. Protein was incubated for 120 
min at 39 ºC, samples were taken at 
different time points and the remaining 
catalytic activity was determined (see 
Experimental Procedures). Two 
independent replicates were assayed, and 
each point represents the average of two 
experiments obtained with different 
protein batches (standard errors less than 
5%). 
 
 
The same experiment was also carried out using the ETFα-Ile171 variant, 
and the results obtained show that in this case the presence of GroEL has 
almost no effect, in agreement with the fact that the ETFα-Ile171 
polymorphism is much less susceptible to destabilization upon thermal stress 
(Fig 5.6).  
 
Figure 5.6: GroEL conformational 
rescue for ETFα-Ile171. Thermal 
inactivation profile of ETFα-Ile171 in 
presence (?) and absence (?) of 
GroEL. Protein was incubated for 90 
min at 39 ºC, samples were taken at 
different time points and the remaining 
catalytic activity was determined (see 
Experimental Procedures). Two 
independent replicates were assayed, 
and each point represents the average of 
two experiments obtained with different 
protein batches (standard errors less 
than 5%). 
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 Clearly, the distinct partitioning of the two variants into GroEL shows 
that, under thermal stress, the polymorphic position modulates the protein 
dynamics and its conformational landscape. In fact, such a preventive effect 
of GroEL during thermal stress is well known in several protein model 
systems, such as dihydrofolate reductase [17]. 
 
5.5. Discussion 
 Thermal stress is an important modulator of disease in mitochondrial beta 
oxidation disorders and point mutations that affect protein stability or activity 
are particularly susceptible to this effect [18-22]. In recent years, important 
progress has been made in the understanding of the molecular and structural 
basis of point mutations affecting different enzymes, including ETF and 
ETF-QO. However, the molecular effects of polymorphic protein variations 
in human disease remains poorly understood, and only now starts to be 
addressed. That is for example the case of the ApoE4 variant which plays a 
role in multiple disease [23], and of the polymorphic variation in the PrP 
protein that acts as a molecular switch in the control of interspecies disease 
transmission [24]. These examples clearly show that polymorphic variations 
may play a key role in the modulation of the biological function, by 
mechanisms which remain to be addressed at the protein-molecular level. 
 Focusing on the effects of the polymorphic variation Ile/Thr at ETFα-
171, we have shown that it affects the protein conformation as evidenced by 
thermal stress, and that the ETFα-Thr171 variant is particularly susceptible to 
thermal destabilization as a result of an increased dynamics. ETF is reported 
to be a highly dynamic protein in the free form in solution and complex with 
it co-partners [25]. Domain II, which accommodates the FAD cofactor, was 
shown to rotate upon complex formation with partner ACDH’s thus bringing 
the FAD bearing moieties in contact in order to allow electron transfer to 
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occur [26]. The dynamics of this domain induces a sampling of more flexible 
conformations that  induce a disorder mechanism that leads to complex 
formation with the partner dehydrogenases [13]. Interestingly, the 
polymorphic position analysed is within domain I, in close contact to domain 
II. One may speculate, on the basis of the available crystal structures, that 
replacement of a isoleucine with a threonine at position 171 in ETFα- may 
influence ETF dynamics in the following way: an isoleucine would favor 
hydrophobic contacts with nearby aliphatic side chains from Domain II (Fig 
5.1), whereas a threonine occupying this position would be less effective, and 
thus make the regions more flexible.  
 A very interesting correlation of our observations with clinical data arises 
from the fact that the ETFα-Thr171 is over represented among patients 
suffering from a mild form of VLCAD deficiency. This finding suggests that 
this polymorphism could eventually account for an increased susceptibility to 
inactivate ETF upon cell stress. This is a common circumstance in metabolic 
disease in which metabolic decompensation is intertwined with mitochondrial 
dysfunction resulting from metabolite accumulation, oxidative stress or fever. 
 Although we have shown that molecular chaperones can rescue these 
destabilised conformations and restore activity to higher levels, their overload 
as a result of massive proteostasis challenges may hinder complete recovery in 
patients. In agreement with this it has been recently reported that fever 
impairs beta oxidation in fibroblasts from patients suffering from different 
mitochondrial fatty acid beta oxidation defects. The analysis of additional 
polymorphic variations such as the one here analysed will contribute to a 
better understanding of the role of polymorphisms as modulators of human 
disease. 
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6.1. Functional and molecular consequences of ETF genetic 
variability  
 FAO disorders are included in the group of loss of function disorders, 
and as in other cases, the severity of the phenotype is dependent on the 
affected gene. This dissertation focuses on MADD, a FAO disorder 
associated to mutations in one of three genes: ETFA, ETFB or ETFDH. 
Since the first MADD report, in 1976, several studies involving patients’ cells 
lead to the identification of over 55 mutations, that range from missense or 
nonsense mutations to frameshifts [1]. A correlation between 
ETFA/ETFB/ETFDH genotype and phenotype has been proposed; 
suggesting that homozygosity for two null mutations causes fetal 
development of congenital anomalies, type I patients [2]. However, even 
minimal amounts of residual ETF or ETF-QO activity seem to be sufficient 
to prevent congenital anomalies during embryonic development, type II 
patient [2]. Single point mutations that result at least in residual levels of 
active enzyme give rise to even milder phenotypes (type III patient). 
However, it has been suggested that milder forms can also be aggravated by 
environmental factors such as temperature [2]. Nevertheless, when 
considering milder phenotypes a directed correlation between genotype and 
the overall effect on protein structure and function that regulates the severity 
of the symptoms has not yet been fully described. The number of MADD 
clinical reports has been increasing over the last years in great extent, mostly 
due to the newborn screening programs; however, there are scarce reports 
focusing on understanding the molecular mechanism of MADD.   
 Salazar et al report an in vitro study on two ETF mutations associated with 
a severe MADD phenotype, ETFα-Thr266Met and ETFα-Gly116Arg. Over-
expression of the ETFα-Gly116 mutant in E. coli was shown to be dependent 
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on the co-expression of GroEL and GroES chaperonins, and even so the 
mutant was not stable enough to further purification [3]. The ETFα-Thr266 
mutant, the most frequent mutation found in patients, was purified and 
characterized. Although its overall structure is similar to wild type protein the 
flavin environment is altered by the mutation [3]. The activity of the ETFα-
Thr266Met is strongly impaired, suggesting that this could be the cause of the 
severe phenotype. Another report has described the heterologous expression 
of ETFβ-Asp128Asn variant, containing a missense mutation identified in a 
patient with a mild phenotype [2]. Those studies have shown that the residual 
activity of the mutant enzyme could be rescued up to 59% of that of wild-
type, when ETFβ-Asp128Asn transformed E. coli cells were grown at low 
temperature (30ºC) rather than at 37ºC. This was an important indication that 
environmental factors such as cellular temperature could play a role 
influencing disease progression.   
 In this perspective, our studies aimed at gaining a better understanding on 
the functional, cellular and molecular effects of the genetic variability in ETF. 
Also, we set to investigate how cellular factors such as increased temperature, 
modulate disease progression.   
 We have compiled an updated list of missense mutation described for 
ETF protein and analysed each mutation at the structural level aiming to find 
a correlation between genotype, phenotype and protein structural behaviour. 
The use of in silico tools for mutagenesis predictions and structural analysis 
permitted us to found that mutations fall essentially in two groups: one in 
which mutations affect protein folding and assembly; and another in which 
mutations impair catalytic activity and disrupt interactions with partner 
dehydrogenases. In the ETF α-subunit, for which 11 missense mutations are 
described, it was observed that there are two affected regions: one region that 
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involves essential interactions with the ETF β-subunit and another conserved 
region rich in FAD and MCAD interacting residues. In the case of the ETF 
β-subunit, we could suggest that there is a region rich in cofactor contacts, 
one that affects subunit interactions and another involved in the “recognition 
loop” implicated in interactions with ACDHs.  
 Moreover, we suggest that amino acid alterations that lead to drastic 
changes in the chemical properties of the residues involved in catalytic 
regions or regions rich in contacts between the subunits or with the cofactor 
have a higher probability to result in severe phenotypes. However, no direct 
correlation can be established between the genotype and the severity of the 
phenotype. Further, we have analysed three of these mutations, ETFβ- 
Cys42Arg, Asp128Asn and Arg191Cys, which typify different scenarios in 
respect to the clinical phenotypes.  
 The ETFβ-Cys42Arg mutation, associated to a severe form of MADD, 
directly affects the AMP binding site and intersubunit contacts, impairing 
correct protein folding. Upon co-expression with GroEL/GroES or 
DnaK/DnaJ/GrpE, ETFβ-Cys42Arg recombinant expression is increased; 
however, the protein has no activity probably due to lack of cofactor 
insertion.  
 The two other mutations, ETFβ- Asp128Asn and Arg191Cys, associated 
with milder forms of MADD, were purified after heterologous expression in 
a prokaryote system. Although none affected the overall α/β fold topology of 
native ETF, as shown by far-UV CD analysis of the purified proteins, both 
substantially decrease its enzymatic activity and conformational stability. The 
ETFβ-Asp128Asn mutation has a stronger impact on conformational stability 
(ΔTm =-8ºC ), as the mutation is near the subunit interface and the FAD 
binding site. Its decreased activity is likely a result of increased susceptibility 
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for FAD loss due to protein instability. The loss of activity in the ETFβ-
Arg191Cys variant seems to result from impaired interaction with the 
electron-donor dehydrogenases since the mutation site is at the interface of 
the complex close to the “recognition loop”, and no drastic decrease on 
stability was observed.  
 
6.2. Molecular rationale for vitamin B2 effects 
 Further, we have used the mild variant ETFβ-Asp128Asn to study the 
molecular rationale of the impact of heat stress on FAO disorders, and 
moreover how disease symptoms could be rescued by vitamin B2 
supplementation.   
 Why some FAO patients are responsive to riboflavin whereas others are 
not is one of the remaining challenges in this field [4-6]. An important 
approach to this topic is to study the flavinylation process in vitro, in order to 
better understand the structural and functional importance of the cofactor. 
Acyl-CoA dehydrogenases have occasionally been purified as apoenzymes, 
lacking FAD, or with substoichiometry FAD binding. Apoenzymes can 
usually be converted into holoenzymes by incubation with FAD. The FAD 
content in the cell is strongly dependent on dietary intake of flavins; low 
nutrient levels of riboflavin resulting in FAD shortage will likely affect the 
function of all these flavoenzymes.  
 Using in vitro translation/import into isolated mitochondria experiments, 
Nagao & Tanaka showed that the effect of low levels of riboflavin/FAD 
inside mitochondria resulted in a decreased proteolytic stability of the mature 
acyl-CoA dehydrogenase molecules. One may thus infer that this might be 
due to increased conformational flexibility of the oligomer lacking FAD, 
which results in higher susceptibility to endoproteases.  
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 Later experiments by the Tanaka laboratory using MCAD as model 
showed that FAD also plays a very important role during the folding process, 
before the assembly of the subunits into the functional tetramer [7]. MCAD 
depends on the assistance of GroEL/GroES chaperonin system for its 
folding [8-9], and according to Saijo and Tanaka’s experiments, FAD appears 
to be incorporated after MCAD monomers are released from the chaperonin 
complex or immediately before, thus assisting folding of the monomer to an 
oligomer assembly competent conformation. The disease-causing MCAD-
Thr68Ala mutation directly affects a residue that is involved in FAD binding 
[10-11]. Although the major effect of this disease allele is on transcription 
levels, expression in a bacterial system and purification of the enzyme 
revealed that the amino acid replacement results in an enzyme that more 
readily looses FAD (~20% of wild type). In agreement, the enzymatic activity 
was decreased, as well as protein thermostability, thus also suggesting a 
structural role for the cofactor [11].  
 Sato et al also reported in vitro folding of ETF and, in connection with 
that, the roles of FAD and AMP on the folding and dimerization process 
[12]. Based on these experiments, a model in which AMP binds to a more 
loose conformation of the dimer was suggested, whereas FAD binds to a 
more compact form. Although this is suggestive of a sequential incorporation, 
in vitro, the two factors can be incorporated sequentially independently of each 
other.  
 In line with these studies, we have shown that the ETFβ-Asp128Asn 
clinical variant deflavinylates 3-fold faster than the wild-type protein during 
heat stress (mimicking a fever episode) with concurrently increased loss of 
activity. This is in agreement with the fact that a patient with this mutation 
has only developed disease symptoms in connection with a virus infection 
and fever [2]. Experiments in the presence of a 2.5 fold excess of FAD in 
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respect to ETF, corresponding to the increase observed in muscle 
mitochondria in riboflavin responsive patients [13], have shown that 
flavinylation improves the conformational and proteolytic stability of the 
protein, also increasing its biological activity [14]. Moreover flavinylation 
prevents activity loss and prevents loss of tertiary contacts during heat stress, 
up incubation at 39ºC. A noteworthy observation is the fact that ETFβ-
Asp128Asn is not directly located in the FAD binding domain. Therefore, the 
observations made could be generalized to other mutations in different 
flavoproteins involved in fatty acid β-oxidation defects. Moreover, the use of 
this mild mutation, which was modulated by environmental factors, provides 
a concrete molecular rationale for the efficiency of riboflavin 
supplementation.  
 Presumably vitamin B2 supplementation increases the intramitochondrial 
flavin content, thereby compensating for the loss of flavin cofactors. Merging 
the different molecular, biochemical and cellular data described in this work, 
has allowed to outline a mechanism that accounts for the structural and 
functional rescue due to flavinylation (Fig. 6.1). After translation and import 
into the mitochondria the apoprotein form may become flavinylated via a 
chaperonin- independent (A) or chaperonin-dependent (B) pathway. In both 
cases, steps involving FAD insertion may eventually be mediated by FAD-
chaperone proteins. The chaperonin-dependent pathway may involve folding 
of the apo monomer which then gets flavinylated upon release or immediately 
after release, like proposed for MCAD. Oligomerization into the functional 
forms (tetramers or dimers) is made starting from the holo-protein form. 
Upon an adverse cellular or patho-physiological condition such as a genetic 
mutation, stress (thermal, oxidative or other) or riboflavin and flavin 
depletion, cofactor lability may be enhanced thus resulting in an equilibrium 
of populations in which there is a significant amount of the enzyme in the 
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apo-form, as suggested by the ETF mild variant. The latter is known to be 
more conformationally destabilized and susceptible to degradation or 
misfolding, resulting in loss of function. In some cases, restoring the intra-
mitochondrial flavin levels as a result of riboflavin supplementation, results in 
an increase of the activity of the affected proteins [13].  
 
Figure 6.1: Cartoon representing different scenarios for pathways through which FAD 
may be inserted into proteins conferring structural and functional rescue. See text for 
details. 
 
 We have proposed a molecular mechanism that could provide a molecular 
rationale for the effect of riboflavin supplementation. However, even for the 
ETFβ-Asp128Asn, for which we proved that flavinylation has beneficial 
results, β-oxidation flux in patient fibroblasts cultured in riboflavin-
supplemented media, using myristate or palmitate as substrates, was only 14% 
and 28% of controls, respectively [15]. This shows that in vivo, even though 
flavinylation can ameliorate the damaging effect of the ETFβ-Asp128Asn 
mutant, it cannot rescue protein activity to the level that is required to restore 
normal β-oxidation flux. This is analogous to other reports on riboflavin 
responsiveness in mild MADD, where biochemical and clinical abnormalities 
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are only partially restored [16-17].  
 Therefore, new strategies for improvement of the clinical treatments need 
to be prepared. Recent interest has been set in the use of fibrates, like 
bezafibrate, which act as an agonist of the peroxisomal proliferators-activated 
receptors (PPARs). The nuclear hormone receptor family of the peroxisomal 
proliferators–activated receptors (PPARs) is involved in the regulatory 
network that controls mitochondrial FAO, so drugs that act as PPAR 
activators could be relevant therapeutic targets to modulate FAO disorders 
[18]. A study on VLCAD patient cell showed that bezafibrate increases the 
level of VLCAD mRNA, protein, and residual enzyme activity [19]. In 
addition, it was reported that bezafibrate also stimulates the expression of 
several FAO genes in human fibroblasts, including carnitine palmitoyl-
transferases, MCAD, LCHAD, ETF and ETF-QO [19]. As reviewed in [18], 
the beneficial effect of fibrates, in particular bezafibrate, has been proven in 
patient cells harbouring milder forms of CPT II or VLCAD deficiencies. 
Moreover, it is noteworthy that bezafibrate has been prescribed as a 
hypolipidaemic agent, and it is generally considered to have a good safe 
profile [20-21]. Hence, it seems clear that in parallel with a detailed study on 
the use of riboflavin in different FAO disorders, the use of bezafibrate could 
also be further tested. 
 
6.3. Role of polymorphisms as modulators of human disease 
 Further, we investigated ETF polymorphism as a model to better 
understand how polymorphic variants can modulate disease development. 
Four polymorphic variants of ETF have been described (ETFα-171Ile/Thr 
and ETFβ-154Met/Thr) [22-23], and has been suggested that one of them 
(ETFα-Thr171) has decreased thermal stability in comparison to the others 
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[24]. It was also proposed that such polymorphisms could constitute 
susceptibility factor for the disease development in VLCAD patients, for 
which the less stable polymorphic variant was overrepresented.   
 In addition, Li and co-workers have recently shown that heat stress in 
cultured fibroblasts (41ºC), increases acetylcarnitine (C2) levels, while it 
significantly decreases the levels of other acylcarnitines in control and 
MCAD-deficient cells. However, CPT2, VLCAD or MTP patient cells have 
an enhanced accumulation of long chain acylcarnitines (C12, C14 and C16) 
[25-26]. Also, culture cells associated with MADD showed a reduction of 
short to medium-chain acylcarnitines but a significant increase in long-chain 
acylcarnitines [26]. These results suggest that long-chain associated FAO 
disorders are more susceptible to heat stress.  
 Aiming to dissect the molecular effects of the polymorphic variation in 
the folding, stability and dynamics of ETF we have performed a detailed in 
vitro investigation of the polymorphism in position 171 of the α-subunit. We 
have shown that the ETFα-Thr171 is prone to faster FAD release, and that it 
exhibits increased conformational dynamics during thermal stress.  
 Through heat stress, such as during fever, cells up regulate several 
molecular chaperones, which are able to rescue thermally destabilized 
proteins. We have shown, in vitro, that in fact, the GroEL chaperonin can 
rescue ETFα-Thr171, as it captures and refolds the dynamic populations of 
the protein, as suggested by the recovery of its biological activity. In the cell, 
this effect could eventually be less significant since several other proteins will 
be affected, and an overload of the cell quality control machinery would 
probably decrease its efficiency. These results are especially important to 
outline how polymorphic variants, which are apparently innocuous, may 
significantly influence disease progression and severity via indirect effects.   
 As a final remark, it would be interesting, in particular in patients with 
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long-chain fatty acid impaired oxidation, to systematically investigate 
expression levels and activity of the FAO enzymes, especially ETF in order to 
better judge on global and indirect effects on the pathway. This knowledge 
could contribute to the design of better therapeutic alternatives.  
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